HK1131833B

HK1131833B - Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis

Info

Publication number: HK1131833B
Application number: HK09110977.7A
Authority: HK
Inventors: Anna Karolina Palucka; Jacques F. Banchereau; Damien Chaussabel
Original assignee: Baylor Research Institute
Priority date: 2006-11-03
Filing date: 2007-11-03
Publication date: 2014-01-30

Description

TECHNICAL FIELD OF THE INVENTION

The present invention relates in general to the field of diagnostic for monitoring indicators of metastatic melanoma and/or immunosuppression, and more particularly, to a system, method and apparatus for the diagnosis, prognosis and tracking of metastatic melanoma and monitoring indicators of immunosuppression associated with transplant recipients (e.g., liver).

BACKGROUND OF THE INVENTION

Pharmacological immunosuppression has been instrumental in transplantation, transforming a last resort experimental procedure into a routinely successful one. Cyclosporin and tacrolimus/FK506 currently constitute the mainstay for transplant recipients. Activated T cells have been considered the main cellular targets for immunosuppressive treatments, but recent reports have also noted a marked effect of these drugs on antigen presenting cells, probably contributing further to the establishment of a generalized state of immune unresponsiveness (Lee et al., 2005b; Woltman et al., 2003). While severe immunosuppression generated by pharmacological treatment is necessary for the maintenance of graft survival and function, it also exposes the recipient to life-threatening infections and malignancies. Skin cancer is a well-established complication in organ transplant recipients (Gerlini et al., 2005). A recent epidemiological study showed that nearly 20% of 1115 renal transplant patients developed skin malignancies in Europe (Bordea et al., 2004), with much higher incidences being observed in less temperate climates, e.g., as high as 28% in Australia (Carroll et al., 2003). In addition to occurring more often, skin malignancies tend to take a more aggressive clinical course in transplanted patients, with a higher propensity to metastasize distantly and lead to a fatal outcome (Barrett et al., 1993).

Tumors maintain their survival by compromising the immune system. Different mechanisms have been identified including secretion of immunosuppressive factors such as cytokines (e.g., IL-10, TGF-beta), hormones (e.g., Prostaglandin E2), and others (e.g., MIA: Melanoma inhibitory activity, Tenascin C)(Jachimczak et al., 2005; Puente Navazo et al., 2001). Furthermore, tumors might promote development of suppressor T cells (Liyanage et al., 2002; Viguier et al., 2004), possibly via modulating dendritic cells (Gabrilovich, 2004; Lee et al., 2005a; Monti et al., 2004).

Thus, immunosuppression, whether from tumors or pharmacological treatments, has been linked to cancer progression. Therefore, a common molecular signature could be identified by profiling genome-wide transcriptional activity in peripheral blood mononuclear cell ("PBMC") samples obtained from immunosuppressed patients with either metastatic melanoma or liver allografts. The analysis of Leukocyte transcriptional profiles generated in the context of the present study supports this notion and identifies a blood signature of immunosuppression.

In Pavey S et al. (Oncogene 23(2004): 4060-4067) a microarray is described which can be used to predict the presence of BRAF mutations in a panel of 61 melanoma cell lines.

Zhou Y et al. (J Invest Dermatol 124(2005): 1044-1052) describe the overexpression of over 190 genes in metastatic melanomas. Thereby they noted that one of the most abundantly expressed genes in metastatic melanoma modules is osteopontin.

In Bittner M et al. (Nature 406(2000): 536-540) gene expression profiling was used to clarify cutaneous malignant melanomas.

SUMMARY OF THE INVENTION

Genomic research is facing significant challenges with the analysis of transcriptional data that are notoriously noisy, difficult to interpret and do not compare well across laboratories and platforms. The present inventors have developed an analytical strategy emphasizing the selection of biologically relevant genes at an early stage of the analysis, which are consolidated into analytical modules that overcome the inconsistencies among microarray platforms. The transcriptional modules developed may be used for the analysis of large gene expression datasets. The results derived from this analysis are easily interpretable and particularly robust, as demonstrated by the high degree of reproducibility observed across commercial microarray platforms.

Applications for this analytical process are illustrated through the mining of a large set of PBMC transcriptional profiles. Twenty-eight transcriptional modules regrouping 4,742 genes were identified. Using the present invention is it possible to demonstrate that diseases are uniquely characterized by combinations of transcriptional changes in, e.g., blood leukocytes, measured at the modular level. Indeed, module-level changes in blood leukocytes transcriptional levels constitute the molecular fingerprint of a disease or sample.

This invention has a broad range of applications. It can be used to characterize modular transcriptional components of any biological system (e.g., peripheral blood mononuclear cells (PBMCs), blood cells, fecal cells, peritoneal cells, solid organ biopsies, resected tumors, primary cells, cells lines, cell clones, etc.). Modular PBMC transcriptional data generated through this approach can be used for molecular diagnostic, prognostic, assessment of disease severity, response to drug treatment, drug toxicity, etc. Other data processed using this approach can be employed for instance in mechanistic studies, or screening of drug compounds. In fact, the data analysis strategy and mining algorithm can be implemented in generic gene expression data analysis software and may even be used to discover, develop and test new, disease- or condition-specific modules. The present invention may also be used in conjunction with pharmacogenomics, molecular diagnostic, bioinformatics and the like, wherein in-depth expression data may be used to improve the results (e.g., by improving or sub-selecting from within the sample population) that mat be obtained during clinical trails.

More particularly, the present invention includes methods for diagnosing a disease or condition by obtaining the transcriptome of a patient; analyzing the transcriptome based on one or more transcriptional modules that are indicative of a disease or condition; and determining the patient's disease or condition based on the presence, absence or level of expression of genes within the transcriptome in the one or more transcriptional modules. The transcriptional modules may be obtained by: iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules for each clusters until all gene clusters are exhausted.

Examples of clusters selected for use with the present invention include, but are not limited to, expression value clusters, keyword clusters, metabolic clusters, disease clusters, infection clusters, transplantation clusters, signaling clusters, transcriptional clusters, replication clusters, cell-cycle clusters, siRNA clusters, miRNA clusters, mitochondrial clusters, T cell clusters, B cell clusters, cytokine clusters, lymphokine clusters, heat shock clusters and combinations thereof. Examples of diseases or conditions for analysis using the present invention include, e.g., autoimmune disease, a viral infection a bacterial infection, cancer and transplant rejection. More particularly, diseases for analysis may be selected from one or more of the following conditions: systemic juvenile idiopathic arthritis, systemic lupus erythematosus, type I diabetes, liver transplant recipients, melanoma patients, and patients bacterial infections such as Escherichia coli, Staphylococcus aureus, viral infections such as influenza A, and combinations thereof. Specific array may even be made that detect specific diseases or conditions associated with a bioterror agent.

Cells that may be analyzed using the present invention, include, e.g., peripheral blood mononuclear cells (PBMCs), blood cells, fetal cells, peritoneal cells, solid organ biopsies, resected tumors, primary cells, cells lines, cell clones and combinations thereof. The cells may be single cells, a collection of cells, tissue, cell culture, cells in bodily fluid, e.g., blood. Cells may be obtained from a tissue biopsy, one or more sorted cell populations, cell culture, cell clones, transformed cells, biopies or a single cell. The types of cells may be, e.g., brain, liver, heart, kidney, lung, spleen, retina, bone, neural, lymph node, endocrine gland, reproductive organ, blood, nerve, vascular tissue, and olfactory epithelium cells. After cells are isolated, these mRNA from these cells is obtained and individual gene expression level analysis is performed using, e.g., a probe array, PCR, quantitative PCR, bead-based assays and combinations thereof. The individual gene expression level analysis may even be performed using hybridization of nucleic acids on a solid support using cDNA made from mRNA collected from the cells as a template for reverse transcriptase.

Pharmacological immunosuppression promotes graft survival in transplant recipients. Endogenous immunosuppression promotes tumor survival in cancer-bearing patients. Leukocytes from patients with metastatic melanoma display an endogenous immunosuppression signature common with liver transplant recipients under pharmacological immunosuppression. Blood microarray analyses were carried out in 25 healthy volunteers, 35 patients with metastatic melanoma, and 39 liver transplant recipients. Disease signatures were identified, and confirmed in an independent dataset, in comparison to healthy controls. Analysis of a set of 69 transcripts over-expressed preferentially in melanoma and transplant groups in comparison to six other diseases revealed remarkable functional convergence, including several repressors of interleukin-2 transcription, powerful inhibitors of NF-kappaB and MAPK pathways as well as antiproliferative molecules. Thus, patients with metastatic melanoma display an endogenous transcriptional signature of immunosuppression. This signature may now be used to identify patients at the high risk of metastatic melanoma progression.

The present invention includes a system and a method to analyze samples for the prognosis and diagnosis of metastatic melanoma and/or monitoring indicators of immunosuppression associated with transplant recipients (e.g., liver) using multiple variable gene expression analysis. The gene expression differences that remain can be attributed with a high degree of confidence to the unmatched variation. The gene expression differences thus identified can be used, for example, to diagnose disease, identify physiological state, design drugs and monitor therapies.

The sample may be screened by quantitating the mRNA, protein or both mRNA and protein level of the expression vector. When the screening is for mRNA levels, it may be quantitated by a method selected from polymerase chain reaction, real time polymerase chain reaction, reverse transcriptase polymerase chain reaction, hybridization, probe hybridization, and gene expression array. The screening method may also include detection of polymorphisms in the biomarker. Alternatively, the screening step may be accomplished using at least one technique selected from the group consisting of polymerase chain reaction, heteroduplex analysis, single stand conformational polymorphism analysis, ligase chain reaction, comparative genome hybridization, Southern blotting, Northern blotting, Western blotting, enzyme-linked immunosorbent assay, fluorescent resonance energy-transfer and sequencing. For use with the present invention the sample may be any of a number of immune cells, e.g., leukocytes or sub-components thereof.

The present invention relates to a method of identifying a patient with melanoma by examining the phenotype a sample for combinations of six, seven, eight, ten, fifteen, twenty, twenty-five or more genes selected from modules M1.1 and M1.2 of Table 12.

In one aspect, the present invention includes a method of identifying gene expression response to pharmacological immunosuppression in transplant recipients by examining the phenotype a sample for combinations of six, seven, eight, ten, fifteen, twenty, twenty-five or more genes selected from modules M1.1 and M1.2 of Table 13.

The sample may be screened by quantitating the mRNA, protein or both mRNA and protein level of the expression vector. When mRNA level is examined, it may be quantitated by a method selected from polymerase chain reaction, real time polymerase chain reaction, reverse transcriptase polymerase chain reaction, hybridization, probe hybridization, and gene expression array. The screening method may also include detection of polymorphisms in the biomarker. Alternatively, the screening step may be accomplished using at least one technique selected from the group consisting of polymerase chain reaction, heteroduplex analysis, single stand conformational polymorphism analysis, ligase chain reaction, comparative genome hybridization, Southern blotting, Northern blotting, Western blotting, enzyme-linked immunosorbent assay, fluorescent resonance energy-transfer and sequencing. For use with the present invention the sample may be any of a number of immune cells, e.g., leukocytes or sub-components thereof.

The expression vector may be screened by quantitating the mRNA, protein or both mRNA and protein level of the expression vector. When the expression vector is mRNA level, it may be quantitated by a method selected from polymerase chain reaction, real time polymerase chain reaction, reverse transcriptase polymerase chain reaction, hybridization, probe hybridization, and gene expression array. The screening method may also include detection of polymorphisms in the biomarker. Alternatively, the screening step may be accomplished using at least one technique selected from the group consisting of polymerase chain reaction, heteroduplex analysis, single stand conformational polymorphism analysis, ligase chain reaction, comparative genome hybridization, Southern blotting, Northern blotting, Western blotting, enzyme-linked immunosorbent assay, fluorescent resonance energy-transfer and sequencing. For use with the present invention the sample may be any of a number of immune cells, e.g., leukocytes or sub-components thereof.

For example, a method of identifying a subject with melanoma by determining a database that includes the level of expression of one or more metastatic melanoma expression vectors. Another embodiment of the present invention includes a computer implemented method for determining the genotype of a sample by obtaining a plurality of sample probe intensities. Diagnosing metastatic melanoma is based upon the sample probe intensities and calculating a linear correlation coefficient between the sample probe intensities and reference probe intensities.

The present invention also includes a computer readable medium including computer-executable instructions for performing the method of determining the genotype of a sample. The method of determining the phenotype includes obtaining a plurality of sample probe intensities and diagnosing melanoma based upon the sample probe intensities for two or more metastatic melanoma expression vectors selected from those listed in modules M1.1 and M1.2 of Table 12 into a dataset; and calculating a linear correlation coefficient between the sample probe intensities and a reference probe intensity. The tentative phenotype is accepted as the phenotype of the sample if the linear correlation coefficient is greater than a threshold value. In addition, the present invention includes a microarray for identifying a human subject with melanoma. A microarray includes the detection of expression of two or more metastatic melanoma genes listed in modules M1.1 and M1.2 of Table 12 into a dataset. The present invention provides a method of distinguishing between metastatic melanoma and immunosuppression associated with transplants by determining the level of expression of one or more genes, and calculating one or more gene expression vectors. The melanoma-specific transcriptome-expression vectors may include values for the upregulation or downregulation of six or more genes listed in modules M1.1 and M1.2 of Table 12. The present invention provides a method of identifying a subject with immunosuppression associated with transplants by determining the level of expression of one or more immunosuppression associated expression vectors. The immunosuppression-specific transcriptome-expression vectors may include values for the upregulation or downregulation of six or more genes listed in modules M1.1 and M1.2 of Table 13.

A computer readable medium is also included that has computer-executable instructions for performing the method for determining the phenotype of a sample. The method for determining the phenotype of a sample includes obtaining a plurality of sample probe intensities and diagnosing immunosuppression based upon the sample probe intensities for two or more immunosuppression associated expression vectors. A linear correlation coefficient is calculated between the sample probe intensities and a reference probe intensity and a tentative phenotype is accepted as the phenotype of the sample if the linear correlation coefficient is greater than a threshold value. The present invention also includes a system for diagnosing immunosuppression including an expression level detector for determining the expression level of two or more immunosuppression expression vectors selected from the 1, 2, 3, 4, 5, 6, 8, 10, 15, 20, 25 or more genes. The melanoma-specific transcriptome-expression vectors that are used to generate expression data for each gene, which is saved into a dataset, may include values for the upregulation or downregulation of six or more genes listed in modules M1.1 and M1.2 of Table 12. The immunosuppression-specific transcriptome-expression vectors may include values in a dataset that includes the upregulation or downregulation of six or more genes listed in modules M1.1 and M1.2 of Table 13. The presence of melanoma or immunosuppression is determined based on the presence of two or more positive indicators in a gene expression vector dataset.

The arrays, methods and systems of the present invention may even be used to select patients for a clinical trial by obtaining the transcriptome of a prospective patient; comparing the transcriptome to one or more transcriptional modules that are indicative of a disease or condition that is to be treated in the clinical trial; and determining the likelihood that a patient is a good candidate for the clinical trial based on the presence, absence or level of one or more genes that are expressed in the patient's transcriptome within one or more transcriptional modules that are correlated with success in a clinical trial. Generally, for each module a vector that correlates with a sum of the proportion of transcripts in a sample may be used, e.g., when each module includes a vector and wherein one or more diseases or conditions is associated with the one or more vectors. Therefore, each module may include a vector that correlates to the expression level of one or more genes within each module.

Herein arrays, e.g., custom microarrays are described that include nucleic acid probes immobilized on a solid support that includes sufficient probes from one or more expression vectors to provide a sufficient proportion of differentially expressed genes to distinguish between one or more diseases. For example, an array of nucleic acid probes immobilized on a solid support, in which the array includes at least two sets of probe modules, wherein the probes in the first probe set have one or more interrogation positions respectively corresponding to one or more diseases. The array may have between 100 and 100,000 probes, and each probe may be, e.g., 9-21 nucleotides long. When separated into organized probe sets, these may be interrogated separately.

One or more nucleic acid probes immobilized on a solid support to form a module array are also described that includes at least one pair of first and second probe groups, each group having one or more probes as defined by Table 1. The probe groups are selected to provide a composite transcriptional marker vector that is consistent across microarray platforms. In fact, the probe groups may even be used to provide a composite transcriptional marker vector that is consistent across microarray platforms and displayed in a summary for regulatory approval. The skilled artisan will appreciate that using the modules of the present invention it is possible to rapidly develop one or more disease specific arrays that may be used to rapidly diagnose or distinguish between different disease and/or conditions.

A method for displaying transcriptome vector data from a transcriptome vector dataset by separating one or more genes into one or more modules to visually display an aggregate gene expression vector value for each of the modules; and displaying the aggregate gene expression vector value for overexpression, underexpression or equal expression of the aggregate gene expression vector value in each module is also described. In one example, overexpression is identified with a first identifier and underexpression is identified with a second identifier. Examples of identifiers include colors, shapes, patterns, light/dark, on/off, symbols and combinations thereof. For example, overexpression is identified with a first identifier and underexpression is identified with a second identifier, wherein the first identifier is a first color and the second identifier is a second color, and wherein first and second identifiers are superimposed to provide a combined color.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:

FIGURES 1A to 1C show the basic microarray data mining strategy steps involved in accepted gene-level microarray data analysis (FIGURE 1A), the modular mining strategy of the present invention FIGURE 1B and a full size representation of the module extraction algorithm FIGURE 1C to generate on or more datasets used to create the expression vectors;
FIGURE 2 is a graph representing transcriptional profiles showing levels of modular gene expression profiles across an independent group of samples;
FIGURE 3 is a distribution of keyword occurrence in the literature obtained for four sets of coordinately expressed genes;
FIGURE 4 illustrates a modular microarray analysis strategy for characterization of the transcriptional system;
FIGURE 5 is an analysis of patient blood leukocyte transcriptional profiles;
FIGURE 6 illustrates module maps of transcriptional changes caused by disease;
FIGURE 7 illustrates the identification of a blood leukocyte transcriptional signature in patients with metastatic melanoma;
FIGURE 8 illustrates the validation of microarray results in an independent set of samples;
FIGURE 9 illustrates the identification of a blood leukocyte transcriptional signature in transplant recipients under immunosuppressive drug therapy
FIGURE 10-13 illustrate detailed results of the module-level analysis;
FIGURE 14 illustrates the module-level analysis for distinctive transcriptional signatures in blood from patients with metastatic melanoma and from liver transplant recipients;
FIGURE 15 illustrates the mapping transcriptional changes in patient blood leukocytes at the module level;
FIGURE 16 illustrates the module-level analysis for common transcriptional signatures in blood from patients with metastatic melanoma and from liver transplant recipients;
FIGURE 17 illustrates the analysis of significance patterns with genes expressed at higher levels in both melanoma and liver transplant patients compared to healthy volunteers;
FIGURE 18 illustrates the modular distribution of ubiquitous and specific gene signatures common to melanoma and transplant groups;
FIGURE 19 illustrates the transcriptional signature of immunosuppression;
FIGURE 20 shows a statistical group comparison between patients and their respective controls;
FIGURE 21 shows the analysis of significance patterns for genes over-expressed in SLE patients but not in patients with acute Influenza A infection;
FIGURE 22 shows the patterns of significance for genes common to Influenza A and SLE; and
FIGURE 23 is a functional analysis of genes shared by patients with Influenza infection and Lupus grouped according to significance patterns.

DETAILED DESCRIPTION OF THE INVENTION

While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., Dictionary Of Microbiology And Molecular Biology (2d ed. 1994); The Cambridge Dictionary Of Science And Technology (Walker ed., 1988); The Glossary Of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary Of Biology (1991).

Various biochemical and molecular biology methods are well known in the art. For example, methods of isolation and purification of nucleic acids are described in detail in WO 97/10365 , WO 97/27317 , Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, (P. Tijssen, ed.) Elsevier, N.Y. (1993); Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part 1. Theory and Nucleic Acid Preparation, (P. Tijssen, ed.) Elsevier, N.Y. (1993); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, N.Y., (1989); and Current Protocols in Molecular Biology, (Ausubel, F. M. et al., eds.) John Wiley & Sons, Inc., New York (1987-1999), including supplements such as supplement 46 (April 1999).

BIOINFORMATICS DEFINITIONS

As used herein, an "object" refers to any item or information of interest (generally textual, including noun, verb, adjective, adverb, phrase, sentence, symbol, numeric characters, etc.). Therefore, an object is anything that can form a relationship and anything that can be obtained, identified, and/or searched from a source. "Objects" include, but are not limited to, an entity of interest such as gene, protein, disease, phenotype, mechanism, drug, etc. In some aspects, an object may be data, as further described below.

As used herein, a "relationship" refers to the co-occurrence of objects within the same unit (e.g., a phrase, sentence, two or more lines of text, a paragraph, a section of a webpage, a page, a magazine, paper, book, etc.). It may be text, symbols, numbers and combinations, thereof

As used herein, "meta data content" refers to information as to the organization of text in a data source. Meta data can comprise standard metadata such as Dublin Core metadata or can be collection-specific. Examples of metadata formats include, but are not limited to, Machine Readable Catalog (MARC) records used for library catalogs, Resource Description Format (RDF) and the Extensible Markup Language (XML). Meta objects may be generated manually or through automated information extraction algorithms.

As used herein, an "engine" refers to a program that performs a core or essential function for other programs. For example, an engine may be a central program in an operating system or application program that coordinates the overall operation of other programs. The term "engine" may also refer to a program containing an algorithm that can be changed. For example, a knowledge discovery engine may be designed so that its approach to identifying relationships can be changed to reflect new rules of identifying and ranking relationships.

As used herein, "semantic analysis" refers to the identification of relationships between words that represent similar concepts, e.g., though suffix removal or stemming or by employing a thesaurus. "Statistical analysis" refers to a technique based on counting the number of occurrences of each term (word, word root, word stem, n-gram, phrase, etc.). In collections unrestricted as to subject, the same phrase used in different contexts may represent different concepts. Statistical analysis of phrase co-occurrence can help to resolve word sense ambiguity. "Syntactic analysis" can be used to further decrease ambiguity by part-of-speech analysis. As used herein, one or more of such analyses are referred to more generally as "lexical analysis." "Artificial intelligence (AI)" refers to methods by which a non-human device, such as a computer, performs tasks that humans would deem noteworthy or "intelligent." Examples include identifying pictures, understanding spoken words or written text, and solving problems.

As used herein, the term "database" or "dataset" refer to repositories for raw or compiled data, even if various informational facets can be found within the data fields. A database is typically organized so its contents can be accessed, managed, and updated (e.g., the database is dynamic). The term "database" and "source" are also used interchangeably in the present invention, because primary sources of data and information are databases. However, a "source database" or "source data" refers in general to data, e.g., unstructured text and/or structured data, which are input into the system for identifying objects and determining relationships. A source database may or may not be a relational database. However, a system database usually includes a relational database or some equivalent type of database or dataset which stores or includes stored values relating to relationships between objects.

As used herein, a "system database" and "relational database" are used interchangeably and refer to one or more collections of data organized as a set of tables containing data fitted into predefined categories. For example, a database table may comprise one or more categories defined by columns (e.g. attributes), while rows of the database may contain a unique object for the categories defined by the columns. Thus, an object such as the identity of a gene might have columns for its presence, absence and/or level of expression of the gene. A row of a relational database may also be referred to as a "set" and is generally defined by the values of its columns. A "domain" in the context of a relational database is a range of valid values a field such as a column may include.

As used herein, a "domain of knowledge" refers to an area of study over which the system is operative, for example, all biomedical data. It should be pointed out that there is advantage to combining data from several domains, for example, biomedical data and engineering data, for this diverse data can sometimes link things that cannot be put together for a normal person that is only familiar with one area or research/study (one domain). A "distributed database" refers to a database that may be dispersed or replicated among different points in a network.

Terms such "data" and "information" are often used interchangeably, as are "information" and "knowledge." As used herein, "data" is the most fundamental unit that is an empirical measurement or set of measurements. Data is compiled to contribute to information, but it is fundamentally independent of it. Information, by contrast, is derived from interests, e.g., data (the unit) may be gathered on ethnicity, gender, height, weight and diet for the purpose of finding variables correlated with risk of cardiovascular disease. However, the same data could be used to develop a formula or to create "information" about dietary preferences, i.e., likelihood that certain products in a supermarket have a higher likelihood of selling.

As used herein, "information" refers to a data set that may include numbers, letters, sets of numbers, sets of letters, or conclusions resulting or derived from a set of data. "Data" is then a measurement or statistic and the fundamental unit of information. "Information" may also include other types of data such as words, symbols, text, such as unstructured free text, code, etc. "Knowledge" is loosely defined as a set of information that gives sufficient understanding of a system to model cause and effect. To extend the previous example, information on demographics, gender and prior purchases may be used to develop a regional marketing strategy for food sales while information on nationality could be used by buyers as a guideline for importation of products. It is important to note that there are no strict boundaries between data, information, and knowledge; the three terms are, at times, considered to be equivalent. In general, data comes from examining, information comes from correlating, and knowledge comes from modeling.

As used herein, "a program" or "computer program" refers generally to a syntactic unit that conforms to the rules of a particular programming language and that is composed of declarations and statements or instructions, divisible into, "code segments" needed to solve or execute a certain function, task, or problem. A programming language is generally an artificial language for expressing programs.

As used herein, a "system" or a "computer system" generally refers to one or more computers, peripheral equipment, and software that perform data processing. A "user" or "system operator" in general includes a person, that uses a computer network accessed through a "user device" (e.g., a computer, a wireless device, etc) for the purpose of data processing and information exchange. A "computer" is generally a functional unit that can perform substantial computations, including numerous arithmetic operations and logic operations without human intervention.

As used herein, "application software" or an "application program" refers generally to software or a program that is specific to the solution of an application problem. An "application problem" is generally a problem submitted by an end user and requiring information processing for its solution.

As used herein, a "natural language" refers to a language whose rules are based on current usage without being specifically prescribed, e.g., English, Spanish or Chinese. As used herein, an "artificial language" refers to a language whose rules are explicitly established prior to its use, e.g., computer-programming languages such as C, C++, Java, BASIC, FORTRAN, or COBOL.

As used herein, "statistical relevance" refers to using one or more of the ranking schemes (O/E ratio, strength, etc.), where a relationship is determined to be statistically relevant if it occurs significantly more frequently than would be expected by random chance.

As used herein, the terms "coordinately regulated genes" or "transcriptional modules" are used interchangeably to refer to grouped, gene expression profiles (e.g., signal values associated with a specific gene sequence) of specific genes. Each transcriptional module correlates two key pieces of data, a literature search portion and actual empirical gene expression value data obtained from a gene microarray. The set of genes that is selected into a transcriptional module based on the analysis of gene expression data (using the module extraction algorithm described above). Additional steps are taught by Chaussabel, D. & Sher, A. Mining microarray expression data by literature profiling. Genome Biol 3, RESEARCH0055 (2002), (http://genomebiology.com/2002/3/10/research/0055) and expression data obtained from a disease or condition of interest, e.g., Systemic Lupus erythematosus, arthritis, lymphoma, carcinoma, melanoma, acute infection, autoimmune disorders, autoinflammatory disorders, etc.).

The Table below lists examples of keywords that were used to develop the literature search portion or contribution to the transcription modules. The skilled artisan will recognize that other terms may easily be selected for other conditions, e.g., specific cancers, specific infectious disease, transplantation, etc. For example, genes and signals for those genes associated with T cell activation are described hereinbelow as Module ID "M 2.8" in which certain keywords (e.g., Lymphoma, T-cell, CD4, CD8, TCR, Thymus, Lymphoid, IL2) were used to identify key T-cell associated genes, e.g., T-cell surface markers (CD5, CD6, CD7, CD26, CD28, CD96); molecules expressed by lymphoid lineage cells (lymphotoxin beta, IL2-inducible T-cell kinase, TCF7; and T-cell differentiation protein mal, GATA3, STAT5B). Next, the complete module is developed by correlating data from a patient population for these genes (regardless of platform, presence/absence and/or up or downregulation) to generate the transcriptional module. In some cases, the gene profile does not match (at this time) any particular clustering of genes for these disease conditions and data, however, certain physiological pathways (e.g., cAMP signaling, zinc-finger proteins, cell surface markers, etc.) are found within the "Underdetermined" modules. In fact, the gene expression data set may be used to extract genes that have coordinated expression prior to matching to the keyword search, i.e., either data set may be correlated prior to cross-referencing with the second data set.

Table 1. Examples of Genes within Distinct Modules


M 1.1	76	Ig, Immunoglobulin, Bone, Marrow, PreB, IgM,Mu.	Plasma cells. Includes genes coding for Immunoglobulin chains (e.g. IGHM, IGJ, IGLL1, IGKC, IGHD) and the plasma cell marker CD38.
M 1.2	130	Platelet, Adhesion, Aggregation, Endothelial, Vascular	Platelets. Includes genes coding for platelet glycoproteins (ITGA2B, ITGB3, GP6, GP1A/B), and platelet-derived immune mediators such as PPPB (pro-platelet basic protein) and PF4 (platelet factor 4).
M 1.3	80	Immunoreceptor, BCR, B-cell, IgG	B-cells. Includes genes coding for B-cell surface markers (CD72, CD79A/B, CD19, CD22) and other B-cell associated molecules: Early B-cell factor (EBF), B-cell linker (BLNK) and B lymphoid tyrosine kinase (BLK).
M 1.4	132	Replication, Repression, Repair, CREB, Lymphoid, TNF-alpha	Undetermined. This set includes regulators and targets of cAMP signaling pathway (JUND, ATF4, CREM, PDE4, NR4A2, VIL2), as well as repressors of TNF-alpha mediated NF-KB activation (CYLD, ASK, TNFAIP3).
M 1.5	142	Monocytes, Dendritic, MHC, Costimulatory, TLR4, MYD88	Myeloid lineage. Includes molecules expressed by cells of the myeloid lineage (CD86, CD163, FCGR2A), some of which being involved in pathogen recognition (CD14, TLR2, MYD88). This set also includes TNF family members (TNFR2, BAFF).
M 1.6	141	Zinc, Finger, P53, RAS	Undetermined. This set includes genes coding for signaling molecules, e.g. the zinc finger containing inhibitor of activated STAT (PIAS1 and PIAS2), or the nuclear factor of activated T-cells NFATC3.
M 1.7	129	Ribosome, Translational, 40S, 60S, HLA	MHC/Ribosomal proteins. Almost exclusively formed by genes coding MHC class I molecules (HLA-A,B,C,G,E)+ Beta 2-microglobulin (B2M) or Ribosomal proteins (RPLs, RPSs).
M 1.8	154	Metabolism, Biosynthesis, Replication, Helicase	Undetermined. Includes genes encoding metabolic enzymes (GLS, NSF1, NAT1) and factors involved in DNA replication (PURA, TERF2, EIF2S1).
M 2.1	95	NK, Killer, Cytolytic, CD8, Cell-mediated, T-cell, CTL, IFN-g	Cytotoxic cells. Includes cytotoxic T-cells amd NK-cells surface markers (CD8A, CD2, CD160, NKG7, KLRs), cytolytic molecules (granzyme, perforin, granulysin), chemokines (CCL5, XCL1) and CTL/NK-cell associated molecules (CTSW).
M 2.2	49	Granulocytes, Neutrophils, Defense, Myeloid, Marrow	Neutrophils. This set includes innate molecules that are found in neutrophil granules (Lactotransferrin: LTF, defensin: DEAF1, Bacterial Permeability Increasing protein: BPI, Cathelicidin antimicrobial protein: CAMP...).
M 2.3	148	Erythrocytes, Red, Anemia, Globin, Hemoglobin	Erythrocytes. Includes hemoglobin genes (HGBs) and other erythrocyte-associated genes (erythrocytic alkirin:ANK1, Glycophorin C: GYPC, hydroxymethylbilane synthase: HMBS, erythroid associated factor: ERAF).
M 2.4	133	Ribonucleoprotein, 60S, nucleolus, Assembly, Elongation	Ribosomal proteins. Including genes encoding ribosomal proteins (RPLs, RPSs), Eukaryotic Translation Elongation factor family members (EEFs) and Nucleolar proteins (NPM1, NOAL2, NAP1L1).
M 2.5	315	Adenoma, Interstitial, Mesenchyme, Dendrite, Motor	Undetermined. This module includes genes encoding immune-related (CD40, CD80, CXCL12, IFNA5, IL4R) as well as cytoskeleton-related molecules (Myosin, Dedicator of Cytokenesis, Syndecan 2, Plexin C1, Distrobrevin).
M 2.6	165	Granulocytes, Monocytes, Myeloid, ERK, Necrosis	Myeloid lineage. Includes genes expressed in myeloid lineage cells (IGTB2/CD18, Lymphotoxin beta receptor, Myeloid related proteins 8/14 Formyl peptide receptor 1), such as Monocytes and Neutrophils.
M 2.7	71	No keywords extracted.	Undetermined. This module is largely composed of transcripts with no known function. Only 20 genes associated with literature, including a member of the chemokine-like factor superfamily (CKLFSF8).
M 2.8	141	Lymphoma, T-cell, CD4, CD8, TCR, Thymus, Lymphoid, IL2	T-cells. Includes T-cell surface markers (CD5, CD6, CD7, CD26, CD28, CD96) and molecules expressed by lymphoid lineage cells (lymphotoxin beta, IL2-inducible T-cell kinase, TCF7, T-cell differentiation protein mal, GATA3, STAT5B).
M 2.9	159	ERK, Transactivation, Cytoskeletal, MAPK, JNK	Undetermined. Includes genes encoding molecules that associate to the cytoskeleton (Actin related protein 2/3, MAPK1, MAP3K1, RAB5A). Also present are T-cell expressed genes (FAS, ITGA4/CD49D, ZNF1A1).
M2.10	106	Myeloid, Macrophage, Dendritic, Inflammatory, Interleukin	Undetermined. Includes genes encoding for Immune-related cell surface molecules (CD36, CD86, LILRB), cytokines (IL15) and molecules involved in signaling pathways (FYB, TICAM2-Toll-like receptor pathway).
M 2.11	176	Replication, Repress, RAS, Autophosphorylation, Oncogenic	Undetermined. Includes kinases (UHMK1, CSNK1G1, CDK6, WNK1, TAOK1, CALM2, PRKCI, ITPKB, SRPK2, STK17B, DYRK2, PIK3R1, STK4, CLK4, PKN2) and RAS family members (G3BP, RAB14, RASA2, RAP2A, KRAS).
M 3.1	122	ISRE, Influenza, Antiviral, IFN-gamma, IFN-alpha, Interferon	Interferon-inducible. This set includes interferon-inducible genes: antiviral molecules (OAS1/2/3/L, GBP1, G1P2, EIF2AK2/PKR, MX1, PML), chemokines (CXCL10/IP-10), signaling molecules (STAT1, STAt2, IRF7, ISGF3G).
M 3.2	322	TGF-beta, TNF,	Inflammation I. Includes genes encoding molecules involved
Inflammatory, Apoptotic, Lipopolysaccharide	in inflammatory processes (e.g. IL8, ICAM1, C5R1, CD44, PLAUR, IL1A, CXCL16), and regulators of apoptosis (MCL1, FOX03A, RARA, BCL3/6/2A1, GADD45B).
M 3.3	276	Inflammatory, Defense, Lysosomal, Oxidative, LPS	Inflammation II. Includes molecules inducing or inducible by inflammation (IL18, ALOX5, ANPEP, AOAH, HMOX1, SERPINB1), as well as lysosomal enzymes (PPT1, CTSB/S, NEU1, ASAH1, LAMP2, CAST).
M 3.4	325	Ligase, Kinase, KIP1, Ubiquitin, Chaperone	Undetermined. Includes protein phosphatases (PPP1R12A, PTPRC, PPP1CB, PPM1B) and phosphoinositide 3-kinase (PI3K) family members (PIK3CA, PIK32A, PIP5K3).
M 3.5	22	No keyword extracted	Undetermined. Composed of only a small number of transcripts. Includes hemoglobin genes (HBA1, HBA2, HBB).
M 3.6	288	Ribosomal, T-cell, Beta-catenin	Undetermined. This set includes mitochondrial ribosomal proteins (MRPLs, MRPs), mitochondrial elongations factors (GFM1/2), Sortin Nexins (SN1/6/14) as well as lysosomal ATPases (ATP6V1C/D).
M 3.7	301	Spliceosome, Methylation, Ubiquitin	Undetermined. Includes genes encoding proteasome subunits (PSMA2/5, PSMB5/8); ubiquitin protein ligases HIP2, STUB1, as well as components ofubiqutin ligase complexes (SUGT1).
M 3.8	284	CDC, TCR, CREB, Glycosylase	Undetermined. Includes genes encoding enzymes: aminomethyltransferase, arginyltransferase, asparagines synthetase, diacylglycerol kinase, inositol phosphatases, methyltransferases, helicases...
M 3.9	260	Chromatin, Checkpoint, Replication, Transactivation	Undetermined. Includes genes encoding kinases (IBTK, PRKRIR, PRKDC, PRKCI) and phosphatases (e.g. PTPLB, PPP2CB/3CB, PTPRC, MTM1, MTMR2).

As used herein, the term "array" refers to a solid support or substrate with one or more peptides or nucleic acid probes attached to the support. Arrays typically have one or more different nucleic acid or peptide probes that are coupled to a surface of a substrate in different, known locations. These arrays, also described as "microarrays", "gene-chips" or DNA chips that may have 10,000; 20,000, 30,000; or 40,000 different identifiable genes based on the known genome, e.g., the human genome. These pan-arrays are used to detect the entire "transcriptome" or transcriptional pool of genes that are expressed or found in a sample, e.g., nucleic acids that are expressed as RNA, mRNA and the like that may be subjected to RT and/or RT-PCR to made a complementary set of DNA replicons. Arrays may be produced using mechanical synthesis methods, light directed synthesis methods and the like that incorporate a combination of non-lithographic and/or photolithographic methods and solid phase synthesis methods. Bead arrays that include 50-mer oligonucleotide probes attached to 3 micrometer beads may be used that are, e.g., lodged into microwells at the surface of a glass slide or are part of a liquid phase suspension arrays (e.g., Luminex or Illumina) that are digital beadarrays in liquid phase and uses "barcoded" glass rods for detection and identification.

Various techniques for the synthesis of these nucleic acid arrays have been described, e.g., fabricated on a surface of virtually any shape or even a multiplicity of surfaces. Arrays may be peptides or nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass or any other appropriate substrate. Arrays may be packaged in such a manner as to allow for diagnostics or other manipulation of an all inclusive device, see for example, U.S. Pat. No. 6,955,788 .

BIOLOGICAL DEFINITIONS

As used herein, the term "disease" refers to a physiological state of an organism with any abnormal biological state of a cell. Disease includes, but is not limited to, an interruption, cessation or disorder of cells, tissues, body functions, systems or organs that may be inherent, inherited, caused by an infection, caused by abnormal cell function, abnormal cell division and the like. A disease that leads to a "disease state" is generally detrimental to the biological system, that is, the host of the disease. With respect to the present invention, any biological state, such as an infection (e.g., viral, bacterial, fungal, helminthic, etc.), inflammation, autoinflammation, autoimmunity, anaphylaxis, allergies, premalignancy, malignancy, surgical, transplantation, physiological, and the like that is associated with a disease or disorder is considered to be a disease state. A pathological state is generally the equivalent of a disease state.

Disease states may also be categorized into different levels of disease state. As used herein, the level of a disease or disease state is an arbitrary measure reflecting the progression of a disease or disease state as well as the physiological response upon, during and after treatment. Generally, a disease or disease state will progress through levels or stages, wherein the affects of the disease become increasingly severe. The level of a disease state may be impacted by the physiological state of cells in the sample.

As used herein, the terms "therapy" or "therapeutic regimen" refer to those medical steps taken to alleviate or alter a disease state, e.g., a course of treatment intended to reduce or eliminate the affects or symptoms of a disease using pharmacological, surgical, dietary and/or other techniques. A therapeutic regimen may include a prescribed dosage of one or more drugs or surgery. Therapies will most often be beneficial and reduce the disease state but in many instances the effect of a therapy will have non-desirable or side-effects. The effect of therapy will also be impacted by the physiological state of the host, e.g., age, gender, genetics, weight, other disease conditions, etc.

As used herein, the term "pharmacological state" or "pharmacological status" refers to those samples that will be, are and/or were treated with one or more drugs, surgery and the like that may affect the pharmacological state of one or more nucleic acids in a sample, e.g., newly transcribed, stabilized and/or destabilized as a result of the pharmacological intervention. The pharmacological state of a sample relates to changes in the biological status before, during and/or after drug treatment and may serve a diagnostic or prognostic function, as taught herein. Some changes following drug treatment or surgery may be relevant to the disease state and/or may be unrelated side-effects of the therapy. Changes in the pharmacological state are the likely results of the duration of therapy, types and doses of drugs prescribed, degree of compliance with a given course of therapy, and/or un-prescribed drugs ingested.

As used herein, the term "biological state" refers to the state of the transcriptome (that is the entire collection of RNA transcripts) of the cellular sample isolated and purified for the analysis of changes in expression. The biological state reflects the physiological state of the cells in the sample by measuring the abundance and/or activity of cellular constituents, characterizing according to morphological phenotype or a combination of the methods for the detection of transcripts.

As used herein, the term "expression profile" refers to the relative abundance of RNA, DNA or protein abundances or activity levels. The expression profile can be a measurement for example of the transcriptional state or the translational state by any number of methods and using any of a number of gene-chips, gene arrays, beads, multiplex PCR, quantitiative PCR, run-on assays, Northern blot analysis, Western blot analysis, protein expression, fluorescence activated cell sorting (FACS), enzyme linked immunosorbent assays (ELISA), chemiluminescence studies, enzymatic assays, proliferation studies or any other method, apparatus and system for the determination and/or analysis of gene expression that are readily commercially available.

As used herein, the term "transcriptional state" of a sample includes the identities and relative abundances of the RNA species, especially mRNAs present in the sample. The entire transcriptional state of a sample, that is the combination of identity and abundance of RNA, is also referred to herein as the transcriptome. Generally, a substantial fraction of all the relative constituents of the entire set of RNA species in the sample are measured.

As used herein, the term "transcriptional vectors," "expression vectors," "genomic vectors" (used interchangeably) refers to transcriptional expression data that reflects the "proportion of differentially expressed genes." For example, for each module the proportion of transcripts differentially expressed between at least two groups (e.g., healthy subjects versus patients). This vector is derived from the comparison of two groups of samples. The first analytical step is used for the selection of disease-specific sets of transcripts within each module. Next, there is the "expression level." The group comparison for a given disease provides the list of differentially expressed transcripts for each module. It was found that different diseases yield different subsets of modular transcripts. With this expression level it is then possible to calculate vectors for each module(s) for a single sample by averaging expression values of disease-specific subsets of genes identified as being differentially expressed. This approach permits the generation of maps of modular expression vectors for a single sample, e.g., those described in the module maps disclosed herein. These vector module maps represent an averaged expression level for each module (instead of a proportion of differentially expressed genes) that can be derived for each sample. These composite "expression vectors" are formed through successive rounds of selection: 1) of the modules that were significantly changed across study groups and 2) of the genes within these modules which are significantly changed across study groups (Figure 2, step II). Expression levels are subsequently derived by averaging the values obtained for the subset of transcripts forming each vector (Figure 2, step III). Patient profiles can then be represented by plotting expression levels obtained for each of these vectors on a graph (e.g. on a radar plot). Therefore a set of vectors results from two round of selection, first at the module level, and then at the gene level. Vector expression values are composite by construction as they derive from the average expression values of the transcript forming the vector.

Using the present invention it is possible to identify and distinguish diseases not only at the module-level, but also at the gene-level; i.e., two diseases can have the same vector (identical proportion of differentially expressed transcripts, identical "polarity"), but the gene composition of the expression vector can still be disease-specific. This disease-specific customization permits the user to optimize the performance of a given set of markers by increasing its specificity.

Using modules as a foundation grounds expression vectors to coherent functional and transcriptional units containing minimized amounts of noise. Furthermore, the present invention takes advantage of composite transcriptional markers. As used herein, the term "composite transcriptional markers" refers to the average expression values of multiple genes (subsets of modules) as compared to using individual genes as markers (and the composition of these markers can be disease-specific). The composite transcriptional markers approach is unique because the user can develop multivariate microarray scores to assess disease severity in patients with, e.g., SLE, or to derive expression vectors disclosed herein. The fact that expression vectors are composite (i.e. formed by a combination of transcripts) further contributes to the stability of these markers. Most importantly, it has been found that using the composite modular transcriptional markers of the present invention the results found herein are reproducible across microarray platform, thereby providing greater reliability for regulatory approval. Indeed, vector expression values proved remarkably robust, as indicated by the excellent reproducibility obtained across microarray platforms; as well as the validation results obtained in an independent set of pediatric lupus patients. These results are of importance since improving the reliability of microarray data is a prerequisite for the widespread use of this technology in clinical practice.

Gene expression monitoring systems for use with the present invention may include customized gene arrays with a limited and/or basic number of genes that are specific and/or customized for the one or more target diseases. Unlike the general, pan-genome arrays that are in customary use, the present invention provides for not only the use of these general pan-arrays for retrospective gene and genome analysis without the need to use a specific platform, but more importantly, it provides for the development of customized arrays that provide an optimal gene set for analysis without the need for the thousands of other, non-relevant genes. One distinct advantage of the optimized arrays and modules of the present invention over the existing art is a reduction in the financial costs (e.g., cost per assay, materials, equipment, time, personnel, training, etc.), and more importantly, the environmental cost of manufacturing pan-arrays where the vast majority of the data is irrelevant. The modules of the present invention allow for the first time the design of simple, custom arrays that provide optimal data with the least number of probes while maximizing the signal to noise ratio. By eliminating the total number of genes for analysis, it is possible to, e.g., eliminate the need to manufacture thousands of expensive platinum masks for photolithography during the manufacture of pan-genetic chips that provide vast amounts of irrelevant data. Using the present invention it is possible to completely avoid the need for microarrays if the limited probe set(s) of the present invention are used with, e.g., digital optical chemistry arrays, ball bead arrays, beads (e.g., Luminex), multiplex PCR, quantitiative PCR, run-on assays, Northern blot analysis, or even, for protein analysis, e.g., Western blot analysis, 2-D and 3-D gel protein expression, MALDI, MALDI-TOF, fluorescence activated cell sorting (FACS) (cell surface or intracellular), enzyme linked immunosorbent assays (ELISA), chemiluminescence studies, enzymatic assays, proliferation studies or any other method, apparatus and system for the determination and/or analysis of gene expression that are readily commercially available.

The "molecular fingerprinting system" of the present invention may be used to facilitate and conduct a comparative analysis of expression in different cells or tissues, different subpopulations of the same cells or tissues, different physiological states of the same cells or tissue, different developmental stages of the same cells or tissue, or different cell populations of the same tissue against other diseases and/or normal cell controls. In some cases, the normal or wild-type expression data may be from samples analyzed at or about the same time or it may be expression data obtained or culled from existing gene array expression databases, e.g., public databases such as the NCBI Gene Expression Omnibus database.

As used herein, the term "differentially expressed" refers to the measurement of a cellular constituent (e.g., nucleic acid, protein, enzymatic activity and the like) that varies in two or more samples, e.g., between a disease sample and a normal sample. The cellular constituent may be on or off (present or absent), upregulated relative to a reference or downregulated relative to the reference. For use with gene-chips or gene-arrays, differential gene expression of nucleic acids, e.g., mRNA or other RNAs (miRNA, siRNA, hnRNA, rRNA, tRNA, etc.) may be used to distinguish between cell types or nucleic acids. Most commonly, the measurement of the transcriptional state of a cell is accomplished by quantitative reverse transcriptase (RT) and/or quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), genomic expression analysis, post-translational analysis, modifications to genomic DNA, translocations, in situ hybridization and the like.

For some disease states it is possible to identify cellular or morphological differences, especially at early levels of the disease state. The present invention avoids the need to identify those specific mutations or one or more genes by looking at modules of genes of the cells themselves or, more importantly, of the cellular RNA expression of genes from immune effector cells that are acting within their regular physiologic context, that is, during immune activation, immune tolerance or even immune anergy. While a genetic mutation may result in a dramatic change in the expression levels of a group of genes, biological systems often compensate for changes by altering the expression of other genes. As a result of these internal compensation responses, many perturbations may have minimal effects on observable phenotypes of the system but profound effects to the composition of cellular constituents. Likewise, the actual copies of a gene transcript may not increase or decrease, however, the longevity or half-life of the transcript may be affected leading to greatly increases protein production. The present invention eliminates the need of detecting the actual message by, in one embodiment, looking at effector cells (e.g., leukocytes, lymphocytes and/or sub-populations thereof) rather than single messages and/or mutations.

The skilled artisan will appreciate readily that samples may be obtained from a variety of sources including, e.g., single cells, a collection of cells, tissue, cell culture and the like. In certain cases, it may even be possible to isolate sufficient RNA from cells found in, e.g., urine, blood, saliva, tissue or biopsy samples and the like. In certain circumstances, enough cells and/or RNA may be obtained from: mucosal secretion, feces, tears, blood plasma, peritoneal fluid, interstitial fluid, intradural, cerebrospinal fluid, sweat or other bodily fluids. The nucleic acid source, e.g., from tissue or cell sources, may include a tissue biopsy sample, one or more sorted cell populations, cell culture, cell clones, transformed cells, biopies or a single cell. The tissue source may include, e.g., brain, liver, heart, kidney, lung, spleen, retina, bone, neural, lymph node, endocrine gland, reproductive organ, blood, nerve, vascular tissue, and olfactory epithelium.

The present invention includes the following basic components, which may be used alone or in combination, namely, one or more data mining algorithms; one or more module-level analytical processes; the characterization of blood leukocyte transcriptional modules; the use of aggregated modular data in multivariate analyses for the molecular diagnostic/prognostic of human diseases; and/or visualization of module-level data and results. Using the present invention it is also possible to develop and analyze composite transcriptional markers, which may be further aggregated into a single multivariate score.

The present inventors have recognized that current microarray-based research is facing significant challenges with the analysis of data that are notoriously "noisy," that is, data that is difficult to interpret and does not compare well across laboratories and platforms. A widely accepted approach for the analysis of microarray data begins with the identification of subsets of genes differentially expressed between study groups. Next, the users try subsequently to "make sense" out of resulting gene lists using pattern discovery algorithms and existing scientific knowledge.

Rather than deal with the great variability across platforms, the present inventors have developed a strategy that emphasized the selection of biologically relevant genes at an early stage of the analysis. Briefly, the method includes the identification of the transcriptional components characterizing a given biological system for which an improved data mining algorithm was developed to analyze and extract groups of coordinately expressed genes, or transcriptional modules, from large collections of data.

The biomarker discovery strategy described herein is particularly well adapted for the exploitation of microarray data acquired on a global scale. Starting from ~44,000 transcripts a set of 28 modules was defined that are composed of nearly 5000 transcripts. Sets of disease-specific composite expression vectors were then derived. Vector expression values (expression vectors) proved remarkably robust, as indicated by the excellent reproducibility obtained across microarray platforms. This finding is notable, since improving the reliability of microarray data is a prerequisite for the widespread use of this technology in clinical practice. Finally, expression vectors can in turn be combined to obtain unique multivariate scores, therefore delivering results in a form that is compatible with mainstream clinical practice. Interestingly, multivariate scores recapitulate global patterns of change rather than changes in individual markers. The development of such "global biomarkers" can be used for both diagnostic and pharmacogenomics fields.

In one example, twenty-eight transcriptional modules regrouping 4742 probe sets were obtained from 239 blood leukocyte transcriptional profiles. Functional convergence among genes forming these modules was demonstrated through literature profiling. The second step consisted of studying perturbations of transcriptional systems on a modular basis. To illustrate this concept, leukocyte transcriptional profiles obtained from healthy volunteers and patients were obtained, compared and analyzed. Further validation of this gene fingerprinting strategy was obtained through the analysis of a published microarray dataset. Remarkably, the modular transcriptional apparatus, system and methods of the present invention using pre-existing data showed a high degree of reproducibility across two commercial microarray platforms.

The present invention includes the implementation of a widely applicable, two-step microarray data mining strategy designed for the modular analysis of transcriptional systems. This novel approach was used to characterize transcriptional signatures of blood leukocytes, which constitutes the most accessible source of clinically relevant information.

As demonstrated herein, it is possible to determine, differential and/or distinguish between two disease based on two vectors even if the vector is identical (+/+) for two diseases - e.g. M1.3 = 53% down for both SLE and FLU because the composition of each vector can still be used to differentiate them. For example, even though the proportion and polarity of differentially expressed transcripts is identical between the two diseases for M1.3, the gene composition can still be disease-specific. The combination of gene-level and module-level analysis considerably increases resolution. Furthermore, it is possible to use 2, 3, 4, 5, 10, 15, 20, 25, 28 or more modules to differentiate diseases.

The term "gene" refers to a nucleic acid (e.g., DNA) sequence that includes coding sequences necessary for the production of a polypeptide (e.g., ), precursor, or RNA (e.g., mRNA). The polypeptide may be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional property (e.g., enzymatic activity, ligand binding, signal transduction, immunogenicity, etc.) of the full-length or fragment is retained. The term also encompasses the coding region of a structural gene and the sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 2 kb or more on either end such that the gene corresponds to the length of the full-length mRNA and 5' regulatory sequences which influence the transcriptional properties of the gene. Sequences located 5' of the coding region and present on the mRNA are referred to as 5'-untranslated sequences. The 5'-untranslated sequences usually contain the regulatory sequences. Sequences located 3' or downstream of the coding region and present on the mRNA are referred to as 3'-untranslated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed "introns" or "intervening regions" or "intervening sequences." Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or "spliced out" from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

As used herein, the term "nucleic acid" refers to any nucleic acid containing molecule, including but not limited to, DNA, cDNA and RNA. In particular, the terms "a gene in Table X" refers to at least a portion or the full-length sequence listed in a particular table, as found hereinbelow. The gene may even be found or detected a genomic form, that is, it includes one or more intron(s). Genomic forms of a gene may also include sequences located on both the 5' and 3' end of the coding sequences that are present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions. The 5' flanking region may contain regulatory sequences such as promoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain sequences that influence the transcription termination, post-transcriptional cleavage, mRNA stability and polyadenylation.

As used herein, the term "wild-type" refers to a gene or gene product isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal" or "wild-type" form of the gene. In contrast, the term "modified" or "mutant" refers to a gene or gene product that displays modifications in sequence and/or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally occurring mutants can be isolated; these are identified by the fact that they have altered characteristics (including altered nucleic acid sequences) when compared to the wild-type gene or gene product.

As used herein, the term "polymorphism" refers to the regular and simultaneous occurrence in a single interbreeding population of two or more alleles of a gene, where the frequency of the rarer alleles is greater than can be explained by recurrent mutation alone (typically greater than 1%).

As used herein, the terms "nucleic acid molecule encoding," "DNA sequence encoding," and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide protein) chain. The DNA sequence thus codes for the amino acid sequence.

As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (i.e., a sequence of nucleotides) related by the base-pairing rules. For example, the sequence "A-G-T," is complementary to the sequence "T-C-A." Complementarity may be "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods that depend upon binding between nucleic acids.

As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the T_m of the formed hybrid, and the G:C ratio within the nucleic acids. A single molecule that contains pairing of complementary nucleic acids within its structure is said to be "self-hybridized."

As used herein the term "stringency" is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. Under "low stringency conditions" a nucleic acid sequence of interest will hybridize to its exact complement, sequences with single base mismatches, closely related sequences (e.g., sequences with 90% or greater homology), and sequences having only partial homology (e.g., sequences with 50-90% homology). Under "medium stringency conditions," a nucleic acid sequence of interest will hybridize only to its exact complement, sequences with single base mismatches, and closely related sequences (e.g., 90% or greater homology). Under "high stringency conditions," a nucleic acid sequence of interest will hybridize only to its exact complement, and (depending on conditions such a temperature) sequences with single base mismatches. In other words, under conditions of high stringency the temperature can be raised so as to exclude hybridization to sequences with single base mismatches.

As used herein, the term "probe" refers to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. Any probe used in the present invention may be labeled with any "reporter molecule," so that it is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, luminescent systems and the like. It is not intended that the present invention be limited to any particular detection system or label.

As used herein, the term "target," refers to the region of nucleic acid bounded by the primers. Thus, the "target" is sought to be sorted out from other nucleic acid sequences. A "segment" is defined as a region of nucleic acid within the target sequence.

As used herein, the term "Southern blot" refers to the analysis of DNA on agarose or acrylamide gels to fractionate the DNA according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized DNA is then probed with a labeled probe to detect DNA species complementary to the probe used. The DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support. Southern blots are a standard tool of molecular biologists (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp 9.31-9.58, 1989).

As used herein, the term "Northern blot" refers to the analysis of RNA by electrophoresis of RNA on agarose gels, to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists (Sambrook, et al., supra, pp 7.39-7.52, 1989).

As used herein, the term "Western blot" refers to the analysis of protein(s) (or polypeptides) immobilized onto a support such as nitrocellulose or a membrane. The proteins are run on acrylamide gels to separate the proteins, followed by transfer of the protein from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized proteins are then exposed to antibodies with reactivity against an antigen of interest. The binding of the antibodies may be detected by various methods, including the use of radiolabeled antibodies.

As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K. B. Mullis (U.S. Pat. Nos. 4,683,195 4,683,202 , and 4,965,188 ), which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified".

As used herein, the terms "PCR product," "PCR fragment," and "amplification product" refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.

As used herein, the term "real time PCR" as used herein, refers to various PCR applications in which amplification is measured during as opposed to after completion of the reaction. Reagents suitable for use in real time PCR embodiments of the present invention include but are not limited to TaqMan probes, molecular beacons, Scorpions primers or double-stranded DNA binding dyes.

As used herein, the term "transcriptional upregulation" as used herein refers to an increase in synthesis of RNA, by RNA polymerases using a DNA template. For example, when used in reference to the methods of the present invention, the term "transcriptional upregulation" refers to an increase of least 1 to 2 fold, 2 to 3 fold, 3 to 10 fold, and even greater than 10 fold, in the quantity of mRNA corresponding to a gene of interest detected in a sample derived from an individual predisposed to SLE as compared to that detected in a sample derived from an individual who is not predisposed to SLE. However, the system and evaluation is sufficiently specific to require less that a 2 fold change in expression to be detected. Furthermore, the change in expression may be at the cellular level (change in expression within a single cell or cell populations) or may even be evaluated at a tissue level, where there is a change in the number of cells that are expressing the gene. Particularly useful differences are those that are statistically significant.

Conversely, the term "transcriptional downregulation" refers to a decrease in synthesis of RNA, by RNA polymerases using a DNA template. For example, when used in reference to the methods of the present invention, the term "transcriptional downregulation" refers to a decrease of least 2 fold, 2 to 3 fold, 3 to 10 fold, and even greater than 10 fold, in the quantity of mRNA corresponding to a gene of interest detected in a sample derived from an individual predisposed to SLE as compared to that detected in a sample derived from an individual who is not predisposed to such a condition or to a database of information for wild-type and/or normal control, e.g., fibromyalgia. Again, the system and evaluation is sufficiently specific to require less that a 2 fold change in expression to be detected. Particularly useful differences are those that are statistically significant.

Both transcriptional "upregulation"/overexpression and transcriptional "downregulation"/underexpression may also be indirectly monitored through measurement of the translation product or protein level corresponding to the gene of interest. The present invention is not limited to any given mechanism related to upregulation or downregulation of transcription.

The term "eukaryotic cell" as used herein refers to a cell or organism with membrane-bound, structurally discrete nucleus and other well-developed subcellular compartments. Eukaryotes include all organisms except viruses, bacteria, and bluegreen algae.

As used herein, the term "in vitro transcription" refers to a transcription reaction comprising a purified DNA template containing a promoter, ribonucleotide triphosphates, a buffer system that includes a reducing agent and cations, e.g., DTT and magnesium ions, and an appropriate RNA polymerase, which is performed outside of a living cell or organism.

As used herein, the term "amplification reagents" refers to those reagents (deoxyribonucleotide triphosphates, buffer, etc.), needed for amplification except for primers, nucleic acid template and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).

As used herein, the term "diagnosis" refers to the determination of the nature of a case of disease. In some embodiments of the present invention, methods for making a diagnosis are provided which permit determination of SLE.

The present invention may be used alone or in combination with disease therapy to monitor disease progression and/or patient management. For example, a patient may be tested one or more times to determine the best course of treatment, determine if the treatment is having the intended medical effect, if the patient is not a candidate for that particular therapy and combinations thereof. The skilled artisan will recognize that one or more of the expression vectors may be indicative of one or more diseases and may be affected by other conditions, be they acute or chronic.

As used herein, the term "pharmacogenetic test" refers to an assay intended to study interindividual variations in DNA sequence related to, e.g., drug absorption and disposition (pharmacokinetics) or drug action (pharmacodynamics), which may include polymorphic variations in one or more genes that encode the functions of, e.g., transporters, metabolizing enzymes, receptors and other proteins.

As used herein, the term "pharmacogenomic test" refers to an assay used to study interindividual variations in whole-genome or candidate genes, e.g., single-nucleotide polymorphism (SNP) maps or haplotype markers, and the alteration of gene expression or inactivation that may be correlated with pharmacological function and therapeutic response.

As used herein, an "expression profile" refers to the measurement of the relative abundance of a plurality of cellular constituents. Such measurements may include, e.g., RNA or protein abundances or activity levels. The expression profile can be a measurement for example of the transcriptional state or the translational state. See U.S. Pat. Nos. 6,040,138 , 5,800,992 , 6,020,135 , 6,033,860 . The gene expression monitoring system, include nucleic acid probe arrays, membrane blot (such as used in hybridization analysis such as Northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See, e.g., U.S. Pat. Nos. 5,770,722 , 5,874,219 , 5,744,305 , 5,677,195 and 5,445,934 . The gene expression monitoring system may also comprise nucleic acid probes in solution.

The gene expression monitoring system according to the present invention may be used to facilitate a comparative analysis of expression in different cells or tissues, different subpopulations of the same cells or tissues, different physiological states of the same cells or tissue, different developmental stages of the same cells or tissue, or different cell populations of the same tissue.

As used herein, the term "differentially expressed: refers to the measurement of a cellular constituent varies in two or more samples. The cellular constituent can be either up-regulated in the test sample relative to the reference or down-regulated in the test sample relative to one or more references. Differential gene expression can also be used to distinguish between cell types or nucleic acids. See U.S. Pat. No. 5,800,992 .

Therapy or Therapeutic Regimen: In order to alleviate or alter a disease state, a therapy or therapeutic regimen is often undertaken. A therapy or therapeutic regimen, as used herein, refers to a course of treatment intended to reduce or eliminate the affects or symptoms of a disease. A therapeutic regimen will typically comprise, but is not limited to, a prescribed dosage of one or more drugs or surgery. Therapies, ideally, will be beneficial and reduce the disease state but in many instances the effect of a therapy will have non-desirable effects as well. The effect of therapy will also be impacted by the physiological state of the sample.

Modules display distinct "transcriptional behavior". It is widely assumed that co-expressed genes are functionally linked. This concept of "guilt by association" is particularly compelling in cases where genes follow complex expression patterns across many samples. The present inventors discovered that transcriptional modules form coherent biological units and, therefore, predicted that the co-expression properties identified in the initial dataset would be conserved in an independent set of samples. Data were obtained for PBMCs isolated from the blood of twenty-one healthy volunteers. These samples were not used in the module selection process described above.

The biomarker discovery strategy that we have developed is particularly well adapted for the exploitation of microarray data acquired on a global scale. Starting from ~44,000 transcripts the inventors defined 28 modules composed of nearly 5000 transcripts. Sets of disease-specific composite expression vectors were then derived. Vector expression values proved remarkably robust, as indicated by the excellent reproducibility obtained across microarray platforms. This finding is notable, since improving the reliability of microarray data is a prerequisite for the widespread use of this technology in clinical practice. Finally, vectors can in turn be combined to obtain unique multivariate scores, therefore delivering results in a form that is compatible with mainstream clinical practice. Interestingly, multivariate scores recapitulate global patterns of change rather than changes in individual markers. The development of such "global biomarkers" constitutes therefore a promising prospect for both diagnostic and pharmacogenomics fields.

Material and methods. Processing of blood samples. All blood samples were collected in acid citrate dextrose tubes (BD Vacutainer) and immediately delivered at room temperature to the Baylor Institute for Immunology Research, Dallas, TX, for processing. Peripheral blood mononuclear cells (PBMCs) from 3-4 ml of blood were isolated via Ficoll gradient and immediately lysed in RLT reagent (Qiagen, Valencia, CA) with beta-mercaptoethanol (BME) and stored at -80°C prior to the RNA extraction step.

Microarray analysis. Total RNA was isolated using the RNeasy kit (Qiagen) according to the manufacturer's instructions and RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA).

Affymetrix GeneChips: These microarrays include short oligonucleotide probe sets synthesized in situ on a quartz wafer. Target labeling was performed according to the manufacturer's standard protocol (Affymetrix Inc., Santa Clara, CA). Biotinylated cRNA targets were purified and subsequently hybridized to Affymetrix HG-U133A and U133B GeneChips (>44,000 probe sets). Arrays were scanned using an Affymetrix confocal laser scanner. Microarray Suite, Version 5.0 (MAS 5.0; Affymetrix) software was used to assess fluorescent hybridization signals, to normalize signals, and to evaluate signal detection calls. Normalization of signal values per chip was achieved using the MAS 5.0 global method of scaling to the target intensity value of 500 per GeneChip. A gene expression analysis software program, GeneSpring, Version 7.1 (Agilent), was used to perform statistical analysis and hierarchical clustering.

Illumina BeadChips: These microarrays include 50mer oligonucleotide probes attached to 3µm beads, which are lodged into microwells at the surface of a glass slide. Samples were processed and acquired by Illumina Inc. (San Diego, CA) on the basis of a service contract. Targets were prepared using the Illumina RNA amplification kit (Ambion, Austin, TX). cRNA targets were hybridized to Sentrix HumanRef8 BeadChips (>25,000 probes), which were scanned on an Illumina BeadStation 500. Illumina's Beadstudio software was used to assess fluorescent hybridization signals.

Literature profiling. The literature profiling algorithm employed in this study has been previously described in detail (Chaussabel, D. & Sher, A. Mining microarray expression data by literature profiling. Genome Biol 3, RESEARCH0055 (2002)). This approach links genes sharing similar keywords. It uses hierarchical clustering, a popular unsupervised pattern discovery algorithm, to analyze patterns of term occurrence in literature abstracts. Step 1: A gene:literature index identifying pertinent publications for each gene is created. Step 2: Term occurrence frequencies were computed by a text processor. Step 3: Stringent filter criteria are used to select relevant keywords (i.e., eliminate terms with either high or low frequency across all genes and retain the few discerning terms characterized by a pattern of high occurrence for only a few genes). Step 4: Two-way hierarchical clustering groups of genes and relevant keywords based on occurrence patterns, providing a visual representation of functional relationships existing among a group of genes.

Modular data mining algorithm. First, one or more transcriptional components are identified that permit the characterization of biological systems beyond the level of single genes. Sets of coordinately regulated genes, or transcriptional modules, were extracted using a novel mining algorithm, which was applied to a large set of blood leukocyte microarray profiles (Figure 1). Gene expression profiles from a total of 239 peripheral blood mononuclear cells (PBMCs) samples were generated using Affymetrix U133A&B GeneChips (>44,000 probe sets). Transcriptional data were obtained for eight experimental groups (systemic juvenile idiopathic arthritis, systemic lupus erythematosus, type I diabetes, liver transplant recipients, melanoma patients, and patients with acute infections: Escherichia coli, Staphylococcus aureus and influenza A). For each group, transcripts with an absent flag call across all conditions were filtered out. The remaining genes were distributed among thirty sets by hierarchical clustering (clusters C1 through C30). The cluster assignment for each gene was recorded in a table and distribution patterns were compared among all the genes. Modules were selected using an iterative process, starting with the largest set of genes that belonged to the same cluster in all study groups (i.e. genes that were found in the same cluster in eight of the eight experimental groups). The selection was then expanded from this core reference pattern to include genes with 7/8, 6/8 and 5/8 matches. The resulting set of genes formed a transcriptional module and was withdrawn from the selection pool. The process was then repeated starting with the second largest group of genes, progressively reducing the level of stringency. This analysis led to the identification of 5348 transcripts that were distributed among twenty-eight modules (a complete list is provided as supplementary material). Each module is assigned a unique identifier indicating the round and order of selection (i.e. M3.1 was the first module identified in the third round of selection).

Analysis of "significance patterns" was performed on gene expression data generated from PBMCs obtained from patients and healthy volunteers using Affymetrix HG-U133A GeneChips that were run on the same Affymetrix system, using standard operating procedures. P values were obtained by comparing 7 groups of patients to their respective healthy control groups (Mann-Whitney rank test). The groups were composed of pediatric patients with: 1) Systemic Lupus Erythomatosus (SLE, 16 samples), 2) Influenza A (16 samples), 3) Staphylococcus aureus (16 samples), 4) Escherichia coli (16 samples) and 5) Streptococcus pneumoniae (14 samples); as well as adult transplant recipients: 6) Liver transplant patients that have accepted the graft under immunosuppressive therapy (16 samples) and 7) bone marrow transplant recipients undergoing graft versus host disease (GVHD, 12 samples). Control groups were also formed taking into account age, sex and project (10 samples in each group). Genes significantly changed (p<0.01) in the "study group" (Influenza A and/or SLE) were divided in two sets: over-expressed versus control and under-expressed versus control. P-values of the genes forming the over-expressed set were obtained for the "reference groups" (infections with E. coli, S. aureus, S. pneumoniae, Liver transplant recipients and graft versus host disease). P-values of the reference groups were set to 1 when genes were under-expressed. The same procedure was used in the set of genes under-expressed in study group, only this time P-values of the reference group were set to 1 when genes were over-expressed. P-value data were processed with a gene expression analysis software program, GeneSpring, Version 7.1 (Agilent), that was used to perform hierarchical clustering and group genes based on significance patterns.

FIGURE 2 shows gene expression profiles of four different modules are shown (Figure 2: M1.2, M1.7, M2.11 and M2.1). In the graphs of Figure 2, each line represents the expression level (y-axis) of a single gene across multiple samples (21 samples on the x-axis). Differences in gene expression in this example represent inter-individual variation between "healthy" individuals. It was found that within each module genes display a coherent "transcriptional behavior". Indeed, the variation in gene expression appeared to be consistent across all the samples (for some samples the expression of all the genes was elevated and formed a peak, while in others levels were low for all the genes which formed a dip). Importantly, inter-individual variations appeared to be module-specific as peaks and dips formed for different samples in M1.2, M2.11 and M2.1. Furthermore, the amplitude of variation was also characteristic of each module, with levels of expression being more variable for M1.2 and M2.11 than M2.1 and especially M1.7. Thus, we find that transcriptional modules constitute independent biological variables.

Functional characterization of transcriptional modules. Next, the modules were characterized at a functional level. A text mining approach was employed to extract keywords from the biomedical literature collected for each gene (described in ¹⁸). The distribution of keywords associated to the four modules that were analyzed is clearly distinct (Figure 3). The following is a list of keywords that may be associated with certain modules.

Keywords highly specific for M1.2 included Platelet, Aggregation or Thrombosis, and were associated with genes such as ITGA2B (Integrin alpha 2b, platelet glycoprotein IIb), PF4 (platelet factor 4), SELP (Selectin P) and GP6 (platelet glycoprotein 6).
Keywords highly specific for M1.3 included B-cell, Immunoglobulin or IgG and were associated with genes such as CD19, CD22, CD72A, BLNK (B cell linker protein), BLK (B lymphoid tyrosine kinase) and PAX5 (paired box gene 5, a B-cell lineage specific activator).
Keywords highly specific for M1.5 included Monocyte, Dendritic, CD14 or Toll-like and were associated with genes such as MYD88 (myeloid differentiation primary response gene 88), CD86, TLR2 (Toll-like receptor 2), LILRB2 (leukocyte immunoglobulin-like receptor B2) and CD163.
Keywords highly specific for M3.1 included Interferon, IFN-alpha, Antiviral, or ISRE and were associated with genes such as STAT1 (signal transducer and activator of transcription 1), CXCL10 (CXC chemokine ligand 10, IP-10), OAS2 (oligoadenylate synthetase 2) and MX2 (myxovirus resistance 2).

This contrasted pattern of term occurrence denotes the remarkable functional coherence of each module. Information extracted from the literature for all the modules that have been identified permit a comprehensive functional characterization of the PBMC system at a transcriptional level. Table 2 provides an example of genes that may be used to distinguish between immune responses to, e.g., melanoma and liver transplant.

Table 2: Genes in Module 1.4 Used to Distinguish Immune Responses


1.4	55544	RNPC1	RNA-binding region (RNP1, RRM) containing 1
1.4	5930	RBBP6	retinoblastoma binding protein 6
1.4	80273	GRPEL1
1.4	57162	PELI1	pellino homolog 1 (Drosophila)
1.4	9921	RNF10	ring finger protein 10 /// ring finger protein 10
1.4	90637	LOC90637	hypothetical protein LOC90637
1.4	80314	EPC1	Enhancer of polycomb homolog 1 (Drosophila)
1.4	---	---	Full length insert cDNA clone ZB81B12
1.4	5756	PTK9	PTK9 protein tyrosine kinase 9
1.4	55038	CDCA4	cell division cycle associated 4
1.4	5187	PER1	period homolog 1 (Drosophila)
1.4	9205	ZNF237	zinc finger protein 237
1.4	25976	TIPARP	TCDD-inducible poly(ADP-ribose) polymerase
1.4	57018	CCNL1	cyclin L1
1.4	64061	TSPYL2	TSPY-like 2
1.4	81488	GRINL1A	glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A
1.4	22850	KIAA0863	KIAA0863 protein
1.4	23764	MAFF	v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)
1.4	29035	PRO0149	PRO0149 protein
1.4	7803	PTP4A1	protein tyrosine phosphatase type IVA, member 1
1.4	11171	STRAP	serine/threonine kinase receptor associated protein
1.4	5814	PURB	purine-rich element binding protein B
1.4	5142	PDE4B	phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)
1.4	30836	ERBP	estrogen receptor binding protein
1.4	6782	STCH	stress 70 protein chaperone, microsome-associated, 60kDa
1.4	10950	BTG3	BTG family, member 3
1.4	7037	TFRC	transferrin receptor (p90, CD71)
1.4	54934	FLJ20436	hypothetical protein FLJ20436
1.4	5144	PDE4D	phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
1.4	9929	KIAA0063	KIAA0063 gene product
1.4	143187	VTI1A	Vesicle transport through interaction with t-SNAREs homolog 1A (yeast)
1.4	440309	---	LOC440309
1.4	150094	SNF1LK	SNF1-like kinase /// SNF1-like kinase
1.4	1850	DUSP8	dual specificity phosphatase 8
1.4	9584	RNPC2	RNA-binding region (RNP1, RRM) containing 2
1.4	140735	Dlc2	dynein light chain 2
1.4	54542	MNAB	membrane associated DNA binding protein
1.4	9262	STK17B	serine/threonine kinase 17b (apoptosis-inducing)
1.4	7128	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
1.4	3183	HNRPC	heterogeneous nuclear ribonucleoprotein C (C1/C2)
1.4	5144	PDE4D	Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
1.4	80311	KLHL15	kelch-like 15 (Drosophila)
1.4	22850	KIAA0863	KIAA0863 protein
1.4	5996	RGS1	---
1.4	468	ATF4	activating transcription factor 4 (tax-responsive enhancer element B67)
1.4	---	---	---
1.4	7430	VIL2	villin 2 (ezrin)
1.4	6627	SNRPA1	small nuclear ribonucleoprotein polypeptide A'
1.4	7750	ZNF198	zinc finger protein 198
1.4	1390	CREM	cAMP responsive element modulator
1.4	10291	SF3A1	splicing factor 3a, subunit 1, 120kDa
1.4	9308	CD83	CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)
1.4	63935	C20orf67	---
1.4	10049	DNAJB6	DnaJ (Hsp40) homolog, subfamily B, member 6
1.4	51526	C20orf111	chromosome 20 open reading frame 111
1.4	55500	ETNK1	ethanolamine kinase 1 /// ethanolamine kinase 1
1.4	79441	C4orf15	chromosome 4 open reading frame 15
1.4	11236	RNF139	ring finger protein 139
1.4	246243	RNASEH1	ribonuclease H1
1.4	3727	JUND	jun D proto-oncogene
1.4	6500	SKP1A	S-phase kinase-associated protein 1A (p19A)
1.4	4204	MECP2	Methyl CpG binding protein 2 (Rett syndrome)
1.4	3189	HNRPH3	heterogeneous nuclear ribonucleoprotein H3 (2H9)
1.4	222161	DKFZp586I1420	hypothetical protein DKFZp586I1420
1.4	266812	NAP1L5	nucleosome assembly protein 1-like 5
1.4	9908	G3BP2	Ras-GTPase activating protein SH3 domain-binding protein
			2
1.4	10425	ARIH2	---
1.4	55422	ZNF331	Zinc finger protein 331
1.4	8454	CUL1	Cullin 1
1.4	51119	SBDS	Shwachman-Bodian-Diamond syndrome
1.4	6309	SC5DL	sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, fungal)-like
1.4	5277	PIGA	phosphatidylinositol glycan, class A (paroxysmal nocturnal hemoglobinuria) /// phosphatidylinositol glycan, class A (paroxysmal nocturnal hemoglobinuria)
1.4	3422	IDI1	isopentenyl-diphosphate delta isomerase
1.4	63935	C20orf67	chromosome 20 open reading frame 67
1.4	7975	MAFK	v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian)
1.4	7456	WASPIP	Wiskott-Aldrich syndrome protein interacting protein
1.4	55975	KLHL7	kelch-like 7 (Drosophila)
1.4	7128	TNFAIP3	tumor necrosis factor, alpha-induced protein 3
1.4	388796	LOC388796	hypothetical LOC388796
1.4	25852	ARMC8	armadillo repeat containing 8
1.4	54542	MNAB	Membrane associated DNA binding protein
1.4	55422	ZNF331	zinc finger protein 331
1.4	1390	CREM	cAMP responsive element modulator
1.4	10209	SUI1	putative translation initiation factor
1.4	10049	DNAJB6	DnaJ (Hsp40) homolog, subfamily B, member 6
1.4	4929	NR4A2	nuclear receptor subfamily 4, group A, member 2
1.4	1540	CYLD	cylindromatosis (turban tumor syndrome)
1.4	4929	NR4A2	nuclear receptor subfamily 4, group A, member 2
1.4	5805	PTS	6-pyruvoyltetrahydropterin synthase
1.4	10926	ASK	activator of S phase kinase
1.4	10923	PC4	activated RNA polymerase II transcription cofactor 4 /// similar to Activated RNA polymerase II transcriptional coactivator p15 (Positive cofactor 4) (PC4) (p14)
1.4	388796	RNU71A	Hypothetical LOC388796
1.4	133746	JMY	junction-mediating and regulatory protein
1.4	90634	CG018	Hypothetical gene CG018
1.4	10209	SUI1	putative translation initiation factor
1.4	1847	DUSP5	dual specificity phosphatase 5
1.4	7088	TLE1	Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
1.4	84275	MGC4399	mitochondrial carrier protein
1.4	---	---	---
1.4	7803	PTP4A1	protein tyrosine phosphatase type IVA, member 1
1.4	55422	ZNF331	zinc finger protein 331
1.4	---	---	CDNA clone IMAGE:30332316, partial cds
1.4	3609	ILF3	interleukin enhancer binding factor 3, 90kDa
1.4	---	---	Homo sapiens, clone IMAGE:4753714, mRNA
1.4	6651	SON	SON DNA binding protein
1.4	11276	AP1GBP1	AP1 gamma subunit binding protein 1
1.4	84124	ZNF394	zinc finger protein 3 94
1.4	63935	C20orf67	---
1.4	1983	EIF5	eukaryotic translation initiation factor 5
1.4	80063	ATF7IP2	Activating transcription factor 7 interacting protein 2
1.4	285831	LOC285831	hypothetical protein LOC285831
1.4	81873	ARPC5L	actin related protein 2/3 complex, subunit 5-like
1.4	144438	LOC144438	hypothetical protein LOC144438
1.4	10209	SUI1	putative translation initiation factor
1.4	3021	H3F3B	H3 histone, family 3B (H3.3B)
1.4	25948	KBTBD2	kelch repeat and BTB (POZ) domain containing 2
1.4	---	---	CDNA FLJ40725 fis, clone TKIDN1000001, highly similar to Translocase of inner mitochondrial membrane 23
1.4	1540	CYLD	cylindromatosis (turban tumor syndrome)
1.4	5144	PDE4D	phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
1.4	51182	HSPA14	heat shock 70kDa protein 14
1.4	29080	HSPC128	HSPC128 protein
1.4	8731	RNMT	RNA (guanine-7-) methyltransferase
1.4	3423	IDS	iduronate 2-sulfatase (Hunter syndrome)
1.4	283991	MGC29814	hypothetical protein MGC29814
1.4	1454	CSNK1E	Casein kinase 1, epsilon
1.4	26051	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
1.4	3422	IDI1	isopentenyl-diphosphate delta isomerase
1.4	5887	RAD23B	RAD23 homolog B (S. cerevisiae)
1.4	5144	PDE4D	Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)
1.4	49854	ZNF295	zinc finger protein 295
1.4	60493	FLJ13149	hypothetical protein FLJ13149
1.4	10950	BTG3	BTG family, member 3

Yet another group that may be used alone or in combination with the genes listed in supplementary table that includes the data shown in Figure 17, denoted P2, and which may include one or more the following genes that are overexpressed, e.g., WARS; IFI53; IFP53; GAMMA-2; FAM46C; FLJ20202; H3F3B; H3.3B; FOXK2; ILF; ILF1; ILF-1; DUSP5; HVH3; ARF6; DKFZp762C186; BRD2; NAT; RNF3; FSRG1; RING3; D6S113E; KIAA9001; RORA; ROR1; ROR2; ROR3; RZRA; NR1F1; DKFZp762C186; DNAJB1; SUI1; CXCR4; HM89; LAP3; NPYR; WHIM; LESTR; NPY3R; HSY3RR; NPYY3R; D2S201E; GRINL1A; CTSB; TRIP-Br2; PDE4B; DPDE4; PDEIVB; PMAIP1; APR; NOXA; BTG2; PC3; TIS21; ASAHL; SON; SUI1; A121; ISO1; HERPUD1; SUP; Mif1; KIAA0025; DUSP2; PAC1; PAC-1; RNF139; RCA1; TRC8; HRCA1; MGC31961; TNFAIP3; A20; TNFA1P2; ARS2; HNRPL; hnRNP-L; P/OKc1.14; C20orf67; C20orf111; HSPC207; dJ1183I21.1; ZNF331; RITA; ZNF361; ZNF463; C20orf67; IER5; SBBI48; ; SUI1; JUN; AP1; CD69; TOB1; H3F3B; H3.3B; FOLR1; TNFAIP3; TCF8; BZP; ZEB; ZEB1; AREB6; ZFHEP; NIL-2A; ZFHX1A; NIL-2-A; DUSP10; MKP5; MKP-5; GGTLA4; MGC50550; dJ831C21.2; PMAIP1; ZC3HAV1; ZAP; FLB6421; ZC3HDC2; FLJ13288; MGC48898; DSIPI; DIP; GILZ; hDIP; TSC-22R; MCL1; TM; EAT; MCL1L; MCL1S; MGC1839; SH3TC1; FLJ20356; CIAS1; FCU; MWS; FCAS; NALP3; Clorf7; PYPAF1; AII/AVP; AGTAVPRL; SLC15A3; PHT2; PTR3; hPTR3; PTDSR; PSR; PTDSR1; KIAA0585; BHLHB2; DEC1; STRA13; Stra14; HMGE; KIAA0063; NR4A2; NOT; RNR1; HZF-3; NURR1; TINUR; NR4A2; NOT; RNR1; HZF-3; NURR1; TINUR; PTS; PTPS; HEAB; CLP1; hClp1; AREG; SDGF; CRDGF; MGC13647; EDG4; LPA2; EDG-4; LPAR2; CREM; ICER; MGC17881; MGC41893; CD83; BL11; HB15; ZNF394; FLJ12298, and combinations thereof.

Module-based microarray data mining strategy. Results from "traditional" microarray analyses are notoriously noisy and difficult to interpret. A widely accepted approach for microarray data analyses includes three basic steps: 1) Use of a statistical test to select genes differentially expressed between study groups; 2) Apply pattern discovery algorithms to identify signatures among the resulting gene lists; and 3) Interpret the data using knowledge derived from the literature or ontology databases.

The present invention uses a novel microarray data mining strategy emphasizing the selection of biologically relevant transcripts at an early stage of the analysis. This first step can be carried out using for instance the modular mining algorithm described above in combination with a functional mining tool used for in-depth characterization of each transcriptional module (FIGURE 4: top panel, Step 1). The analysis does not take into consideration differences in gene expression levels between groups. Rather, the present invention focuses instead on complex gene expression patterns that arise due to biological variations (e.g., inter-individual variations among a patient population). After defining the transcriptional components associated to a given biological system the second step of the analysis includes the analysis of changes in gene expression through the comparison of different study groups (FIGURE 4: bottom panel, Step 2). Group comparison analyses are carried out independently for each module. Changes at the module level are expressed as the proportion of genes that meet the significance criteria (represented by a pie chart in FIGURE 5 or a spot in FIGURE 6). Notably, carrying out comparisons at the modular level permits to avoid the noise generated when thousands of tests are performed on "random" collections of genes.

Perturbation of modular PBMC transcriptional profiles in human diseases. To illustrate the second step of the microarray data mining strategy described above (FIGURE 4), gene expression data for PBMC samples obtained from two pediatric patient populations composed of eighteen children with systemic lupus erythematosus (SLE) and sixteen children with acute influenza A infection was obtained, compared and analyzed. Each patient cohort was matched to its respective control group (healthy volunteers: eleven and ten donors were matched to the SLE and influenza groups, respectively). Following the analytical scheme depicted in FIGURE 4, a statistical group comparisons between patient and healthy groups for each individual module and measured the proportion of genes significantly changed in each module (FIGURE 5) was performed. The statistical group comparison approach allows the user to focus the analysis on well defined groups of genes that contain minimal amounts of noise and carry identifiable biological meaning. A key to the graphical representation of these results is provided in Figure 4.

The following findings were made: (1) that a large proportion of genes in M3.1 ("interferon-associated") met the significance level in both Flu and SLE groups (84% and 94%, respectively). This observation confirms earlier work with SLE patients ¹⁹ and identifies the presence of an interferon signature in patients with acute influenza infection. (2) Equivalent proportions of genes in M1.3 ("B-cell-associated") were significantly changed in both groups (53%), with over 50% overlap between the two lists. This time, genes were consistently under-expressed in patient compared to healthy groups. (3) Modules were also found that differentiate the two diseases. The proportion of genes significantly changed in Module 1.1 reaches 39% in SLE patients and is only 7% in Flu patients, which at a significance level of 0.05 is very close to the proportion of genes that would be expected to be differentially expressed only by chance. Interestingly, this module is almost exclusively composed of genes encoding immunoglobulin chains and has been associated with plasma cells. However, this module is clearly distinct from the B-cell associated module (M1.3), both in terms of gene expression level and pattern (not shown). (4) As illustrated by module M1.5, gene-level analysis of individual modules can be used to further discriminate the two diseases. It is also the case for M1.3, where, despite the absence of differences at the module-level (FIGURE 4: 53% under-expressed transcripts), differences between Flu and SLE groups could be identified at the gene-level (only 51% of the under-expressed transcripts in M1.3 were common to the two disease groups). These examples illustrate the use of a modular framework to streamline the analysis and interpretation of microarray results.

Mapping changes in gene expression at the modular level. Data visualization is paramount for the interpretation of complex datasets and the present invention includes a comprehensive graphical illustration of changes that occur at the modular level. Changes in gene expression levels caused by different diseases were represented for the twenty-eight PBMC transcriptional modules (FIGURE 6). Each disease group is compared to its respective control group composed of healthy donors who were matched for age and sex (eighteen patients with SLE, sixteen with acute influenza infection, sixteen with metastatic melanoma and sixteen liver transplant recipients receiving immunosuppressive drug treatment were compared to control groups composed of ten to eleven healthy subjects). Module-level data were represented graphically by spots aligned on a grid, with each position corresponding to a different module (See Table 1 for functional annotations on each of the modules).

The spot intensity indicates the proportion of genes significantly changed for each module. The spot color indicates the polarity of the change (red: proportion of over-expressed genes, blue: proportion of under-expressed genes; modules containing a significant proportion of both over- and under-expressed genes would be purple-though none were observed). This representation permits a rapid assessment of perturbations of the PBMC transcriptional system. Such "module maps" were generated for each disease. When comparing the four maps, we found that diseases were characterized by a unique modular combination. Indeed, results for M1.1 and M1.2 alone sufficed to distinguish all four diseases (M1.1/M1.2: SLE = +/+; FLU=0/0; Melanoma=-/+; transplant=-/-). A number of genes in M3.2 ("inflammation") were over-expressed in all diseases (particularly so in the transplant group), while genes in M3.1 (interferon) were over-expressed in patients with SLE, influenza infection and, to some extent, transplant recipients. "Ribosomal protein" module genes (M1.7 and M2.4) were under-expressed in both SLE and Flu groups. The level of expression of these genes was recently found to be inversely correlated to disease activity in SLE patients (Bennett et al., submitted). M2.8 includes T-cell transcripts which are under-expressed in lymphopenic SLE patients and transplant recipients treated with immunosuppressive drugs targeting T-cells.

Interestingly, differentially expressed genes in each module were predominantly either under-expressed or over-expressed (FIGURE 5 and FIGURE 6). Yet, modules were purely selected on the basis of similarities in gene expression profiles, not changes in expression levels between groups. The fact that changes in gene expression appear highly polarized within each module denotes the functional relevance of modular data. Thus, the present invention enables disease fingerprinting by a modular analysis of patient blood leukocyte transcriptional profiles.

Validation of PBMC modules in a published dataset. Next, the validity of the PBMC transcriptional modules described above in a "third-party" dataset was tested. The study from Connolly, et al., who investigated the effects of exercise on gene expression in human PBMCs²⁰ was tested.

Blood samples were obtained from 35 patients with metastatic melanoma enrolled in three phase I/II clinical trials designed to test the efficacy of a dendritic cell therapeutic vaccine as seen in the table below. Gene expression signatures were generated from blood samples collected prior to the initiation of vaccine therapy, and at least 4 weeks after the last systemic therapy if a patient had undergone such.

Table 3: Clinical and demographic characteristics of 35 patients with metastatic melanoma

ID	Sex	Age	Stage	Diagnosis	Time from Dx to Blood Draw (Months)	Blood Draw	Status	Blood Draw to Time of Death (Months)
MEL 23	F	61	M1a	02/14/00	16	06/28/01	Deceased	28
MEL 24	M	53	M1c	09/01/99	22	07/05/01	Deceased	5
MEL 26	F	52	M1c	10/01/97	45	07/18/01	Deceased	2
MEL 27	F	54	M1a	07/10/93	98	09/14/01	Deceased	5
MEL 29	M	41	M1c	10/26/94	83	09/26/01	Deceased	14
MEL 30	F	58	M1c	10/04/99	23	09/25/01	Deceased	11
MEL 32	M	56	M1b	01/17/94	95	12/17/01	Deceased	24
MEL 34	F	28	M1b	04/01/01	10	02/05/02	Deceased	42
MEL 35	M	29	M1a	08/25/98	43	03/12/02	Deceased	12
MEL 36	F	69	M1b	01/01/85	205	02/19/02	Deceased	7
MEL 40	F	43	M1c	07/02/91	132	07/19/02	Deceased	19
MEL 43	M	60	M1a	08/14/94	100	12/04/02	Alive 05/16/05	*
MEL 44	F	68	M1c	05/01/99	44	01/28/03	Deceased	12
MEL 45	F	53	M1a	02/01/02	10	12/17/02	Alive 5/5/05	*
MEL 46	F	47	M1c	11/18/97	61	12/27/02	Deceased	22
MEL 47	F	35	M1c	03/02/02	10	01/09/03	Deceased	2
MEL 48	M	68	M1b	*1992	>120	03/12/03	Alive 05/10/05	*
MEL 49	M	71	M1b	12/05/97	64	04/10/03	Alive 07/05/05	*
MEL 50	M	52	M1c	07/08/97	69	04/11/03	Deceased	18
MEL 51	M	56	M1c	10/01/01	18	04/16/03	Alive 05/17/05	*
MEL 52	M	42	M1c	03/01/02	13	04/17/03	Deceased	9
MEL 54	M	50	M1b	07/20/90	153	04/25/03	Alive 04/08/05	*
MEL 56	M	71	M1c	03/01/01	26	05/29/03	Deceased	9
MEL 57	F	36	M1b	07/01/02	11	06/05/03	Deceased	20
MEL 58	M	67	M1c	10/01/99	45	07/18/03	Deceased	10
MEL 59	M	61	M1c	unknown	*	07/25/03	Alive 06/22/05	*
MEL 60	M	41	M1c	11/01/02	9	08/14/03	Deceased	7
MEL 61	F	54	M1a	03/03/99	54	09/10/03	Alive 05/18/05	*
MEL 62	M	46	M1b	12/01/01	22	10/09/03	Deceased	5
MEL 63	M	75	M1b	12/01/00	34	10/29/03	Alive 03/16/05	*
MEL 64	F	53	M1b	04/01/00	42	10/30/03	Alive 03/05/04	*
MEL 65	M	62	M1b	08/14/94	111	11/14/03	Alive 05/16/05	*
MEL 68	M	74	M1b	06/09/04	1	07/29/04	Deceased	9
MEL 70	M	67	M1b	04/06/04	5	09/23/04	Alive 8/18/2005	*
MEL 72	M	50	M1c	09/23/04	2	11/10/04	Deceased	*

The Table provides both clinical and demographic characteristics of 35 patients with metastatic melanoma.

A second group of patients included 39 liver transplant recipients maintaining their graft under pharmacological immunosuppressive therapy, time from transplant had a median of 729 days and a range of between 338 and 1905 days. Outpatients coming for routine exams were recruited for this study. All patients received standard treatment regimens with calcineurin inhibitors (e.g., Tacrolimus: n=25; Cyclosporin A: n=13). The main indications for liver transplant were hepatitis C (n = 19) and Laennec's cirrhosis (n = 7). The table below provides both clinical and demographic characteristics of 39 liver transplant recipients.

Table 4: Clinical and demographic characteristics of 39 liver transplant recipients

Patient ID	Age	Sex	Transpl. to Blood Draw (Days)	TAC	CsA	Primary Dx
R1292	47	M	1854	yes		Hepatitis C
R1297	48	M	1868		yes	Hepatitis C
R1308	66	F	1905		yes	Primary Biliary Cirrhosis
R1322	32	F	1821		yes	Hepatitis C
R1323	45	M	1828		yes	Hepatitis C
R1325	50	M	1801		yes	Hepatitis C
R1329	51	F	1781	yes		Laennec's Cirrhosis
R1340	50	M	1829		yes	Laennec's Cirrhosis
R1348	64	F	1802	yes		Fulminant Hepatic Failure
R1355	61	M	1780	yes		Cryptogenic
R1364	42	M	1756	yes		Hepatitis C
R1413	52	M	1856		yes	Laennec's Cirrhosis
R1673	60	F	756	yes		Hepatitis B
R1674	45	M	729	yes		Hepatitis C
R1684	65	F	721	yes		Mx. Carcinoid
R1686	59	M	704	yes		Hepatitis B
R1689	43	M	692	yes		Hepatitis C
R1700	53	M	732		yes	Hepatitis C
R1701	45	M	737	yes		Hepatitis C
R1702	48	M	726	yes		Hepatitis C
R1706	57	M	721	yes		Laennec's Cirrhosis
R1710	50	F	736	yes		Cryptogenic
R1714	63	F	718	yes		Nonalcoholic Steatohepatitis
R1718	53	F	707		yes	Hepatitis C
R1754	51	F	589	yes		Primary Sclerosing Cholangitis
R1771	42	F	812			Hepatitis C
R1787	60	F	794	yes		Laennec's Cirrhosis
R1805	42	M	735	yes		Laennec's Cirrhosis & Postnecrotic Cirrhosis Type C
R1814	45	M	427	yes		Hepatitis C
R1838	66	F	360	yes		Autoimmune Hepatitis
R1839	56	M	354	yes		Cryptogenic
R1841	52	M	363	yes		PSC-UC
R1843	48	M	361		yes	Hepatitis C
R1845	44	F	338	yes		Primary Biliary Cirrhosis
R1846	41	F	338		yes	Hepatitis C
R1847	53	M	358	yes		Laennec's Cirrhosis
R1854	50	M	350		yes	Hepatitis C
R1971	46	M	367		yes	Hepatitis C; Hepatocellular Carcinoma with Cirrhosis
R1974	54	M	341	yes		Hepatitis C

Blood samples were also obtained from 25 healthy donors that constituted the control groups. The table below provides the demographic characteristics of the 25 healthy donors.

Table 5: Demographic characteristics of 25 healthy donors

Healthy Volunteers	Sex	Age
D-001	M	41
D-002	F	53
D-005	F	40
D-007	F	44
D-008	M	40
D-010	M	46
D-011	F	43
D-013	M	58
D-014	F	47
D-015	M	42
D-016	F	40
D-017	M	25
D-018	M	46
D-019	F	40
D-020	M	39
D-021	M	45
D-022	M	50
D-024	F	44
D-025	F	48
D-027	F	43
D-028	F	43
D-029	M	43
D-031	M	35
D-032	F	43
D-033	F	43

Identification of disease-associated blood leukocyte transcriptional signatures. Blood leukocyte gene expression signatures were identified in patients with metastatic melanoma and liver transplant recipients. Each set of patients was compared to a control group of healthy volunteers. Patient samples were divided into a training set, used to identify disease-associated and predictive expression signatures, and an independent test set. This step-wise analysis allowed validation of results in samples that were not used to establish the disease signature. Stringent criteria were employed to select the samples forming training sets in order to avoid confounding the analysis with biological and/or technical factors. The table below illustrates the composition of sample sets taking into account age, gender and sample processing method used for the identification (training) and validation (testing) of expression signatures associated with metastatic melanoma.

Table 6: Composition of sample sets associated with metastatic melanoma.

			Total n
Fresh	Frozen		Fresh	Frozen
Male	7	7	14	Male	5	0	5
Female	0	9	9	Female	8	0	8
	7	16	23		13	0	13	36

Table 6: Composition of sample sets associated with metastatic melanoma.

Fresh	Frozen		Fresh	Frozen
Male	3	9	12	Male	0	11	11
Female	0	10	10	Female	0	5	5
	3	19	22		0	16	16	38
		Total	45			Total	29

Similarly, the table below provides the composition of sample sets used taking into account age, gender and sample processing method for the identification (training) and validation (testing) of expression signatures associated with liver transplant recipients undergoing immunosuppressive drug therapy.

Table 7: Composition of sample sets associated with liver transplant recipients undergoing immunosuppressive drug therapy.

Total n
Fresh	Frozen		Fresh	Frozen
Male	12	5	17	Male	0	2	2
Female	8	2	10	Female	0	7	7
	20	7	27		0	9	9	36

	Fresh	Frozen			Fresh	Frozen
Male	9	3	12	Male	15	0	15
Female	9	1	10	Female	6	0	6
	18	4	22		21	0	21	43
		Total	49			Total	30

Table 8 lists the genes differentially expressed in patients with metastatic melanoma in comparison to healthy volunteers. Statistical comparison of a group of twenty-two patients with metastatic melanoma versus twenty-three healthy volunteers, training set, identified 899 differentially expressed genes (p<0.01, non parametric Mann-Whitney rank test and >1.25 fold change; 218 overexpressed and 681 underexpressed genes). The Tables provide a correlation to the modules from which there were identified, their expression level, various nomenclatures for their individual identification.

FIGURES 7A-7D are images of the hierarchical clustering of genes. FIGURE 7A illustrates the hierarchical clustering of genes that produce a reciprocal expression pattern; which was confirmed in an independent test set shown in FIGURE 7B. FIGURE 7B displays results from 13 healthy volunteers versus 16 patients. Next, class prediction algorithms were applied to the initial training set. These algorithms yielded 81 genes with the best ability to classify healthy volunteers and patients based on their differential expression as shown in FIGURE 7C and Table 9). Table 9 illustrates the expression levels of a set of transcripts discriminating patients with melanoma from healthy volunteers. Using these 81 genes, an independent test set was classified with 90% accuracy; the class of only three was indeterminate as illustrated in FIGURE 7D.

FIGURES 8A and 8B are plots of the microarray results in an independent set of samples to confirm the reliability of the results by correlating expression levels obtained for the training and test sets. Genes with the best ability to discriminate between patients and healthy volunteers were identified in a training set using a class prediction algorithm (k-Nearest Neighbors). Fold change expression levels between healthy controls and patients were measured for discriminative genes in the training set and an independent test set. Fold change values obtained in training and test sets were correlated: FIGURE 8A illustrates results for metastatic melanoma and produced 81 genes with a Pearson correlation of r²=0.83 and a p<0.0001 and FIGURE 8B illustrates results for liver transplant recipients and produced 65 genes with a Pearson correlation of r²=0.94 and a p<0.0001.

FIGURES 9A-9D are images of the hierarchical clustering of genes for the identification of a blood leukocyte transcriptional signature in transplant recipients under immunosuppressive drug therapy. Samples were divided into a training set (27 healthy, 22 patients) used to identify differentially expressed genes in liver transplant recipients versus healthy volunteers as seen in FIGURE 9A and FIGURE 9C respectively. A test set of nine healthy and 21 patients were used to independently validate this signature as seen in FIGURE 9B and FIGURE 9D. Class comparison identified 2,589 differentially expressed genes (Mann-Whitney test p < 0.01, fold change > 1.25). FIGURE 9A illustrates a similar signature in the test set and FIGURE 9B illustrates the class prediction that identified 81 genes. FIGURE 9C shows that the discrimination of the independent test set with 90% accuracy. FIGURE 9D illustrates the class could not be identified for two samples out of 30; one sample was incorrectly predicted (i.e. transplant recipient classified as healthy).

The same analysis strategy was applied to Liver transplant patients. Statistical comparison of a group of 22 transplant recipients versus 27 healthy volunteers identified 2,589 differentially expressed genes (p<0.01, non-parametric Mann-Whitney rank test and >1.25 fold change; 938 overexpressed and 1651 underexpressed genes; Table 10). Table 10 illustrates genes that are expressed differentially in liver transplant recipients under treatment with immunosuppressive drugs in comparison to healthy volunteers. Hierarchical clustering of genes produced a reciprocal expression pattern that was observed in both training as seen in FIGURE 9A and independent test sets as seen in FIGURE 9B. Sixty-five classifier genes were established in the training set and are illustrates in FIGURE 9C and Table 11. Table 11 illustrates the expression level of a set of transcripts discriminating liver transplant recipients under treatment with immunosuppressive drugs from healthy volunteers. The sixty-five classifier genes were applied to an independent test set of 9 healthy donors and 21 patients. Samples were correctly classified 90% of the time: class could not be determined in two cases and one sample was misclassified as seen in FIGURE 9D. The results obtained for both of these sets were highly correlated, e.g., pearson correlation, r²=0.94, p<0.0001, as seen in FIGURE 8B. Thus, the blood leukocyte transcriptional signatures associated with patients with metastatic melanoma and in liver transplant recipients have been identified and validated.

Module-level analysis of patients PBMC transcriptional profiles was performed. A custom microarray data mining strategy was used to further characterize disease-associated gene expression patterns. The analysis of a set of 239 blood leukocytes transcriptional signatures identified 28 transcriptional modules regrouping 4,742 probe sets. These "transcriptional modules" are sets of genes that follow similar expression patterns across a large number of samples in multiple studies, identified through co-expression meta-analysis. Each module is associated with a unique identifier that indicates the round of selection and order (e.g., M2.8 designates the eighth module of the second round of selection). Upon extraction each transcriptional module is functionally characterized with the help of a literature profiling algorithm (Chaussabel and Sher, 2002).

FIGURES 10 to 13 illustrate detailed statistical comparisons between healthy and disease groups of the module-level analysis. For example, twenty-eight sets of coordinately expressed genes, or transcriptional modules, were identified through the analysis of 239 PBMC microarray profiles. For each of these modules changes in expression levels between groups of healthy volunteers and either patients with metastatic melanoma or transplant recipients were tested. A pie chart indicates the proportion of genes that were significantly changed in each module, where red indicates overexpressed genes and blue illustrates underexpressed genes, with a p<0.05 for the Mann-Whitney test. For each module, keywords extracted from the literature are listed in green along with a functional assessment of relationships existing among the genes.

FIGURE 14 is a plot of the changes observed in a few representative modules represented by a transcriptional profile. Each differentially expressed gene is represented by a line that indicates relative levels of expression across healthy volunteer and patient samples. Peaks and dips respectively indicate relatively higher and lower gene expression in a given patient. Genes that were not significantly different are not represented. The levels of expression of genes associated with a platelet signature changed in opposite directions: 28% of the genes forming this signature (M1.2) were overexpressed in patients with melanoma and 27% were underexpressed in transplant recipients. Furthermore, half of the genes belonging to module M2.1 (cytotoxic cell signature) were underexpressed in transplant recipients. This trend was not observed in patients with melanoma (7% overexpressed with p<0.05 where 5% of changes are expected by chance only). Similarly, a massive down-regulation of genes associated to T cells was observed in transplant recipients (74% of genes in M2.8). This finding most likely reflects pharmacological immunosuppression. In patients with melanoma 29% of these T-cell related genes were down-regulated. In addition, 44% of interferon-inducible genes that form module M3.1 were overexpressed in transplant recipients, while 26% were underexpressed in patients with melanoma. Lists of differentially expressed genes in each module are available in Tables 12 and 13.

Patients with metastatic melanoma and transplant recipients display common transcriptional profiles at the modular level. This analysis identified similarities as well as differences in blood leukocyte transcriptional signatures of patients with metastatic melanoma and liver transplant recipients.

FIGURE 15 is an image of the modular changes observed in both groups of patients vs. their respective healthy control group. The proportion of differentially expressed genes for each module is indicated by a spot of variable intensity. For example, in the overlay a change in transplant is represented by a yellow, while a change in melanoma is indicated by a blue color and a change in both is indicated by a green color.

Proportions of underexpressed and overexpressed transcripts are represented on separate grids. Modules that were common between the two groups of patients include M1.4 (regulator of cAMP and NF-kB signaling pathways), M2.6 (including genes expressed in myeloid lineage cells), M3.2 and M3.3 (both M3.2 and 3.3 include factors involved in inflammation; as seen in FIGURES 10-13).

FIGURE 16 is an image illustrating the module-level analysis of the present invention. Common transcriptional signatures in blood from patients with metastatic melanoma and from liver transplant recipients. Expression profiles of genes belonging to blood leukocyte transcriptional modules M1.1, M1.3, M1.4 and M3.2. The total number of probes is indicated for each module (U133A), along with a brief functional interpretation. Keywords extracted by literature profiling are indicated in green. From the total number in each module, the proportion of genes that were significantly changed (Mann-Whitney test, p<0.05) in patients compared to the appropriate healthy control group is indicated in a pie chart with overexpressed genes are expressed in red and underexpressed genes are expressed in blue. Graphs represent transcriptional profiles of the genes that were significantly changed, with each line showing levels of expression on the y-axis of a single transcript across multiple conditions (samples, x-axis).

The association between metastatic melanoma and liver transplant phenotype was strongest for M1.4 and M3.2 as seen in FIGURE 16. Interestingly, a majority of underexpressed modules were common to melanoma and transplant groups, with the most striking similarities in the case of M1.1 (including plasma cell associated genes), M1.3 (including B-cell associated genes) and M1.8 (including genes coding for metabolic enzymes and factors involved in DNA replication).

Identification of a common transcriptional signature that is unique to metastatic melanoma and liver transplant patients. The extent of the similarities between patients with metastatic melanoma and liver transplant recipients were specific to these two groups of patients were examined. Statistical group comparison was carried out between patients and healthy controls across all samples (e.g., thirty-eight melanoma, forty-three transplant, thirty-six healthy). Briefly, 323 transcripts were identified that were significantly overexpressed and 918 that were significantly underexpressed in both liver transplant recipients and patients with metastatic melanoma (Mann-Whitney test, p<0.01, filtered >1.25 fold change). Next, group comparisons for these transcripts were carried using samples from patients with Systemic Lupus Erythematosus ("SLE"), acute infections (S. pneumoniae, S. aureus, E. coli, and Influenza A) and Graft versus Host Disease ("GVHD") compared to relevant healthy controls. This analysis yielded p-values whose hierarchical clustering identified distinct significance patterns among transcripts common to the melanoma and transplant groups. This analysis identified sets of genes that changed across all diseases as seen in FIGURE 17 with P1 being ubiquitously overexpressed; P3 being ubiquitously underexpressed, while others were associated more specifically with the melanoma and transplant groups as seen in FIGURE 18 with P2 being overexpressed; and P4 being underexpressed. Table 14 illustrates the significance levels across 8 diseases of the genes forming patterns P1, P2, P3 and P4.

FIGURE 17 is an image of the analysis of significance patterns. Genes expressed at higher levels in both stage IV melanoma or liver transplant patients compared to healthy volunteers were selected. P-values were similarly obtained from gene expression profiles generated in other disease models: in PBMCs obtained from patients suffering from systemic lupus erythematosus (SLE), Graft versus Host Disease (GVHD), or acute infections with influenza virus (Influenza A), Escherichia coli (E. coli), Streptococcus pneumoniae (Strep. Pneumo.) or Staphylococcus aureus (Staph. aureus). Each of these cohorts was compared to the appropriate control group of healthy volunteers accrued in the context of these studies. The genes expressed at significantly higher or lower levels in PBMCs obtained from both patients with melanoma and liver transplant recipients (OVER-XP and UNDER-XP, respectively) were ranked by hierarchical clustering of p-values generated for all the conditions listed above. P-values are represented according to a color scale: Green represents low p-value/significant, while white represents high p-value/not significant. Distinct significant patterns are identified, where P1 and P3 are ubiquitous and P2 and P4 are most specific to melanoma and liver transplant groups.

FIGURE 18 is a chart of the modular distribution of ubiquitous and specific gene signatures common to melanoma and transplant groups. Distribution among 28 PBMC transcriptional modules was determined for genes that form ubiquitous (P1) and specific (P2) transcriptional signatures common to the melanoma and transplant groups. Gene lists of each of the modules were compared in turn to the 109 and 69 transcripts that form P1 and P2. For each module, the proportion of genes shared with either P1 or P2 was recorded. These results are represented by a bar graph of FIGURE 18.

Thus, genes forming transcriptional signatures common to the melanoma and transplant groups can be partitioned into distinct sets based on two properties: (1) coordinated expression as seen in the transcriptional modules of FIGURE 13; and (2) change in expression across diseases as seen in the significance patterns of FIGURE 17. The results from these two different mining strategies were recouped by examining the modular distribution of ubiquitous (P1) and specific (P2) PBMC transcriptional signatures. FIGURE 18 clearly shows that the distribution of P1 and P2 across the 28 PBMC transcriptional modules that have been identified to date is not random. Indeed, P1 transcripts are preferentially found among M3.2 (characterized by transcripts related to inflammation), whereas M1.4 transcripts almost exclusively belonged to P2, which includes genes that are more specifically overexpressed in patients with melanoma and liver transplant recipients.

FIGURE 19 is an illustration of the transcriptional signature of immunosuppression. Transcripts overexpressed most specifically in patients with melanoma and transplant recipients (P1) include repressors of immune responses that inhibit: 1) NF-kB translocation; 2) Interleukin 2 production and signaling; 3) MAPK pathways and 4) cell proliferation. Some of these factors are well characterized anti-inflammatory molecules and others are expressed in anergic T-cells.

Molecular signature of immunosuppression. The genes that were most specifically overexpressed in melanoma and transplant groups (P1) were examined. From the 69 probe sets, 55 unique gene identifiers were identified. A query against a literature database indexed by gene, have developed to aid the interpretation of microarray gene expression data, identified 6527 publications associated with 47 genes, 30 of which were associated with more than ten publications. FIGURE 19 illustrates a remarkable functional convergence among the genes forming this signature and includes genes encoding molecules that possess immunoregulatory functions (e.g., anti-proliferative genes: BTG2, TOB1, AREG, SUI1 or RNF139; anti-inflammatory genes: TNFAIP3); inhibitors of transcription: (SON, ZC3HAV1, ZNF394); stress-induced molecules (HERPUD1); while others possess well established immunosuppressive properties. For example, dual specificity phosphatases 2, 5 and 10 (DUSP2, 5, 10) interfere with the MAP kinases ERK1/2, which are known targets of calcineurin inhibitors such as Tacrolimus/FK506. DUSP10 selectively dephosphorylates stress activated kinases(Theodosiou et al., 1999). Interestingly, DUSP5 was found to have a negative feedback role in IL2 signaling in T-cells(Kovanen et al., 2003). CREM, FOXK2 and TCF8 directly bind the IL2 promoter and can contribute to the repression of IL-2 production in T cell anergy(Powell et al., 1999). BHLHB2 (Stra13) negatively regulates lymphocyte development and function in vivo(Seimiya et al., 2004). CIAS1 codes for the protein Cryopyrin, which regulates NF-kappa B activation and production of proinflammatory cytokines. Mutations of this gene have been identified in several inflammatory disorders(Agostini et al., 2004). DSIPI, a leucine zipper protein, is known to mediate the immunosuppressive effects of glucocorticoids and IL10 by interfering with a broad range of signaling pathways (NF-kappa B, NFAT/AP-1, MEK, ERK 1/2), leading to the general inhibition of inflammatory responses in macrophages and down-regulation of the IL2 receptor in T cells. Noatably, the expression of DSIPI in immune cells was found to be augmented after drug treatment (dexamethasone)(D'Adamio et al., 1997) or long term exposure to tumor cells (Burkitt Lymphoma)(Berrebi et al., 2003).

Other immunosuppressive molecules, which did not belong to P1, were also found overexpressed in melanoma and transplant groups. Notably, DDIT4, another dexamethasone-induced gene which was recently found to inhibit mTOR, the mammalian target for rapamycin (Corradetti et al., 2005). Thus, this endogenous factor appears capable of reproducing the action of potent immunosuppressive drugs. HMOX1, a cytoprotective molecule that also demonstrates anti-inflammatory properties. Most recently, HMOX1 expression was found to be induced by FOXP3 and to mediate immunosuppressive effects of CD4+ CD25+ regulatory T cells (Choi et al., 2005). Accordingly, an increase in transcriptional activity of HMOX1 has been correlated with favorable outcomes in experimental transplant models (Soares et al., 1998). Both DDIT4 and HMOX1 genes were also overexpressed in patients with acute E. coli or S. aureus infections. The immunophilin FKBP1A (FKBP12), a member of the FK506-binding protein family, is a key mediator of T-cell immunosuppression by the drugs FK506 (tacrolimus) and rapamycin (Xu et al., 2002). Expression of this gene was elevated in comparison to healthy donors in all patient groups.

Blood is an accessible tissue and lends itself to comparative analyses across multiple diseases. Parmacological and tumor-mediated immunosuppression would produce a common transcriptional signature in blood leukocytes. Metastatic melanoma and transplant recipients disease-associated transcriptional signatures were identified in the blood of patients. These signatures were identified and confirmed through several analytical approaches. Analysis of transcriptional modules identified alterations in blood leukocytes transcriptional components associated to cell types (e.g., Plasma cells, B-cells, T-cells, Cytotoxic cells) and to immune reactions (e.g., Inflammation, Interferon). Furthermore, using both transcriptional modules and gene expression levels similarities between blood transcriptional signatures in patients with metastatic melanoma and liver transplant recipients were identified. However, this common transcriptional signature could not be entirely attributed to immunosuppression. For instance, expression levels of B-cell associated genes (M1.3) were not only decreased in the melanoma and transplant groups, but also in patients with acute influenza infection and systemic lupus erythematosus (SLE) (53% of genes were underexpressed, in comparison to healthy controls; Chaussabel et al.). Conversely, nearly 40% of the genes associated with plasma cells (M1.1) were overexpressed in SLE patients and there was no change in patients with acute influenza infection (7% of the genes were overexpressed at p<0.05), whereas expression levels were significantly decreased in both patients with melanoma and transplant recipients (61 % and 62% of the genes in M1.1, respectively). In order to select the most specific transcripts common between melanoma and transplant signatures a gene-level analysis was carried out across a total of eight groups of patients. This led to the identification of a set of transcripts that was most specifically overexpressed in immunosuppressed patients. The identified set of genes showed marked functional convergence and included genes coding for repressors of Interleukin-2 transcription, inhibitors of NF-kB or MAPK pathways, and anti-proliferative molecules. Interestingly, these signatures are consistent with the mechanism of action of drugs used for pharmacological immunosuppression, which inhibit the activity of calcineurin, a calcium-dependent serine threonine protein phosphatase responsible for the nuclear translocation of NF-AT and NF-kappaB upon T-cell activation. Indicating a functional convergence between immunosuppressive mechanisms operating in patients with advanced melanoma and pharmacologically treated transplant recipients. The fact that the transcripts more specifically induced in immunosuppressed patients include glucocorticoids-inducible genes (e.g., DSIPI, CXCR4, JUN) and hormone nuclear receptors (NR4A2 and RORA)(Winoto and Littman, 2002) suggest a possible role for steroid hormones in tumor-mediated immunosuppression.

Patients with metastatic melanoma display an endogenous transcriptional signature of immunosuppression similar to that induced by pharmacological treatments in patients who underwent liver transplant. The present invention provides a method and apparatus to identify patients at high risk of melanoma progression. In addition the present invention also provides a method and apparatus for monitoring indicators of immunosuppression could help adjusting the dosage of immunosuppressive drugs and balance risks of rejection and side effects for liver transplant recipients.

Examples of patient information and processing of blood samples include the following. Blood was obtained after informed consent as approved by the institutional IRB (Liver transplant recipients: 002-1570199-017; patients with melanoma: 000-048, 002-094; 003-187). Blood samples were obtained in acid citrate dextrose yellow-top tubes (BD Vaccutainer) at the Baylor University Medical Center in Dallas, TX. Samples were immediately delivered at room temperature to the Baylor Institute for Immunology Research, Dallas, TX, for processing. Fresh PBMCs isolated via Ficoll gradient were either stored in liquid nitrogen (e.g., viable freezing) or immediately lysed in RLT buffer, containing β-mercaptoethanol (Qiagen, Valencia, CA). Total RNA was extracted from cells previously frozen in liquid nitrogen ("frozen") or from cells that were lysed immediately after isolation ("fresh"), using the RNEASY^® Mini Kit according to the manufacturer's recommended protocol (Qiagen, Valencia, CA). This parameter was taken into account in the experimental design taking into account the age, gender and sample processing method used for the identification (training) and validation (testing) of expression signatures associated with metastatic melanoma and liver transplant recipients undergoing immunosuppressive drug therapy.

Microarray assays. Total RNA was isolated using the RNEASY^® kit (Qiagen, Valencia, CA) according to the manufacturer's instructions and the RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). Although, the skilled artisan will recognize that other methods of isolation may be used. From 2-5 micrograms of total RNA, double-stranded cDNA containing the T7-dT (24) promoter sequence (Operon Biotechnologies, Huntsville, AL) was generated. This cDNA was then used as a template for in vitro transcription single round amplification with biotin labels (Enzo BioArray HighYield RNA Transcript Labeling Kit from Affymetrix Inc, Santa Clara, CA). Biotinylated cRNA targets were purified using the Sample Cleanup Module and subsequently hybridized to human U133A GeneChips (Affymetrix Inc, Santa Clara, CA) according to the manufacturer's standard protocols. Affymetrix U133A GeneChips that contain 22,283 probe sets, represented by ten to twenty unique probe pairs (perfect match and its corresponding mismatch), which allow detection of 14,500 different genes and expressed sequence tags (ESTs). Arrays were scanned using a laser confocal scanner (Agilent). The samples were processed by the same team, at the same core facility, and were randomized between each array run. Raw data are deposited with GEO (www.ncbi.nltn.nih.gov/geo/).

Data analysis. For each Affymetrix U133A GENE CHIP^® raw intensity data were normalized to the mean intensity of all measurements on that array and scaled to a target intensity value of 500 (TGT) in Affymetrix Microarray Suite 5.0. With the aid of GeneSpring software, version 7.2, the measurement for each gene per patient sample array was divided by the median of that gene's measurement from the cohort of healthy volunteers. A filter was applied based on Affymetrix flag calls: probe sets were selected if "Present" in at least 75% of samples in either group (healthy controls or patients). This step insured a more reliable intensity measurement of the genes used in downstream analyses. Class comparison was performed using a non-parametric ranking statistical analysis test (Mann-Whitney) applied to the selected set of genes. In the vertical direction, hierarchical clusters of genes were generated using the Pearson correlation around zero, Genespring's standard correlation measure. Normalized gene expression data were examined with a nonparametric univariate analysis (Fisher's exact test) to identify genes potentially discriminating two different groups. A supervised learning algorithm, the K-Nearest Neighbors Method, was applied that assigned a sample to pre-defined classes in three steps: 1) identification of genes (observations) that have strong correlations to classes to be distinguished; 2) confirmation that identified genes distinguish pre-defined classes; and 3) validation with "unknown samples".

Identification of transcriptional modules. A total of 239 blood leukocyte gene expression profiles were generated using Affymetrix U133A&B GENECHIPS (>44K probe sets). Transcriptional data were obtained for 8 groups including Systemic Juvenile Idiopathic Arthritis, SLE, liver transplant recipients, melanoma patients, and patients with acute infections: Escherichia coli, Staphylococcus aureus and Influenza A. For each group, transcripts that were present in at least 50% of all conditions were segregated into 30 clusters (k-means clustering: clusters C1 through C30). The cluster assignment for each gene was recorded in a table and distribution patterns were compared among all the genes. Modules were selected using an iterative process, starting with the largest set of genes that belonged to the same cluster in all study groups (i.e. genes that were found in the same cluster in 8 of the 8 groups). The selection was then expanded from this core reference pattern to include genes with 7/8, 6/8 and 5/8 matches. The resulting set of genes formed a transcriptional module and was withdrawn from the selection pool. The process was then repeated starting with the second largest group of genes, progressively reducing the level of stringency. This analysis led to the identification of 4742 transcripts that were distributed among 28 modules. Each module is attributed a unique identifier indicating the round and order of selection (e.g., M3.1 was the first module identified in the third round of selection).

Analysis of significance patterns. Gene expression data were generated for PBMCs obtained from patients and healthy volunteers using Affymetrix HG-U133A GENECHIPS. P values were obtained for six reference datasets by comparing groups of patients to their respective healthy control groups (Mann-Whitney rank test). The groups were composed of patients with: 1) Systemic Lupus Erythematosus (SLE, 16 samples), 2) Influenza A (16 samples), 3) Escherichia coli (16 samples), 4) Staphylococcus aureus (16 samples), and 5) Streptococcus pneumoniae (14 samples); and 7) bone marrow transplant recipients undergoing graft versus host disease (GVHD, 12 samples). Control groups were also formed taking into account age, sex and project (10 samples in each group). Genes significantly changed (p<0.01) in the "study group" (Melanoma and Transplant) were divided in two sets: overexpressed versus control and underexpressed versus control. P-values of the genes forming the overexpressed set were obtained for the "reference groups" (SLE, GVHD and infections with influenza virus, E. coli, S. aureus, S. pneumoniae). P-value data were processed with a gene expression analysis software program, GeneSpring, Version 7.2 (Agilent), which was used to perform hierarchical clustering and group genes based on significance patterns.

Example 2. Determination and Analysis of Patterns of Significance are used to identify ubiquitous and disease-specific gene expression signatures in patient peripheral blood leukocytes.

The use of gene expression microarrays in patient-based research creates new prospects for the discovery of diagnostic biomarkers and the identification of genes or pathways linked to pathogenesis. Gene expression signatures were generated from peripheral blood mononuclear cells isolated from over one hundred patients with conditions presenting a strong immunological component (patient with autoimmune, graft versus host and infectious diseases, as well as immunosuppressed transplant recipients). This dataset permitted the opportunity to carry out comparative analyses and define disease signatures in a broader context. It was found that nearly 20% of overlap between lists of genes significantly changed versus healthy controls in patients with Systemic Lupus Erythematosus (SLE) and acute influenza infection. Transcriptional changes of 22,283 probe sets were evaluated through statistical group comparison performed systematically for 7 diseases versus their respective healthy control groups. Patterns of significance were generated by hierarchical clustering of p-values. This "Patterns of Significance" approach led to the identification of a SLE-specific "diagnostic signature", formed by genes that did not change compared to healthy in the other 6 diseases. Conversely, "sentinel signatures" were characterized that were common to all 7 diseases. These findings allow for the use of blood leukocyte expression signatures for diagnostic and early disease detection.

Briefly, blood is a reservoir and migration compartment for immune cells exposed to infectious agents, allergens, tumors, transplants or autoimmune reactions. Leukocytes isolated from the peripheral blood of patients constitute an accessible source of clinically-relevant information and a comprehensive molecular phenotype of these cells can be obtained by microarray analysis. Gene expression microarrays have been extensively used in cancer research, and proof of principle studies analyzing Peripheral Blood Mononuclear Cell (PBMC) samples isolated from patients with Systemic Lupus Erythematosus (SLE) lead to a better understanding of mechanisms of disease onset and responses to treatment. Two main applications have been found for gene expression microarrays in the context of patient-based research: (1) the discovery of biomarkers and establishment of diagnosis / prognosis signatures (e.g. prediction of survival of breast cancer patients) (2) the identification of genes/pathways involved in pathogenesis, leading for instance to the discovery of the role of interleukin-1 in the pathogenesis of systemic onset juvenile idiopathic arthritis. However, the analysis of microarray data still constitutes a considerable challenge. The ability to simultaneously acquire data for tens of thousands of features in a single test is one of the most appealing characteristic of microarrays, but it can also be a major shortcoming7. This 'curse of dimensionality' is compounded by the fact that the numbers of samples analyzed is usually small. The imbalance between the numbers of genes and conditions analyzed considerably weakens data interpretation capabilities. A microarray gene expression database was created that constitutes samples obtained from patients with diseases that possess a strong immune component. The meta-analysis strategy of the present invention allows for the identification of ubiquitous as well as disease-specific signatures.

Processing of Blood Samples. Blood samples were collected by venipuncture and immediately delivered at room temperature to the Baylor Institute for Immunology Research, Dallas, TX, for processing. Peripheral blood mononuclear cells (PBMCs) from 3-4 ml of blood were isolated via Ficoll gradient and immediately lysed in RLT reagent (Qiagen, Valencia, CA) with beta-mercaptoethanol (BME) and stored at -80°C prior to the RNA extraction step.

Microarray analysis. Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions and RNA integrity was assessed by using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). Target labeling was performed according to the manufacturer's standard protocol (Affymetrix Inc, Santa Clara, CA). Biotinylated cRNA targets were purified and subsequently hybridized to Affymetrix HG-U133A GeneChips (22,283 probe sets). Arrays were scanned using an Affymetrix confocal laser scanner. Microarray Suite, Version 5.0 (MAS 5.0; Affymetrix) software was used to assess fluorescent hybridization signals, to normalize signals, and to evaluate signal detection calls. Normalization of signal values per chip was achieved using the MAS 5.0 global method of scaling to the target intensity value of 500 per GeneChip. A gene expression analysis software program, GeneSpring, Version 7.1 (Agilent), was used to perform statistical analysis, hierarchical clustering and classification of samples.

Development and Analysis of Patterns of Significance. Gene expression data were generated for PBMCs obtained from patients and healthy volunteers using Affymetrix HG-U133A GeneChips that were run on the same Affymetrix system, using standard operating procedures. P values were obtained by comparing 7 groups of patients to their respective healthy control groups (Mann-Whitney rank test). The groups were composed of pediatric patients with: 1) Systemic Lupus Erythomatosus (SLE, 16 samples), 2) Influenza A (16 samples), 3) Staphylococcus aureus (16 samples), 4) Escherichia coli (16 samples) and 5) Streptococcus pneumoniae (14 samples); as well as adult transplant recipients: 6) Liver transplant patients that have accepted the graft under immunosuppressive therapy (16 samples) and 7) bone marrow transplant recipients undergoing graft versus host disease (GVHD, 12 samples). Control groups were also formed taking into account age, sex and project (10 samples in each group). Genes significantly changed (p<0.01) in the "study group" (Influenza A and/or SLE) were divided in two sets: over-expressed versus control and under-expressed versus control. P-values of the genes forming the over-expressed set were obtained for the "reference groups" (infections with E .coli, S. aureus, S. pneumoniae, Liver transplant recipients and graft versus host disease). P-values of the reference groups were set to 1 when genes were under-expressed. The same procedure was used in the set of genes under-expressed in study group, only this time P-values of the reference group were set to 1 when genes were over-expressed. P-value data were processed with a gene expression analysis software program, GeneSpring, Version 7.1 (Agilent), that was used to perform hierarchical clustering and group genes based on significance patterns.

Identification of blood leukocytes transcriptional signatures associated with acute Influenza A infection and SLE. Microarray gene expression data obtained from pediatric patients with either SLE or acute influenza A infections were used to identify transcriptional signatures characteristic of these two diseases (Figure 20). Statistical comparison of a similar number of patients (18 samples) to their respective control group (10 samples) identified: (1) 1826 differentially expressed genes that formed the Influenza signature (of those 703 were over-expressed (red) relative to controls and 1123 were under-expressed (blue), see Figure (20A); 2) 3382 differentially expressed genes formed the SLE signature (of those 1019 were over-expressed relative to controls and 2363 were under-expressed, see Figure 20B).

Figure 20 shows a statistical group comparison between patients and their respective controls. Figure 20A. Microarray expression obtained for PBMC isolated from 16 children with acute Influenza A infection (FLU) and 10 healthy volunteers (HV) were compared (Mann-Whitney rank test, p<0.01). Out of 1826 differentially expressed genes, 703 were over-expressed and 1123 under-expressed in patients. Figure 20B. An equivalent number of children with Systemic Lupus Erythomatosus (SLE) were compared to their respective set of 10 healthy volunteers (HV) (Mann-Whitney rank test, p<0.01). Out of 3382 differentially expressed genes, 1019 were over-expressed and 2363 under-expressed in patients. Figure 20C. Comparison of over-expressed and under-expressed gene lists obtained for SLE and FLU samples relative to their respective control groups (healthy volunteers).

Transformed expression levels are indicated by color scale, with red representing relatively high expression and blue indicating relatively low expression compared to the median expression for each gene across all donors.

Analysis of significance patterns. Next, the specificity of these signatures for each disease was determined. A substantial overlap was found between the sets of genes that were differentially expressed in FLU and SLE (Figure 20C), with 279 over-expressed and 490 under-expressed genes common to both diseases (19% and 16% of similarities, respectively). This observation was used to determine whether a specific disease signature could be obtained in the context of a broader set of diseases.

In order to address this question the analysis was extended to PBMC transcriptional datasets obtained for patients with acute infections caused by bacteria (E. coli, S. aureus and S. pneumoniae) as well as transplant recipients (liver recipients who have accepted the allograft under pharmacological immunosuppressive therapy and bone marrow recipients with graft versus host disease). Patterns of significance were analyzed for genes that were specifically over-expressed in SLE compared to Influenza (Figure 1, 740 genes). This approach allowed the visualization of the significance of changes in levels of gene expression for each disease compared to its respective control group (age and sex matched healthy volunteers). Genes were arranged according to significance patterns by hierarchical clustering.

Of the 4 patterns identified, 2 were found to be largely specific to SLE (Figure 21: P1 - 98 genes, and P3 - 193 genes). In conclusion, the method was used to identify sets of genes, particularly among P3, that displayed a high degree of specificity for SLE when compared to 6 other diseases.

Figure 21 is an analysis of patterns of significance for genes over-expressed in SLE patients but not in patients with acute Influenza A infection. The genes used for this analysis were significantly over-expressed in patients with SLE compared to their respective control group (Mann-Whitney P<0.05) and not in patients with acute influenza A infection were selected for this analysis (740 genes). P values were obtained for five additional groups of patients: E. coli, S. aureus, S. pneumoniae, Liver transplant recipients and patients with graft vs host disease. The values were imported into a microarray data analysis software package (see methods for details). Four patterns were identified: SLE-1 to 4. Significance levels are indicated by color scale, with darker green representing lower P-values and white indicating a P-value of 1.

Identification of a common disease signature. An important proportion of genes from Figure 21 were induced ubiquitously (P2 - 222 genes and P4 - 225 genes). This finding suggests that these different diseases may share common transcriptional components in the blood constituting a "sickness" signature. In order to investigate this possibility sets of genes were analyzed that were shared between Influenza and SLE signatures (Figure 20C: 279 genes over-expressed, and 490 under-expressed).

Figure 22 shows Patterns of Significance for genes common to Influenza A and SLE. Genes overexpressed (left panel, OVER) and underexpressed (right panel, UNDER) in both patients with Influenza A (FLU) and SLE were examined in the context of other diseases: acute infections with E. coli, S. aureus, S. pneumoniae, liver transplant recipients (transplant) and bone marrow recipients with graft versus host disease (GVHD). Significance levels are indicated by color scale, with dark green representing lower P-values and white indicating a P-value of 1.

Patterns of significance were generated for these genes across all 7 diseases as described above. Three subsets were identified among the genes that were over-expressed in patients with Influenza A infection and SLE: one changing in most diseases, another presenting significant differences in all diseases, while the third was more specific to Influenza and SLE (Figure 22A, respectively P1, P2 and P3). Equivalent patterns can be found upon analysis of a set of under-expressed genes common to Influenza and SLE (Figure 22B, P4-7). Interestingly, the group of patient with significance patterns that were the most similar to Influenza and SLE had Graft Versus Host Disease. The parallelism was particularly striking for the set of under-expressed genes (Figure 22B).

Functional analysis of significance patterns. Finally, functional annotations associated to the patterns identified on Figure 22 were extracted. Genes associated with "defense response" were preferentially found in two patterns (P2-3 on Figures 3 & 4; Fisher's test for over-representation of this functional category: p<0.0005). These genes were expressed at higher levels compared to healthy. The list includes Defensin alpha 3, Azurocidin 1, Stabilin 1 (P2); the tumor necrosis factor family member TRAIL, and Galectin 3 binding protein (P3). Conversely under-expressed genes belonging to patterns P4-6 were preferentially associated with "structural constituent of ribosome" (Fisher's test for over-representation of this functional category in P4-6: p<0.0001). These genes include multiple ribosomal protein family members (e.g. RPS10, RPL37, and RPL13). Genes belonging to the set of over-expressed genes the most specific to Influenza and SLE (P3) were preferentially associated to "interferon response" (p<0.0001, e.g. myxovirus resistance 1, interferon alpha-inducible protein 16, double stranded RNA inducible protein kinase), while genes in P1 were uniquely associated to "heavy metal binding" (p<0.0001, reflecting an overabundance of members of the metallothionein family).

Figure 23 is a functional analysis of genes shared by patients with Influenza infection and Lupus grouped according to significance patterns. Sets of genes forming the different patterns indicated on Figure 22 (P1-7) were subjected to functional analyses. The histograms indicate the percentage of genes associated to a given annotation for each of the sets. Over-expressed genes = red, under-expressed = blue. P1 n= 71 genes; P2 n=118; P3 n=85; P4 n=117; P5 n=184; P6 n=120; P7 n=46.

The comparative analysis of PBMC transcriptional patterns identified disease-specific as well as ubiquitous expression signatures. Different degrees of disease specificity were observed among the genes found to be common between the transcriptional profiles of PBMCs obtained from patients with Influenza infection and SLE. Differences in significance patterns were translated into distinct functional associations. Indeed, the genes that were most specific to Influenza and SLE relative to 5 other diseases were the most strongly associated to biological themes such as: "Interferon induction" (over-expressed genes; Figures 22 and 23: P3) or "structural constituent of ribosome" (under-expressed genes; Figures 22 and 24: P4). These observations permit to validate the relevance of this approach. This analysis facilitates the interpretation of microarray data by placing disease signatures in a much broader context.

In addition to contributing to a better understanding of disease processes the meta-analysis of PBMC transcriptional datasets has important implications for clinical diagnostic with: (1) the identification of discriminatory disease-specific signatures; as the screening of tens of thousands of potential markers will in most cases permit to pinpoint a limited number of transcripts that uniquely characterize a disease; and (2) the identification of a sentinel signature; as sets of genes for which expression changes in a wide range of health disorders could potentially be used in a screening assay for early disease detection.

Patients with metastatic melanoma display an endogenous transcriptional signature of immunosuppression similar to that induced by pharmacological treatments in patients who underwent liver transplant. The present invention provides a method and apparatus to identify patients at high risk of melanoma progression. In addition, the present invention also provides a method and apparatus for monitoring indicators of immunosuppression could help adjusting the dosage of immunosuppressive drugs and balance risks of rejection and side effects for liver transplant recipients.

It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.

REFERENCES

Agostini, L., Martinon, F., Bums, K., McDermott, M. F., Hawkins, P. N., and Tschopp, J. (2004). NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325.
Barrett, W. L., First, M. R., Aron, B. S., and Penn, I. (1993). Clinical course of malignancies in renal transplant recipients. Cancer 72, 2186-2189.
Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., Maillot, M. C., Portier, A., Couderc, J., Galanaud, P., et al. (2003). Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 101, 729-738.
Bordea, C., Wojnarowska, F., Millard, P. R., Doll, H., Welsh, K., and Morris, P. J. (2004). Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 77, 574-579.
Carroll, R. P., Ramsay, H. M., Fryer, A. A., Hawley, C. M., Nicol, D. L., and Harden, P. N. (2003). Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 41, 676-683.
Chaussabel, D., and Sher, A. (2002). Mining microarray expression data by literature profiling. Genome Biol 3, RESEARCH0055.
Choi, B. M., Pae, H. O., Jeong, Y. R., Kim, Y. M., and Chung, H. T. (2005). Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 327, 1066-1071.
Corradetti, M. N., Inoki, K., and Guan, K. L. (2005). The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280, 9769-9772.
D'Adamio, F., Zollo, O., Moraca, R., Ayroldi, E., Bruscoli, S., Bartoli, A., Cannarile, L., Migliorati, G., and Riccardi, C. (1997). A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7, 803-812.
Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4, 941-952.
Gerlini, G., Romagnoli, P., and Pimpinelli, N. (2005). Skin cancer and immunosuppression. Crit Rev Oncol Hematol 56, 127-136.
Jachimczak, P., Apfel, R., Bosserhoff, A. K., Fabel, K., Hau, P., Tschertner, I., Wise, P., Schlingensiepen, K. H., Schuler-Thurner, B., and Bogdahn, U. (2005). Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int J Cancer 113, 88-92.
Kovanen, P. E., Rosenwald, A., Fu, J., Hurt, E. M., Lam, L. T., Giltnane, J. M., Wright, G., Staudt, L. M., and Leonard, W. J. (2003). Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem 278, 5205-5213.
Lee, J. H., Torisu-Itakara, H., Cochran, A. J., Kadison, A., Huynh, Y., Morton, D. L., and Essner, R. (2005a). Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11, 107-112.
Lee, Y. R., Yang, I. H., Lee, Y. H., Im, S. A., Song, S., Li, H., Han, K., Kim, K., Eo, S. K., and Lee, C. K. (2005b). Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood.
Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., and Linehan, D. C. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169, 2756-2761.
Monti, P., Leone, B. E., Zerbi, A., Balzano, G., Cainarca, S., Sordi, V., Pontillo, M., Mercalli, A., Di Carlo, V., Allavena, P., and Piemonti, L. (2004). Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 172, 7341-7349.
Powell, J. D., Lerner, C. G., Ewoldt, G. R., and Schwartz, R. H. (1999). The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol 163, 6631-6639.
Puente Navazo, M. D., Valmori, D., and Ruegg, C. (2001). The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 167, 6431-6440.
Seimiya, M., Wada, A., Kawamura, K., Sakamoto, A., Ohkubo, Y., Okada, S., Hatano, M., Tokuhisa, T., Watanabe, T., Saisho, H., et al. (2004). Impaired lymphocyte development and function in ClastS/Stral3/DECl-transgenic mice. Eur J Immunol 34, 1322-1332.
Soares, M. P., Lin, Y., Anrather, J., Csizmadia, E., Takigami, K., Sato, K., Grey, S. T., Colvin, R. B., Choi, A. M., Poss, K. D., and Bach, F. H. (1998). Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 4, 1073-1077.
Theodosiou, A., Smith, A., Gillieron, C., Arkinstall, S., and Ashworth, A. (1999). MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene 18, 6981-6988.
Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., and Ferradini, L. (2004). Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173, 1444-1453.
Winoto, A., and Littman, D. R. (2002). Nuclear hormone receptors in T lymphocytes. Cell 109 Suppl, S57-66.
Woltman, A. M., van der Kooij, S. W., Coffer, P. J., Offringa, R., Daha, M. R., and van Kooten, C. (2003). Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101, 1439-1445.
Xu, X., Su, B., Barndt, R. J., Chen, H., Xin, H., Yan, G., Chen, L., Cheng, D., Heitman, J., Zhuang, Y., et al. (2002). FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation 73, 1835-1838.

Table 12 Module-by-module comparison of genes expression levels in patients with metastatic melanoma vs. healthy volunteers. Patients with melanoma (n=22) vs. Healthy Volunteer (n=23) - training test Mann Whitney U test p-value<0.05, no mtc

221739_at	0.95782816	1236.3346	1.1074278	1418.6411	0.0419
217148_x_at	1.0001118	1071.8698	0.8419552	919.35004	0.0395
221004_s_at	0.9632601	358.4826	0.6395204	275.68634	0.0373
214973_x_at	0.95571476	425.2174	0.7533219	331.37726	0.0275
217227_x_at	1.030817	252.42172	0.7421306	194.39093	0.0267
217281_x_at	0.9731019	195.9739	0.5853659	134.62273	0.0228
221253_s_at	1.0117456	1245.6392	0.8528783	1057.9501	0.0187
214768_x_at	0.9577761	382.38693	0.7833054	317.42725	0.0187
214916_x_at	1.0031506	836.6	0.7976999	648.4591	0.0187
216207_x_at	0.99609053	1815.187	0.76317847	1397.0773	0.0175
216557_x_at	0.976244	291.37393	0.7877697	237.53636	0.0108
211635_x_at	0.95895207	312.03043	0.65123487	220.43636	0.00867
211634_x_at	0.9670513	337.26523	0.67734057	237.45454	0.00641
211798_x_at	0.9414217	490.5	0.6210052	330.48642	0.00593
205267_at	0.9441677	1333.8263	0.59434533	875.75	0.00398
215214_at	1.0556614	210.14351	0.6043143	141.03635	0.00337
216401_x_at	0.90682054	343.88696	0.41231337	181.18634	0.00261
214836_x_at	1.0400113	1534.1781	0.6920298	1034.5046	0.00116
211881_x_at	0.96697015	412.35217	0.7305791	315.13635	0.00116
211650_x_at	0.9814827	215.1913	0.40998137	108.97729	0.00105
217022_s_at	0.83105236	5844.505	0.32260314	3146.8455	0.000867
216853_x_at	0.9752875	187.34348	0.56240225	122.90455	0.000384
217179_x_at	1.0001303	404.84348	0.61423665	278.5318	0.000384
215121_x_at	1.011581	7666.9604	0.5861822	5019.491	0.000345
209138_x_at	0.99642843	7415.57	0.58257836	4781.964	0.000223
211645_x_at	1.0724704	1021.34796	0.66694844	655.9682	0.000158
211908_x_at	1.0104389	154.12175	0.48859146	78.85	0.000158
215176_x_at	0.9650824	1707.6132	0.52609867	967.5227	0.000141
221651_x_at	1.0071738	13620.529	0.63826245	9160.868	0.000111
216984_x_at	0.9702421	631.7958	0.53891784	363.07272	0.000111
217258_x_at	0.92905986	192.33913	0.45039603	114.42273	0.00008
212592_at	1.0162625	873.5739	0.44719663	393.49088	0.00006
214677_x_at	0.95363015	8469.707	0.52562743	5229.05	0.00005
221671_x_at	1.0028782	13795.262	0.5931697	8619.091	0.00003
214669_x_at	0.9574678	2535.991	0.5320335	1533.1046	0.00002
211644_x_at	0.9865403	714.4	0.59137183	491.3318	0.00001
215379_x_at	0.94754726	1798.8262	0.60458195	1160.209	0.00001
213502_x_at	1.0198038	1779.4697	0.647953	1129.6864	0.00000
215946_x_at	1.0226241	968.33484	0.652376	634.5455	0.00000
211430_s_at	0.9557637	3228.7043	0.34361708	1392.868	0.00000
215118_s_at	1.0264945	666.8652	0.45220152	296.60913	0.00000
214777_at	0.9772283	331.58698	0.45065597	171.59091	0.00000
				27
				0

215240_at
214525_x_at	0.9848302	322.36084	1.3282202	442.75455	0.0443
201108_s_tt	0.9146578	356.29565	1.3576593	612.44104	0.0395
202555_s_at	0.9885717	296.20438	1.3414105	362.7636	0.0373
208792_s_at	0.8612959	807.19556	1.2635909	1124.9318	0.0373
34408_at	0.96183056	182.31737	1.1373757	219.56363	0.0373
217963_s_at	1.1339012	1563.9651	1.5669028	2227.7456	0.0351
216956_s_at	0.7829213	204.1348	1.5463859	415.91818	0.0331
201121_s_at	1.0322056	1613.4347	1.2225119	1934.8318	0.0243
218771_s_at	0.99680185	431.49997	1.42558	581.89545	0.0228
201120_s_at	0.94010484	340.50867	1.42432	520.25	0.0214
208546_x_at	0.8914968	153.6913	1.3705896	228.33636	0.0153
206390_x_at	0.92774665	5643.8003	1.3453588	8165.2554	0.0143
221211_s_at	0.91162527	728.28687	1.5703968	1208.6091	0.0133
215492_x_at	1.0163302	440.34348	1.2563187	549.9545	0.0124
200665_s_at	0.88955754	1178.2607	1.3896513	1828.4362	0.0124
204081_at	1.0017431	4611.0264	1.3459872	5716.1274	0.01
209301_at	0.8715413	527.3521	1.6178412	996.9409	0.00867
209911_x_at	1.0457131	499.37827	1.4152079	703.6182	0.00835
206110_at	0.91896015	598.5217	1.5700213	915.52264	0.00692
203585_at	0.9754219	985.7871	1.2642365	1237.1998	0.00431
204069_at	0.97689235	183.36089	1.3654811	258.06366	0.00239
203414_at	0.91576725	1835.5477	1.4408619	2731.3635	0.00168
204838_s_at	1.0724757	356.96957	1.802362	579.2273	0.00168
208527_x_at	0.99865276	315.16528	1.2899728	411.1136	0.00153
206655_s_at	0.95771337	710.26086	1.7583773	1352.2181	0.00031
202708_s_at	1.020722	641.77405	1.6268821	1041.6364	0.00001


M1.1	Total = 69 transcripts	1	Overexpressed
41	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
221739_at	IL27w	AL524093	56005
217148_x_at	IGLV	immunoglobulin lambda variable region			AJ249377	28831
221004_s_at	ITM2C; E25; BRI3; E25C; ITM3; BRICD2C	integral membrane protein 3			NM_030926	81618
214973_x_at	IGVH3	immunoglobulin heavy chain variable region			AJ275469	3502
217227_x_at	IGL@	immunoglobulin lambda light chain VJC region			X93006	3535
217281_x_at	IGHV	immunoglobulin heavy chain variable region			AJ239383	3502
221253_s_at	TXNDC5; ERP46; UNQ364; EndoPDI; MGC3178	thioredoxin domain containing 5 isoform 2; thioredoxin domain containing 5 isoform 1			NM_030810	81567
214768_x_at	IGKC	BG540628	3514
214916_x_at	IGHM	BG340548	3507
216207_x_at	IGKV1D-13	AW408194	28902
216557_x_at	A1VH3	rearranged immunoglobulin heavy chain			U92706	3502
211635_x_at	IGH@	M24670	3507
211634_x_at	IGH@	M24669	3507
211798_x_at	IGLJ3	single-chain antibody			AB001733	28831
205267_at	POU2AF1; BOB1; OBF1; OCAB; OBF-1	POU domain, class 2, associating factor 1			NM_006235	5450
215214_at	IGL@	H53689	3535
216401_x_at	IGKV	immunoglobulin kappa chain variable region			AJ408433
214836_x_at	IGKC	BG536224	3514
211881_x_at	IGLJ3	VEGF single chain antibody			AB014341	28831
211650_x_at	IGHM	L34164	3507
217022_a_at	IGHM	immunoglobulin A1-A2 lambda hybrid GAU heavy chain			S55735	3507
216853_x_at	IGLJ3	immunoglobulin light chain variable region			AF234255	28831
217179_x_at	IGL@	immunoglobulin lambda light chain			X79782	3535
215121_x_at	IGLJ3	AA680302	28831
209138_x_at	IGLJ3	M87790	28831
211645_x_at	IgK	immunoglobulin kappa-chain VK-1			M85256	3514
211908_x_at	IGHM	IgM			M87268	3507
215176_x_at	IGKC	AW404894	3514
221651_x_at	IGKC	Unknown (protein for MGC:12418)			BC005332	3514
216984_x_at	IGLJ3	immunoglobulin light chain V-J region			D84143	28831
217258_x_at	IGL	immunoglobulin lambda chain			AF043583
212592_at	IGJ	AV733266	3512
214677_x_at	IGLJ3	X57812	28831
221671_x_at	IGKC	M63438	3514
214669_x_at	IGKC	BG485135	3514
211644_x_at	IGKC	L14458	3514
215379_x_at	IGLJ3	AV698647	3535
213502_x_at	IGLL3; 16.1	lambda L-chain C region			X03529	91316
215946_x_at	LOC91316	AL022324	91316
211430_s_at	IGHG3	M87789	3502
215118_s_at	AW519168
214777_at	IGKC	BG482805	3514
M1.2 Total = 96 transcripts			27	Overexpressed
0	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
215240_at	ITGB3	AI189839	3690
214525_x_at	MLH3; HNPCC; S240II117	mutL homolog 3		AB039667	27030
201108_a_at	THBS1	AI812030	7057
202555_s_at	MYLK; KRP; MLCK; MLCK108; MLCK210; FLJ12216	myosin light chain kinase isoform 6; myosin light chain kinase isoform 1; myosin light chain kinase isoform 2; myosin light chain kinase isoform 3A; myosin light chain kinase isoform 3B; myosin light chain kinase isoform 4; myosin light chain kinase isofo		NM_005965	4638
208792_s_at	CLU; CLI; APOJ; SGP2; SGP-2; SP-40; TRPM2; TRPM-2; MGC24903	clusterin isoform 1; clusterin isoform 2		M25915	1191
34408_at	RTN2; NSP2; NSPL1	reticulon 2 isoform A; reticulon 2 isoform B; reticulon 2 isoform C; reticulon 2 isoform D		AF004222	6253
217963_s_at	NGFRAP1; Bex; BEX3; NADE; HGR74; DXS6984E	nerve growth factor receptor (TNFRSF16) associated protein 1 isoform b; nerve growth factor receptor (TNFRSF16) associated protein 1 isoform a		NM_014380	27018
216956_s_at	ITGA2B; GTA; CD41; GP2B; CD41B; GPIIb	integrin alpha 2b precursor		AF098114	3674
201121_s_at	PGRMC1; MPR; HPR6.6	progesterone receptor membrane component 1		NM_006667	10857
218711_s_at	SDPR; SDR; PS-p68	serum deprivation response protein		NM_004657	8436
201121_s_at	PGRMC1	AL547946	10857
208546_x_at	HIST1H2BH; H2B/j; H2BFJ	H2B histone family, member J		NM_003524	8345
206390_x_at	PF4; CXCL4; SCYB4	platelet factor 4 (chemokine (C-X-C motif) ligand 4)		NM_002619	5196
221211_s_at	C21orf7; TAK1L	chromosome 21 open reading frame 7		NM_020152	56911
215492_x_at	PTCRA	AL035587	17155
200665_s_at	SPARC; ON	secreted protein, acidic, cysteine-rich (osteonectin)		NM_003118	6678
204081_at	NRGN; RC3; hng	neurogranin		NM_006176	4900
209301_at	CA2; CA-II	carbonic anhydrase II		M36532	760
209911_x_at	HIST1H2BD; H2B/b; H2BFB; H2B.1B; HIRIP2; dJ221C16.6	H2B histone family, member B		BC002842	3017
206110_at	HIST1H3H; H3/k; H3FK; H3F1K	H3 histone family, member K		NM_003536	8357
203585_at	ZNF185	zinc finger protein 185 (LIM domain)		NM_007150	7739
204069_at	MEIS1	Meis1 homolog		NM_002398	4211
203414_at	MMD; MMA; PAQR11	monocyte to macrophage differentiation-associated precursor		NM_012329	23531
204838_s_at	MLH3; HNPCC; S240II117	mutL homolog 3		NM_014381	27030
208527_x_at	HIST1H2BE; H2B.h; H2B/h; H2BFH; dJ221C16.8	H2B histone family, member H		NM_003523	8344
206655_s_at	GP1BB; CD42c	glycoprotein Ib beta polypeptide precursor		NM_000407	2812
202708_s_at	HIST2H2BE; GL105; H2B.1; H2B/q; H2BFQ	H2B histone family, member Q		NM_003528	8349
M1.3	Total = 47 transcripts	0	Overexpressed
38	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
202431_s_at	MYC; c-Myc	v-myc myelocytomatosis viral oncogene homolog		NM_002467	4609
213674_x at	IGHG3	AI858004	3502
204208_at	RNGTT; HCE; HCE1; hCAP; CAP1A	RNA guanylyltransferase and 5'-phosphatase		NM_003800	8732
202759_s_at	AKAP2	BE879367	11217
215925_s_at	CD72; LYB2	CD72 antigen		AF283777	971
39318_at	TCL1A	T-cell lymphoma-1		X82240	8115
219471_at	C13orf18; FLJ21562	chromosome 13 open reading frame 18		NM_025113	80183
212827_at	IGHM; MU	X17115	3507
206896_s_at	GNG7	guanine nucleotide binding protein (G protein), gamma 7		NM_005145	2788
218781_at	SMC6L1; FLJ22116	SMC6 protein		NM_024624	79677
206398_s_at	CD19; B4; MGC12802	CD19 antigen		NM_001770	930
201689_s_at	TPD52	BE974098	7163
205297_s_at	CD79B; B29; IGB	CD79B antigen isoform 1 precursor; CD79B antigen isoform 2 precursor		NM_000626	974
210889_s_at	FCGR2B; CD32; FCG2; IGFR2	Fc fragment of IgG, low affinity IIb, receptor for (CD32) isoform 2; Fc fragment of IgG, low affinity IIb, receptor for (CD32) isoform 3; Fc fragment of IgG, low affinity IIb, receptor for (CD32) isoform 4; Fc fragment of IgG, low affinity IIb, receptor f		M31933	2213
217979_at	TM4SF13; NET-6; FLJ22934	tetraspan NET-6		NM_014399	27075
206478_at	KIAA0125	KIAA0125 gene product		NM_014792	9834
204004_at	PAWR	AI336206	5074
220068_at	VPREB3; 8HS20; N27C7-2	pre-B lymphocyte gene 3		NM_013378	29802
204581_at	CD22; SIGLEC-2	CD22 antigen		NM_001771	933
206759_at	FCER2; CD23; FCE2; CD23A; IGEBF	Fc fragment of IgE, low affinity II, receptor for (CD23A)		NM_002002	2208
206255_at	BLK; MGC10442	B lymphoid tyrosine kinase		NM_001715	640
203642_s_at	COBLL1; KIAA0977	COBL-like 1		NM_014900	22837
213772_s_at	GGA2	BF196572	23062
209583_s_at	CD200; MRC; MOX1; MOX2; OX-2	CD200 antigen isoform b; CD200 antigen isoform c; CD200 antigen isoform a precursor		AF063591	4345
212386_at	AK021980
219498_s_at	BCL11A; EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; KIAA1809; BCL11A-XL	B-cell CLL/lymphoma 11A isoform 2; B-cell CLL/lymphoma 11A isoform 1; B-cell CLL/lymphoma 11A isoform 5; B-cell CLL/lymphoma 11A isoform 3		NM_018014	53335
219497_s_at	BCL11A; EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; KIAA1809; BCL11A-XL	B-cell CLL/lymphoma 11A isoform 2; B-cell CLL/lymphoma 11A isoform 1; B-cell CLL/lymphoma 11A isoform 5; B-cell CLL/lymphoma 11A isoform 3		NM_022893	53335
44790_s_at	C13orf18	AI129310	80183
205671_s_at	HLA-DOB	major histocompatibility complex, class II, DO beta precursor		NM_002120	3112
210356_x_at	MS4A1; B1; S7; Bp35; CD20; MS4A2; LEU-16; MGC3969	membrane-spanning 4-domains, subfamily A, member 1		BC002807	931
207777_s_at	SP140; LYSP100-A; LYSP100-B	SP140 nuclear body protein isoform 2; SP140 nuclear body protein isoform 1		NM_007237	11262
213891_s_at	AI927067
220059_at	BRDG1; STAP1; STAP-1	BCR downstream signaling 1		NM_012108	26228
217418_x_at	MS4A1; B1; S7; Bp35; CD20; MS4A2; LEU-16; MGC3969	membrane-spanning 4-domains, subfamily A, member 1		X12530	931
205861_at	SPIB; SPI-B	Spi-B transcription factor (Spi-1/PU.1 related)		NM_003121	6689
207655_s_at	BLNK; Ly57; SLP65; BLNK-s; SLP-65	B-cell linker		NM_013314	29760
219073_s_at	OSBPL10; ORP10; OSBP9; FLJ20363	oxysterol-binding protein-like protein 10		NM_017784	11488
219667_s_at	BANK1; FLJ20706	B-cell scaffold protein with ankyrin repeats 1		NM_017935	55024
M1.4	Total = 87 transcripts	53	Overexpressed
0	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
221727_at	PC4	BF209507	10923
218319_at	PELI1	pellino protein			NM_020651	57162
210281_s_at	ZNF198; FIM; MYM; RAMP; SCLL	zinc finger protein 198			AL136621	7750
212434_at	HMGE	AL542571	80273
208881_x_at	IDI1	isopentenyl-diphosphate delta isomerase		BC005247	3422
209967_s_at	CREM; ICER; MGC17881; MGC41893	cAMP responsive element modulator isoform b; cAMP responsive element modulator isoform a; cAMP responsive element modulator isoform d; cAMP responsive element modulator isoform e; cAMP responsive element modulator isoform f; cAMP responsive element modula			D14826	1390
200870_at	STRAP; MAWD; PT-WD; UNRIP	serine/threonine kinase receptor associated protein			NM_007178	11171
60084_at	CYLD	AI453099	1540
202644_s_at	TNFAIP3; A20; TNFA1P2	tumor necrosis factor, alpha-induced protein 3			NM_006290	7128
218399_s_at	CDCA4; HEPP; FLJ20764;	cell division cycle associated 4		NM_017955	55038
204440_at	CD83; BL11; HB15	CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)		NM_004233	9308
203708_at	PDE4B; DPDE4; PDEIVB	phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)		NM_002600	5142
213134_x_at	BTG3	AI765445	10950
212665_at	DKFZP434J214	AL556438	25976
211999_at	H3F3B; H3.3B	H3 histone, family 3B	NM_005324	3021
208811_s_at	HSJ2	DnaJ-like 2 protein	AF080569	10049
208931_s_at	ILF3; MMP4; MPP4; NF90; NFAR; TCP80; DRBP76; NFAR-1; MPHOSPH4; NF-AT-90	interleukin enhancer binding factor 3 isoform b; interleukin enhancer binding factor 3 isoform a: interleukin enhancer binding factor 3 isoform c			AF147209	3609
214714_at	ZNF394; FLJ12298	zinc finger protein 99		AK022360	84124
205548_s_at	BTG3; ANA; TOB5; TOFA; TOB55; MGC8928	B-cell translocation gene 3		NM_006806	10950
212241_at	GRINL1A	AI632774	81488
216248_s_at	NR4A2; NOT; RNR1; HZF-3; NURR1; TINUR	nuclear receptor subfamily 4, group A, member 2 isoform a; nuclear receptor subfamily 4, group A, member 2 isoform b; nuclear receptor subfamily 4, group A, member 2 isoform c; nuclear receptor subfamily 4, group A, member 2 isoform d			S77154	4929
36711_at	MAFF	AL021977	23764
220046_s_at	CCNL1; BM-001; ania-6a	cyclin L1	NM_020307	57018
205281_s_at	PIGA; GPI3; PIG-A	phosphatidylinositol N-acetylglucosaminyltransferase subunit A isoform 1; phosphatidylinositol N-acetylglucosaminyltransferase subunit A isoform 2; phosphatidylinositol N-acetylglucosaminyltransferase subunit A isoform 3			NM_002641	5277
200731_s_at	PTP4A1	BF576710	7803
203752_s_at	JUND	jun D proto-oncogene	NM_005354	3727
220239_at	KLHL7; KLHL6; SBBI26	SBBI26 protein	NM_018846	55975
219228_at	ZNF331; RITA; ZNF361; ZNF463	zinc finger protein 331	NM_018555	55422
201751_at	KIAA0063	KIAA0063 gene product	NM_014876	9929
209020_at	C20orf111; HSPC207; dJ1183I21.1	chromosome 20 open reading frame 111			AF217514	51526
202861_at	PER1; hPER; RIGUI	period 1	NM_002616	5187
222044_at	C20orf67	AI199589	63935
213538_at	SON	AI936458	6651
207332_s_at	TFRC; CD71; TRFR	transferrin receptor	NM_003234	7037
210110_x_at	HNRPH3; 2H9	heterogeneous nuclear ribonucleoprotein H3 isoform a; heterogeneous nuclear ribonucleoprotein H3 isoform b			AF132363	3189
204622_x_at	NR4A2; NOT; RNR1; HZF-3; NURR1; TINUR	nuclear receptor subfamily 4, group A, member 2 isoform a; nuclear receptor subfamily 4, group A, member 2 isoform b; nuclear receptor subfamily 4, group A, member 2 isoform c; nuclear receptor subfamily 4, group A, member 2 isoform d			NM_006186	4929
212430_at	RNPC1	AL109955	55544
205214_at	STK17B; DRAK2	serine/threonine kinase 17b (apoptosis-inducing)			NM_004226	9262
202558_s_at	STCH	stress 70 protein chaperone, microsome-associated, 60kDa precursor			NM_006948	6782
210837_s_at	PDE4D; DPDE3; STRK1	cAMP-specific phosphodiesterase 4D			AF012074	5144
209510_at	RNF139; RCA1; TRC8; HRCA1; MGC31961	ring finger protein 139			AF064801	11236
208632_at	RNF10; RIE2; KIAA0262	ring finger protein 10			AL578551	9921
209457_at	DUSP5; HVH3	dual specificity phosphatase 5			U16996	1847
208078_s_at	TCF8; BZP; ZEB; ZEB1; AREB6; ZFHEP; NIL-2A; ZFHX1A; NIL-2-A	transcription factor 8 (represses interleukin 2 expression)			No_030751	6935
89948_at	C20orf67	AI743331	63935
202021_x_at	SUI1; A121; ISO1	putative translation initiation factor			AF083441	10209
212130_x_at	SUI1	AL537707	10209
212227_x_at	SUI1	AL516854	10209
207630_s_at	CREM; ICER; MGC17881; MGC41893	cAMP responsive element modulator isoform b; cAMP responsive element modulator isoform a; cAMP responsive element modulator isoform d; cAMP responsive element modulator isoform e; cAMP responsive element modulator isoform f; cAMP responsive element modula			NM_001881	1390
222045_s_at	C20orf67	iduronate-2-sulfatase isoform a precursor; iduronate-2-sulfatase isoform b precursor			AI199589	63935
206342_x_at	IDS; MPS2; SIDS				NM_006123	3423
200732_s_at	PTP4A1	BF576710	7803
200779_at	ATF4; CREB2; TXREB; CREB-2; TAXREB67	activating transcription factor 4			NM_001675	468
M1.5	Total = 130 transcripts	28	Overexpressed
0	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
209263_x_at	TM4SF7; NAG-2; TSPAN-4;	transmembrane 4 superfamily member 7		BC000389	7106
211284_s_at	GRN; PEPI; PCDGF	granulin		BC000324	2896
204393_s_at	ACPP; PAP; ACP3; ACP-3	prostatic acid phosphatase precursor		NM_001099	55
221731_x_at	CSPG2; VERSICAN	chondroitin sulfate proteoglycan 2 (versican)		J02814	1462
209949_at	NCF2; NOXA2; p67phox; P67-PHOX	neutrophil cytosolic factor 2		BC001606	4688
208702_x_at	APLP2; APPH; APPL2; CDEBP	amyloid beta (A4) precursor-like protein 2		BC000373	334
203508_at	TNFRSF1B; p75; TBPII; TNFBR; TNFR2; CD120b; TNFR80; TNF-R75; p75TNFR; TNF-R-II	tumor necrosis factor receptor 2 precursor		NM_001066	7133
222218_s_at	PILRA; FDF03	paired immunoglobulin-like type 2 receptor alpha isoform 1 precursor; paired immunoglobulin-like type 2 receptor alpha isoform 2 precursor; paired immunoglobulin-like type 2 receptor alpha isoform 3 precursor		AJ400843	29992
201743_at	CD14	CD14 antigen precursor		NM_000591	929
201360_at	CST3; AD8	cystatin C precursor		NM_000099	1471
217865_at	RNF130; GP; G1RZFP; GOLIATH	ring finger protein 130		NM_018434	55819
200743_s_at	CLN2; TPP1; LINCL; TPP I; TPP-I	tripeptidyl-peptidase I precursor		NM_000391	1200
217897_at	FXYD6	FXYD domain-containing ion transport regulator 6		NM_022003	53826
202902_s_at	CTSS; MGC3886	cathepsin S preproprotein		NM_004079	1520
218217_at	SCPEP1; RISC; HSCP1	serine carboxypeptidase 1 precursor protein		NM_021626	59342
217764_s_at	RAB31; Rab22B	RAB31, member RAS oncogene family		AF183421	11031
208248_x_at	APLP2; APPH; APPL2; CDEBP	amyloid beta (A4) precursor-like protein 2		NM_001642	334
208130_s_at	TBXAS1; TS; TXS; CYP5; THAS; TXAS; CYP5A1	thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) isoform TXS-I; thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) isoform TXS-II		NM_030984	6916
215049_x_at	CD163; M130; MM130	CD163 antigen isoform a; CD163 antigen isoform b		Z22969	9332
200838_at	CTSB; APPS; CPSB	cathepsin B preproprotein		NM_001908	1508
202833_s_at	SERPINA1; A1A; AAT; PI1; A1AT; MGC9222; MGC23330	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1		NM_000295	5265
215051_x_at	AIF1	BF213829	199
218454_at	FLJ22662	hypothetical protein FLJ22662		NM_024829	79887
205237_at	FCN1; FCNM	ficolin 1 precursor		NM_002003	2219
203773_x_at	BLVRA; BVRA	biliverdin reductase A		NM_000712	644
211729_x_at	BLVRA; BVRA	biliverdin reductase A		BC005902	644
209901_x_at	AIF1; IBA1; AIF-1; IRT-1	allograft inflammatory factor 1 isoform 3; allograft inflammatory factor 1 isoform 2; allograft inflammatory factor 1 isoform 1		U19713	199
201995_at	EXT1	exostosin 1		NM_000127	2131
M1.6	Total = 28 transcripts	0	Overexpressed
1	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
215221_at	AK025064
M1.7	Total = 127 transcripts	14	Overexpressed
0	Underexpressed
Systematic	Common _Affy	Product	Genbank	LocusLink
214459_x_at	HLA-C; D6S204; HLA-Cw7; HLA-JY3	major histocompatibility complex, class I, C precursor			M12679	51353
217740_x_at	RPL7A; TRUP; SURF3	ribosomal protein L7a			NM_000972	6130
201665_x_at	RPS17; RPS17L1; RPS17L2	ribosomal protein S17			NM_001021	6218
200716_x_at	RPL13A	ribosomal protein L13a			NM_012423	23521
211942_x_at	BF979419
201254_x_at	RPS6	ribosomal protein S6			NM_001010	6194
211296_x_at	UBC; HMG20	ubiquitin C			AB009010	7316
212788_x_at	FTL	BG537190	2512
221700_s_at	UBA52; CEP52; RPL40; HUBCEP52	ubiquitin and ribosomal protein L40 precursor			AF348700	7311
208729_x_at	HLA-B	D83043	3106
200905_x_at	HLA-E; HLA-6.2	major histocompatibility complex, class I, E precursor			NM_005516	3133
204102_s_at	EEF2; EEF-2	eukaryotic translation elongation factor 2			NM_001961	1938
212581_x_at	GAPD	BE561479	2597
211528_x_at	HLA-G2.2	b2 microglobulin			M90685	3135
M1.8	Total = 86 transcripts	0	Overexpressed
73	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
201447_at	TIA1	TIA1 protein isoform 1; TIA1 protein isoform 2			NM_022037
221081_s_at	FLJ22457	hypothetical protein FLJ22457			NM_024901	79961
213405_at	N95443
221865_at	DKFZp547P234	BF969986	20319
202184_s_at	NUP133; hNUP133; FLJ10814; MGC21133	nucleoporin 133kDa			NM_018230	55746
202453_s_at	GTF2H1; BTF2; TFIIH	general transcription factor IIH, polypeptide 1, 62kDa			NM_005316	2965
219243_at	HIMAP4; IAN1; hIAN1; MSTP062; FLJ11110	immunity associated protein 4			NM_018326	55303
202227_s_at	BRD8; SMAP; p120	bromodomain containing 8 isoform 1; bromodomain containing 8 isoform 2; bromodomain containing 8 isoform 3			NM_006696	10902
218455_at	NFS1; NIFS; HUSSY-08	NFS1 nitrogen fixation 1 isoform a precursor;			NM_021100	9054
NFS1 nitrogen fixation 1 isoform b precursor
208121_a_at	PTPRO; PTPU2; GLEPP1; PTP-U2	receptor-type protein tyrosine phosphatase O isoform b precursor; receptor-type protein tyrosine phosphatase O isoform a precursor; receptor-type protein tyrosine phosphatase O isoform d precursor; receptor-type protein tyrosine phosphatase O isoform c pr			NM_002848	5800
212378_at	GART	BE966876	2618
218303_x_at	LOC51315	hypothetical protein LOC51315		NM_016618	51315
218614_at	FLJ10652	hypothetical protein FLJ10652		NM_018169	55196
209175_at	SEC23IP; P125; MSTP053	Sec23-interacting protein p125		AK001135	11196
213838_at	RANBP9	AA191426	51406
210053_at	TAF5	AW138827	6877
219146_at	FLJ22729	hypothetical protein FLJ22729		NM_024683	79736
212872_s_at	USP49; TRFP; PR00213;	TRF-proximal protein	AK023092	25862
201121_s_at	PUM2; PUMH2; PUML2; KIAA0235	pumilio homolog 2	D87078	23369
218371_s_at	PSPC1; PSP1; FLJ10955	paraspeckle protein 1	NM_018282	55269
203159_at	GLS; GLS1; KIAA0838	glutaminase C	NM_014905	2744
210541_s_at	RFP; RNF76; TRIM27	ret finger protein isoform alpha; ret finger protein isoform beta			AF230394	5987
212116_at	RFP; RNF76; TRIM27	ret finger protein isoform alpha; ret finger protein isoform beta			NM_006510	5987
214129_at	PDE4DIP	AI821791	9659
218716_x_at	MTO1; CGI-02	mitochondrial translation optimization 1 homolog; mitochondrial translation optimization 1 homolog isoform IV			NM_012123	25821
212405_s_at	CGI-01; KIAA0859	CGI-01 protein isoform 2; CGI-01 protein isoform 1			AL049669	51603
209828_s_at	IL16; LCF; IL-16; prIL-16; HsT19289	interleukin 16 isoform 1 precursor; interleukin 16 isoform 2			M90391	3603
218588_s_at	C5orf3; 133K02	chromosome 5 open reading frame 3		NM_018691	10827
212170_at	RBM12; SWAN; KIAA0765; HRIHFB2091	RNA binding motif protein 12		AB018308	10137
207338_s_at	ZNF200	zinc finger protein 200		NM_003454	7752
204676_at	DKFZP564K2062	DKFZP564K2062 protein		NM_015421	25880
219303_at	C13orf7; FLJ13449	chromosome 13 open reading frame 7		NM_024546	79596
64418_at	AI472320
213626_at	CBR4; FLJ14431	carbonic reductase 4	AL049442	84869
212632_at	AF131808
206734_at	JRKL; HHMJG	jerky homolog-like	NM_003772	8690
208968_s_at	ZFP64; ZNF338	zinc finger protein 64 isoform a; zinc finger protein 64 isoform b; zinc finger protein 64 isoform c; zinc finger protein 64 isoform d			NM_018197	55734
53968 at	KIAA1698	AI869988	80789
212740_at	PIK3R4	BF740111	30849
206332_s_at	IFI16; IFNGIP1	interferon, gamma-inducible protein 16			NM_005531	3428
217907_at	MRPL18; HSPC071; MRP-L18	mitochondrial ribosomal protein L18			NM_014161	29074
203584_at	KIAA0103	KIAA0103	NM_014673	9694
203614_at	UTP14C; KIAA0266; 2700066J21Rik	UTP14, U3 small nucleolar ribonucleoprotein, homolog C			NM_021645	9724
218534_s_at	VG5Q; FLJ10283; HSU84971; HSU84971	angiogenic factor VG5Q		NM_018046	55109
203143_s_at	KIAA0040	T79953	9674
205140_at	FPGT; GFPP	fucose-1-phosphate guanyltransferase		NM_003838	8790
219130_at	FLJ10287; FLJ11219	hypothetical protein FLJ10287	NM_019083	54482
219123_at	ZNF232	zinc finger protein 232		NM_014519	7775
214440_at	NAT1; AAC1	N-acetyltransferase 1		NM_000662	9
222028_at	ZNF45	AI967981	7596
212453_at	KIAA1279; DKFZP586B0923	KIAA1279		AB033105	26128
202060_at	SH2BP1; TSBP; p150TSP;	SH2 domain binding protein 1		NM_014633	9646
218138_at	MKKS; KMS; MKS; BB56; HMCS	McKueick-Kaufman syndrome protein		NM_018848	8195
41329_at	FLJ10706	AI458463	57147
202983_at	SMARCA3	AI760760	6596
220992_s_at	Clorf25; MGC57134; bG120K12.3	N2,N2-dimethylguanosine tRNA methyltransferase-like			NM_030934	81627
203611_at	TERF2; TRF2; TRBF2	telomeric repeat binding factor 2			NM_005652	7014
201142_at	EIF2S1	AA577698	1965
219467_at	FLJ20125	hypothetical protein FLJ20125			NM_017676	54826
219913_s_at	CRNKL1; HCRN; MSTP021	crooked neck-like 1 protein			NM_016652	51340
202322_s_at	GGPS1; GGPPS; GGPPS1	geranylgeranyl diphosphate synthase 1			NM_004837	9453
203427_at	ASF1A; CIA; DKFZP547E2110	ASF1 anti-silencing function 1 homolog A			NM_014034	25842
219777_at	hIAN2; FLJ22690	human immune associated nucleotide 2			NM_024711	79765
201832_s_at	VDP; TAP; P115	vesicle docking protein p115			NM_003715	8615
219128_at	FLJ20558	hypothetical protein FLJ20558			NM_017880	54980
200854_at	NCOR1; N-CoR; TRAC1; hN-CoR; KIAA1047; hCIT529I10	nuclear receptor co-repressor 1			NM_006311	9611
209662_at	CETN3; CEN3; MGC12502	centrin 3			BC005383	1070
211758_x_at	TXNDC9; APACD	ATP binding protein associated with cell differentiation			BC005968	10190
214988_s_at	SON; SON3; BASS1; DBP-5; NREBP; C21orf50; FLJ21099; KIAA1019	SON DNA-binding protein isoform G; SON DNA-binding protein isoform B; SON DNA-binding protein isoform E; SON DNA-binding protein isoform A; SON DNA-binding protein isoform C; SON DNA-binding protein isoform F			X63071	6651
207513_s_at	ZNF189	zinc finger protein 189			NM_003452	7743
218056_at	BFAR; BAR; RNF47	apoptosis regulator			NM_016561	51283
212402_at	KIAA0853	BE895685	23091
218242_s_at	SUV420H1; CGI-85; MGC703; MGC21161	suppressor of variegation 4-20 homolog 1 isoform 2; suppressor of variegation 4-20 homolog 1 isoform 1			NM_017635	51111
M2.1	Total = 72 transcripts	1	Overexpressed
4	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
204655_at	CCLS; SISd; SCYAS; RANTES; TCP228; D17S136E; MGC17164	small inducible cytokine A5 precursor		NM_002985	6352
216920_s_at	TCRGC2	M27331	6965
209813_x_at	TRGV9; V2; TCRGV9	M16768	6965
215806_x_at	TRGC2; TCRGC2; TRGC2(2X); TRGC@ (3X)	M13231	6967
207723_s_at	KLRC3; NKG2E; NKG2-E	killer cell lectin-like receptor subfamily C, member 3 isoform NKG2-E; killer cell lectin-like receptor subfamily C, member 3 isoform NKG2-H		NM_002261	3823
M2.2	Total = 44 transcripts	5	Overexpressed
6	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
201161_s_at	CSDA; DBPA; ZONAB	cold shock domain protein A		NM_003651	8531
207205_at	CEACAM4; CGM7	carcinoembryonic antigen-related cell adhesion molecule 4		NM_001817	1089
219281_at	MSRA	methionine sulfoxide reductase A		NM_012331	4482
212531_at	LCN2; NGAL	lipocalin 2 (oncogene 24p3)		NM_005564	3934
208650_s_at	CD24	BG327863	934
204881_s_at	UGCG; GCS	ceramide glucosyltransferase		NM_003358	7357
208651_x_at	CD24; CD24A	CD24 antigen		M58664	934
266_s_at	CD24; CD24A	CD24 antigen		L33930	934
204351_at	S100P	S100 calcium binding protein P		NM_005980	6286
216379_x_at	CD24	AK000168	934
209771_x_at	CD24	AA761181	934
M2.3	Total = 94 transcripts	12	Overexpressed
2	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
217748_at	ADIPOR1; PAQR1; ACDCR1; CGI-45	adiponectin receptor 1		NM_015999	51094
218847_at	IMP-2; IMP2; VICKZ2	IGF-II mRNA-binding protein 2		NM_006548	10644
202947_s_at	GYPC; GE; GPC	glycophorin C isoform 1; glycophorin C isoform 2		NM_002101	2995
221824_s_at	MGC26766	AA770170	22097
204848_x_at	HBG1; HBGA; HBGR	A-gamma globin		NM_000559	3047
209018_s_at	PINK1	BF432478	65018
207827_x_at	SNCA; PD1; NACP; PARK1; PARK4	alpha-synuclein isoform NACP140; alpha-synuclein isoform NACP112		L36675	6622
200075_s_at	GUK1; GMK	guanylate kinase 1		BC006249	2987
220757_s_at	UBXD1; UBXDC2	UBX domain containing 1		NM_025241	80700
219458_s_at	NSUN3; FLJ22609	NOL1/NOP2/Sun domain family 3		NM_022072	63899
207667_s_at	MAP2K3; MEK3; MKK3; MAPKK3; PRKMK3	mitogen-activated protein kinase kinase 3 isoform A; mitogen-activated protein kinase kinase 3 isoform B; mitogen-activated protein kinase kinase 3 isoform C		NM_002756	5606
201178_at	FBXO7; FBX7; FBX07	F-box only protein 7		NM_012179	25793
214273_x_at	CGTHBA	AV704353	8131
211475_s_at	BAG1	BCL2-associated athanogene isoform 1L		AF116273	573
M2.4	Total = 118 transcripts	10	Overexpressed
1	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
217906_at	KLHDC2; LCP; HCLP-1	kelch domain containing 2		NM_014315	23588
201993_x_at	HNRPDL; HNRNP; JKTBP; JKTBP2; laAUF1	heterogeneous nuclear ribonucleoprotein D-like		NM_005463	9987
200631_s_at	SET; 2PP2A; IGAAD; I2PP2A; PHAPII; TAF-IBETA	SET translocation (myeloid leukemia-associated)		NM_003011	6418
201258_at	RPS16	ribosomal protein S16		NM_001020	6217
211666_x_at	RPL3; TARBP-B	ribosomal protein L3		L22453	6122
222099_s_at	DKFZP434D1335	AW593859	26065
201230_s_at	ARIH2; ARI2; TRIAD1	ariadne homolog 2		NM_006321	10425
221476_s_at	RPL15; EC45; RPL10; RPLY10; RPYL10	ribosomal protein L15		AF279903	6138
217747_s_at	RPS9	ribosomal protein S9		NM_001013	6203
207132_x_at	PFDN5; MM1; MM-1; PFD5; MGC5329	prefoldin 5 isoform alpha; prefoldin 5 isoform beta; prefoldin 5 isoform gamma		NM_002624	5204
200081_s_at	RPS6	BE741754	6194
M2.5	Total = 242 transcripts	3	Overexpressed
1	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
216809_at	CYLC1; CYCL1	cylicin	Z22780	1538
218692_at	FLJ20366	hypothetical protein FLJ20366			NM_017786	55638
220375_s_at	NM_024752
211572_s_at	SLC23A2; NBTL1; SVCT2; YSPL2;	solute carrier family 23 (nucleobase			AF092511	9962
SLC23A1; KIAA0238	transporters), member 2
M2.6 Total = 110 transcripts			33	Overexpressed
1	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
213590_at	SLC16A5	AA705628	9121
201422_at	IFI30; GILT; IP30; IFI-30; MGC32056	interferon, gamma-inducible protein 30 preproprotein		NM_006332	10437
212041_at	ATP6V0D1	AL566172	9114
202917_s_at	S100A8; P8; MIF; NIF; CAGA; CFAG; CGLA; L1Ag; MRP8; CP-10; MA387; 60B8AG	S100 calcium-binding protein A8		NM_002964	6279
208949_a_at	LGALS3; GAL3; MAC2; CBP35; GALBP; LGALS2	galectin-3		BC001120	3958
208704_x_at	APLP2; APPH; APPL2; CDEBP	amyloid beta (A4) precursor-like protein 2		BC000373	334
202192_s_at	GAS7	growth arrest-specific 7 isoform b		NM_005890	8522
204232_at	FCER1G	Fc fragment of IgE, high affinity I, receptor for, gamma polypeptide precursor		NM_004106	2207
202388_at	RGS2; G0S8	regulator of G-protein signalling 2, 24kDa		NM_002923	5997
201425_at	ALDH2; ALDM; ALDHI; ALDH-E2; MGC1806	mitochondrial aldehyde dehydrogenase 2 precursor		NM_000690	217
205922_at	VNN2; FOAP-4; GPI-80	vanin 2 isoform 1 precursor; vanin 2 isoform 2		NM_004665	8875
204122_at	TYROBP; DAP12; KARAP; PLOSL	TYRO protein tyrosine kinase binding protein isoform 1 precursor; TYRO protein tyrosine kinase binding protein isoform 2 precursor		NM_003332	7305
211474_s_at	SERPINB6	BC004948	5269
213187_x_at	BG538564
209179_s_at	LENG4; BB1	leukocyte receptor cluster (LRC) member 4 protein		BC003164	79143
202201_at	BLVRB; FLR; BVRB	biliverdin reductase B (flavin reductase (NADPH))		NM_000713	645
211429_s_at	SERPINAL	PR02275		AF119873	5265
203645_s_at	CD163; M130; MM130	CD163 antigen isoform a; CD163 antigen isoform b		NM_004244	9332
200839_s_at	CTSB; APPS; CPSB	cathepsin B preproprotein		NM_001908	1508
208703_s_at	APLP2; APPH; APPL2; CDEBP	amyloid beta (A4) precursor-like protein 2		BC000373	334
202426_s_at	RXRA; NR2B1	retinoid X receptor, alpha		NM_002957	6256
203535_at	S100A9; MIF; NIF; P14; CAGB; CFAG; CGLB; L1AG; LIAG; MRP14; 60B8AG; MAC387	S100 calcium-binding protein A9		NM_002965	6280
203167_at	TIMP2; CSC-21K	tissue inhibitor of metalloproteinase 2 precursor		NM_003255	7077
204053_x_at	PTEN; BZS; MHAM; TEP1; MMAC1; PTEN1; MGC11227	phosphatase and tensin homolog		U96180	5728
213006_at	CEBPD	AV655640	1052
211404_s_at	APLP2; APPH; APPL2; CDEBP	amyloid beta (A4) precursor-like protein 2		BC004371	334
214875_x_at	APLP2	AW001847	334
201200_at	CREG1	cellular repressor of E1A-stimulated genes		NM_003851	8804
200645_at	GABARAP; MM46	GABA(A) receptor-associated protein		NM_007278	11337
202803_s_at	ITGB2; LAD; CD18; MF17; MFI7; LCAMB; LFA-1	integrin beta chain, beta 2 precursor		NM_000211	3689
209288_s_at	CDC42EP3; UB1; CEP3; BORG2	Cdc42 effector protein 3		AL136842	10602
200701_at	NPC2; HE1; NP-C2; MGC1333	Niemann-Pick disease, type C2 precursor		NM_006432	10577
221541_at	DKFZP434B044	hypothetical protein DKFZp434B044		AL136861	83716
205068_s_at	GRAF	BE671084	23092
M2.7	Total = 43 transcripts	0	Overexpressed
0	Underexpressed
M2.8	Total = 104 transcripts	1	Overexpressed
29	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
204019_s_at	SH3YL1; Ray; DKFZP586F1318	SH3 domain containing, Ysc84-like 1		NM_015677	26751
219315_s_at	C16orf30; CLP24; FLJ20898	claudin-like protein 24		NM_024600	79652
212413_at	SEPT6; SEP2; KIAA0128; MGC16619; MGC20339	septin 6 isoform B; septin 6 isoform A; septin 6 isoform D		D50918	23157
213340_s_at	KIAA0495	KIAA0495		AB007964	57212
218877_s_at	C6orf75; MDS024; dJ187J11.2	chromosome 6 open reading frame 75		NM_021820	60487
216262_s_at	.TIF2	AL050318	60436
213971_s_at	JJAZ1	AI924660	23512
212549_at	AL080218
221558_s_at	LEF1; TCF1ALPHA	lymphoid enhancer binding factor-1		AF288571	51176
214482_at	ZNF46; KUP; ZBTB25	zinc finger protein 46 (KUP)		NM_006977	7597
218259_at	MKL2; MRTF-B; NPD001	megakaryoblastic leukemia 2 protein		NM_014048	57496
202969_at	DYRK2	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 1; dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 2		Y09216
218918_at	MAN1C1; HMIC; MAN1A3	mannosidase, alpha, class 1C, member 1		NM_020379	57134
219765_at	FLJ12586	hypothetical protein FLJ12586		NM_024620	79673
212771_at	LOC221061	AU150943
216945_x_at	PASK; STK37; PASKIN; KIAA0135; DKFZP434O051	PAS domain containing serine/threonine kinase		U79240	23178
218510_x_at	FLJ20152	AI816291	54463
212642_s_at	HIVEP2	AL023584	3097
212313_at	MGC29816	hypothetical protein MGC29816		BC004344	91782
219724_s_at	KIAA0748	NM_014796	9840
212400_at	AL043266
213039_at	ARHGEF18; KIAA0521; MGC15913	Rho-specific guanine nucleotide exchange factor p114		AB011093	23370
218437_s_at	LZTFL1	leucine zipper transcription factor-like 1		NM_020347	54585
221601_s_at	TOSO	AI084226	9214
221602_s_at	TOSO	regulator of Fas-induced apoptosis		AF057557	9214
219734_at	SIDT1; SID1; SID-1; FLJ20174; B830021E24Rik	SID1 transmembrane family, member 1		NM_017699	54847
206337_at	CCR7; BLR2; EBI1; CDw197;	chemokine (C-C motif) receptor 7 precursor		NM_001838	1236
218932_at	FLJ20729; FLJ20760	hypothetical protein FLJ20729		NM_017953	54680
215967_s_at	LY9	AL582804	4063
57082_at	ARH	AA169780	26119
M2.9	Total = 122 transcripts	2	Overexpressed
5	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
211537_x_at	MAP3K7; TAK1; TGF1a	mitogen-activated protein kinase kinase kinase 7 isoform A; mitogen-activated protein kinase kinase kinase 7 isoform B; mitogen-activated		AF218074	6885
protein kinase kinase kinase 7 isoform C; mitogen-activated protein kinase kinase kinase 7 isoform D
210235_s_at	PPFIA1; LIP1; LIP.1; LIPRIN; MGC26800	PTPRF interacting protein alpha 1 isoform b; PTPRF interacting protein alpha 1 isoform a		U22815	8500
200839_s_at	SMAP-5; SB140; FLJ30014	golgi membrane protein SB140		NM_030799	81555
200839_s_at	ENO1; NNE; PPH; MPB1; MBP-1; ENO1	enolase 1		U88968
207724_s_at	SPG4; FSP2; ADPSP; SPAST;	spastin isoform 1; spastin isoform 2		NM_014946	6683
221268_s_at	SGPP1; SPPasel	sphingosine-1-phosphatase		NM_030791	81537
201044_x_at	DUSP1	AA530892	1843
M2.10	Total = 44 transcripts	2	Overexpressed
4	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
221656_s_at	FLJ10521	hypothetical protein FLJ10521		BC003073	55160
208056_s_at	CBFA2T3; MTG16; MTGR2; ZMYND4	myeloid translocation gene-related protein 2 isoform MTG16a; myeloid translocation gene-related protein 2 isoform MTG16b		NM_005187	863
207761_s_at	DKFZP586A0522	DKFZP586A0522 protein		NM_014033	25840
201944_at	HEXB	hexosaminidase B peproprotein		NM_000521	3074
214030_at	DKFZp667G2110	BE501352	13154
221539_at	EIF4EBP1; PHAS-I	eukaryotic translation initiation factor 4E binding protein 1		AB044548	1978
M2.11	Total = 77 transcripts	0	Overexpressed
15	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
203627_at	IGF1R; JTK13	insulin-like growth factor 1 receptor precursor		NM_000875
221830_at	RAP2A	AI302106	5911
200839_s_at	TPR	BF110993	7175
200839_s_at	YY1; DELTA; NF-E1; UCRBP; YIN-YANG-1	YY1 transcription factor		NM_003403	7528
207700_s_at	NCOA3; ACTR; AIB1; RAC3; SRC3; pCIP; CTG26; CAGH16; TNRC14; TNRC16; TRAM-1	nuclear receptor coactivator 3 isoform b; nuclear receptor coactivator 3 isoform a		NM_006534	8202
200839_s_at	SNX27; MY014; KIAA0488; MGC20471	sorting nexin family member 27		NM_030918	81609
211503_s_at	RAB14	ras-related protein rab-14		AF112206	51552
200839_s_at	ZNF148; BERF-1; BFCOL1; ZBP-89; ZFP148; pHZ-52; HT-BETA	zinc finger protein 148 (pHZ-52)		L04282	7707
202971_s_at	DYRK2	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 1; dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 2		NM_006482	8445
200839_s_at	PRKCI; PKCI; DXS1179E; MGC26534; nPKC-iota	protein kinase C, iota		L18964	5584
209750 at	NR1D2	N32859	9975
200839_s_at	ALS2CR3	AV705253	66008
219757_s_at	C14orf101; FLJ20392	chromosome 14 open reading frame 101		NM_017799	54916
205798 at	IL7R; CD127; CDW127; IL-7R-alpha	interleukin 7 receptor precursor		NM_002185	3575
215342_s_at	RABGAP1L; HHL; TBC1D18;	RAB GTPase activating protein 1-like		AB019490	9910
M3.1	Total = 80 transcripts	0	Overexpressed
21	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
204747_at	IFIT3; IRG2; IFI60; IFIT4; ISG60; RIG- G; CIG-49; GARG-49	interferon-induced repeats 3 protein with tetratricopeptide		NM_001549	3437
203882_at	ISGF3G; p48; IRF9; IRF-9	interferon-stimulated gamma 48kDa transcription factor 3,		NM_006084	10379
211429_s_at	TRIM5; RNF88	tripartite motif tripartite motif tripartite motif protein TRIM5 isoform alpha; protein TRIM5 isoform gamma; protein TRIM5 isoform delta		AF220028	85363
209761_s_at	SP110; IFI41; IFI75; FLJ22835	SP110 nuclear body nuclear body protein body protein isoform protein isoform a; SP110 isoform b; SP110 nuclear c		AF280094	3431
202270_at	GBP1	guanylate binding inducible, 67kD protein 1, interferon-		NM_002053	2633
219014_at	PLAC8; C15	placenta-specific 8		NM_016619	51316
211429_s_at	OAS1; OIAS; IFI-4; OIASI	2',5'-oligoadenylate 2',5'-oligoadenylate synthetase 1 isoform E16; synthetase 1 isoform E18		NM_002534	4938
219209_at	IFIH1; Hlcd; MDA5; MDA-5	melanoma differentiation associated protein-5		NM_022168	64135
202869_at	OAS1; OIAS; IFI-4; OIASI	2',5'-oligoadenylate synthetase 1 isoform E16; 2',5'-oligoadenylate synthetase 1 isoform E18		NM_016816	4938
213361_at	PCTAIRE2BP	AW129593	23424
204972_at	OAS2; P69	2'-5'oligoadenylate synthetase 2 isoform p69; 2'-5'oligoadenylate synthetase 2 isoform p71		NM_016817	4939
219439_at	C1GALT1	core 1 alpha-R beta UDP-galactose:N-acetylgalactosamine-1,3-galactosyltransferase		NM_020156	56913
211429_s_at	STAT1; ISGF-3; STAT91	signal transducer 1 isoform alpha; of transcription 1 and activator of transcription signal transducer and activator isoform beta		NM_007315	6772
218085_at	SNF7DC2	SNF7 domain containing 2		NM_015961	51510
211429_s_at	FLJ20035; FLJ10787	hypothetical protein FLJ20035		NM_017631	55601
206133_at	HSXIAPAF1; XAF1	XIAP associated factor-1 isoform 1; XIAP associated factor-1 isoform 2		NM_017523	54739
202687_s_at	TNFSF10; TL2; APO2L; TRAIL; Apo-2L	tumor necrosis factor member 10 (ligand) superfamily,		U57059	8743
213293_s_at	TRIM22	AA083478	10346
218943_s_at	DDX58; RIG-I; FLJ13599	DEAD/H (Asp-Glu-Ala-Asp/His) polypeptide RIG-I box		NM_014314	23586
202269_x_at	GBP1	guanylate binding inducible, 67kD protein 1, interferon-		BC002666	2633
219691_at	SAMD9; C7orf5; FLJ20073; KIAA2004	sterile alpha motif domain containing 9		NM_017654	54809
M3.2	Total = 230 transcripts	99	Overexpressed
0	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
218032_at	SNN	Stannin			AF070673	8303
211429_s_at	LMNA; FPL; LFP; EMD2; FPLD; HGPS; LDP1; LMN1; LMNC; PRO1; CMD1A; CMT2B1; LGMD1B	lamin A/C isoform 2; precursor; lamin A/C lamin A/C isoform 1 isoform 3			NM_005572	4000
203140 at	BCL6; BCL5; LAZ3; BCL6A; ZNF51; ZBTB27	B-cell lymphoma 6 protein			NM_001706	604
206115_at	EGR3; PILOT	early growth response 3			NM_004430	1960
207993_s_at	CHP; SLC9A1BP	calcium binding protein P22			NM_007236	11261
213191_at	TRIF; TICAM1; PRVTIRB; MGC35334	TIR domain containing interferon-beta adaptor inducing			AF070530	14802
200868_s_at	ZNF313; RNF114	zinc finger protein 313			NM_018683	55905
201055_s_at	HNRPAO; hnRNPA0	heterogeneous nuclear ribonucleoprotein A0			NM_006805	10949
91682_at	FLJ20591	AI571298	54512
203003_at	MEF2D	AL530331	4209
201329_s_at	ETS2	v-ets erythroblastosis virus E26 oncogene			NM_005239	2114
homolog 2
201739_at	SGK; SGK1	serum/glucocorticoid regulated kinase			NM_005627	6446
211506_s_at	IL8	interleukin 8 C-terminal variant			AF043337	3576
217996_at	PHLDA1	AA576961	22822
216268_s_at	JAG1; AGS; AHD; AWS; HJ1; JAGL1	jagged 1 precursor	U77914	182
216260_at	DICER1; Dicer; HERNA; KIAA0928	dicerl	AK001827	23405
202498_s_at	SLC2A3; GLUT3	solute carrier family 2 (facilitated glucose transporter), member 3			NM_006931	6515
203888_at	THBD; TM; THRM; CD141	thrombomodulin precursor	NM_000361	7056
208092_s_at	FAM49A; FLJ11080; DKFZP566A1524	family with sequence similarity 49, member A			NM_030797	81553
219257_s_at	SPHK1	sphingosine kinase 1	NM_021972	8877
212432_at	HMGE	AL542571	80273
203887_s_at	THBD; TM; THRM; CD141	thrombomodulin precursor	NM_000361	7056
219382_at	SERTAD3; RBT1	RPA-binding trans-activator	NM_013368	29946
221654_s_at	USP3	SIH003	AF077040	9960
201858_s_at	PRG1; PPG; MGC9289; SERGLYCIN	proteoglycan 1, secretory granule precursor			J03223	5552
202672_s_at	ATF3	activating transcription factor 3 long isoform; activating transcription factor 3 delta Zip isoform			NM_001674	467
201531_at	ZFP36; TTP; GOS24; TIS11; NUP475; RNF162A	zinc finger protein 36, C3H type, homolog			NM_003407	7538
202657_s_at	TRIP-Br2	NM_014755	9792
209808_x_at	ING1	AW193656	3621
201490_s_at	PPIF; CYP3	peptidylprolyl isomerase F precursor			NM_005729	10105
203370_s_at	PDLIM7	enigma protein isoform 1; enigma protein isoform 2; enigma protein isoform 3; enigma protein isoform 4			NM_005451	9260
209545_s_at	RIPK2; RICK; RIP2; CARD3; CARDIAK	receptor-interacting serine-threonine kinase 2			AF064824	8767
220088_at	C5R1; C5A; C5AR; CD88	complement component 5 receptor 1 (C5a ligand)			NM_001736	728
217739_s_at	PBEF1	pre-B-cell colony enhancing factor 1 isoform a; pre-B-cell colony enhancing factor 1 isoform b			NM_005746	10135
203045_at	NINJ1; NIN1; NINJURIN	ninjurin 1	NM_004148	4814
208786_s_at	MAP1LC3B; MAP1A/1BLC3	microtubule-associated proteins 1A/1B light chain 3			AF183417	81631
217738_at	PBEF	BF575514	10135
212769_at	TLE3	AI567426	7090
216236_s_at	SLC2A3; GLUT3	solute carrier family 2 (facilitated glucose transporter), member 3			AL110298	6515
201236_s_at	BTG2; PC3; TIS21	B-cell translocation gene 2	NM_006763	7832
220712_at	NM_024984
205114_s_at	CCL3; MIP1A; SCYA3; G0S19-1; LD78ALPHA; MIP-1-alpha	chemokine (C-C motif) ligand 3		NM_002983	6348
201170_s_at	BHLHB2; DEC1; STRA13; Stra14	differentiated embryo chondrocyte expressed gene 1			NM_003670	8553
210190_at	STX11	syntaxin 11	AF071504	8676
200797_s_at	MCL1; TM; EAT; MCL1L; MCL1S; MGC1839	myeloid cell leukemia sequence 1 isoform 1; myeloid cell leukemia sequence 1 isoform 2			NM_021960	4170
202284_s_at	CDKN1A; P21; CIP1; SDI1; WAF1; CAP20; MDA-6	cyclin-dependent kinase inhibitor 1A			NM_000389	1026
36994_at	ATP6V0C; ATPL; VATL; Vma3; ATP6C; ATP6L	ATPase, H+ transporting, lysosomal, V0 subunit c			M62762	527
203094_at	MAD2L1BP; CMT2; KIAA0110; MGC11282	MAD2L1 binding protein isoform 1; MAD2L1 binding protein isoform 2			NM_014628	9587
201460_at	MAPKAPK2	AI141802	9261
217202_s_at	glutamine synthetase			U08626
204908_s_at	BCL3; BCL4; D19S37	B-cell CLL/lymphoma 3			NM_005178	602
200711_s_at	SKP1A	NM_003197	6500
219434_at	TREM1; TREM-1	triggering receptor expressed on myeloid cells 1			NM_018643	54210
206472_s_at	TLE3; ESG; ESG3; HsT18976; KIAA1547	transducin-like enhancer protein 3			NM_005078	7090
213138_at	ARID5A; MRF-1	AT rich interactive domain 5A isoform 2; AT rich interactive domain 5A isoform 1			M62324	10865
37028_at	PPP1R15A; GADD34	protein phosphatase 1, regulatory subunit 15A			U83981	23645
212146_at	PLEKHM2; KIAA0842	KIAA0842 protein	AB020649	23207
38037_at	DTR; DTS; HBEGF; HEGFL	diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor)			M60278	1839
212171_x_at	VEGF	H95344	7422
204095_s_at	ELL	AL521391	8178
202638_s_at	ICAM1; BB2; CD54	intercellular adhesion molecule 1 precursor			NM_000201	3383
216015_s_at	CIAS1; FCU; MWS; FCAS; NALP3; Clorf7; PYPAF1; AII/AVP; AGTAVPRL	cryopyrin isoform a; cryopyrin isoform b			AK027194	11454
212723_at	PTDSR; PSR; PTDSR1; KIAA0585	phosphatidylserine receptor			AK021780	23210
205409_at	FOSL2; FRA2; FLJ23306	FOS-like antigen 2	NM_005253	2355
203574_at	NFIL3; E4BP4; IL3BP1; NFIL3A; NF-IL3A	nuclear factor, interleukin 3 regulated			NM_005384	4783
213300_at	KIAA0404	AW168132	23130
204370_at	HEAB; CLP1; hClp1	ATP/GTP-binding protein	NM_006831	10978
211458_s_at	GABARAPL3	GABA-A receptor-associated protein			AF180519	23766
202497_x_at	SLC2A3; GLUT3	solute carrier family 2 (facilitated glucose transporter), member 3			NM_006931	6515
215501_s_at	DUSP10; MKP5; MKP-5	dual specificity phosphatase 10 isoform a; dual specificity phosphatase 10 isoform b			AK022513	11221
218033_s_at	SNN	Stannin	NM_003498	8303
212770_at	TLE3	AI567426	7090
202014_at	PPP1R15A; GADD34	protein phosphatase 1, regulatory subunit 15A			NM_014330	23645
210845_s_at	PLAUR; CD87; UPAR; URKR	plasminogen activator, urokinase receptor isoform 2 precursor; plasminogen activator, urokinase receptor isoform 3 precursor; plasminogen activator, urokinase receptor isoform 1 precursor			U08839	5329
203821_at	DTR; DTS; HBEGF; HEGFL	diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor)			NM_001945	1839
200663_at	CD63; MLA1; ME491; LAMP-3; OMA81h	CD63 antigen	NM_001780	967
208785_s_at	MAP1LC3B	BE893893	81631
201489_at	PPIF; CYP3	peptidylprolyl isomerase F precursor			BC005020	10105
210365_at	RUNX1; AML1; CBFA2; AMLCR1; PEBP2A2; PEBP2aB	runt-related transcription factor 1 isoform b; runt-related transcription factor 1 isoform a			D43967	861
205349_at	GNA15; GNA16	guanine nucleotide binding protein (G protein), alpha 15 (Gq class)			NM_002068	2769
222088_s_at	SLC2A14,	AA778684	14419
218023_s_at	C5orf6	putative nuclear protein	NM_016605	51307
202859_x_at	IL8; K60; NAF; GCP1; IL-8; LECT; LUCT; NAP1; 3-10C; CXCL8; GCP-1; LYNAP; MDNCF; MONAP; NAP-1; SCYB8; TSG-1; AMCF-I; b-ENAP	interleukin 8 precursor	NM_000584	3576
209304_x_at	GADD45B; MYD118; GADD45BETA; DKFZP566B133	growth arrest and DNA-damage-inducible, beta			AF087853	4616
218881_s_at	FOSL2	FOS-like antigen 2	NM_024530	79579
200919_at	PHC2; EDR2; HPH2	polyhomeotic 2-like isoform b; polyhomeotic 2-like isoform a			NM_004427	1912
203234_at	UPP1; UPASE; UDRPASE	uridine phosphorylase 1	NM_003364	7378
214696_at	MGC14376; DKFZp686006159	hypothetical protein MGC14376	AF070569	84981
209345_s_at	PI4KII	AL561930	55361
211924_s_at	PLAUR; CD87; UPAR; URKR	plasminogen activator, urokinase receptor isoform 2 precursor; plasminogen activator, urokinase receptor isoform 3 precursor; plasminogen activator, urokinase receptor isoform 1 precursor			AY029180	5329
210264_at	GPR35	G protein-coupled receptor 35			AF089087	2859
200730_s_at	PTP4A1	BF576710	7803
208937_s_at	ID1	inhibitor of DNA binding 1 isoform a; inhibitor of DNA binding 1 isoform b			D13889	3397
218880_at	FOSL2	N36408	2355
212722_s_at	PTDSR; PSR; PTDSR1; KIAA0585	phosphatidylserine receptor			AK021780	23210
219622_at	RAB20; FLJ20429	RAB20, member RAS oncogene family			NM_017817	55647
208869_s_at	GABARAPL1; GEC1; APG8L	GABA(A) receptor-associated protein like 1			AF087847	23710
213524_s_at	G0S2	putative lymphocyte G0/G1 switch gene			NM_015714	50486
201631_s_at	IER3; DIF2; IEX1; PRG1; DIF-2; GLY96; IEX-1; IEX-1L	immediate early response 3 immediate early response 3 isoform short; isoform long			NM_003897	8870
M3.3	Total = 230 transcripts	54	Overexpressed
6	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
214500_at	H2AFY; H2A.y; H2A/y; H2AFJ; mH2A1; H2AF12M; MACROH2A1.1; MACROH2A1.2	H2A histone family, member Y isoform 2; H2A histone family, member Y isoform 1; H2A histone family, member Y isoform 3		AF044286	9555
216338_s_at	C6orf109; KLIP1; dJ337H4.3; DKFZP566C243	chromosome 6 open reading frame 109		AK021433	25844
217995_at	SQRDL; CGI-44	sulfide dehydrogenase like		NM_021199	58472
211742_s_at	EVI2B; EVDB; D17S376	ecotropic viral integration site 2B		BC005926	2124
218388_at	PGLS; 6PGL	6-phosphogluconolactonase		NM_012088	25796
218017_s_at	FLJ22242	NM_025070	80140
207168_s_at	H2AFY; H2A.y; H2A/y; H2AFJ; mH2A1; H2AF12M; MACROH2A1.1; MACROH2A1.2	H2A histone family, member Y isoform 2; H2A histone family, member Y isoform 1; H2A histone family, member Y isoform 3		NM_004893	9555
220990_s_at	VMP1; DKFZP566I133	hypothetical protein DKFZp566I133		NM_030938	81671
205639_at	AOAH	acyloxyacyl hydrolase precursor		NM_001637	313
206488_s_at	CD36; FAT; GP4; GP3B; GPIV; PASIV; SCARB3	CD36 antigen		NM_000072	948
201463_s_at	TALDO1; TAL-H; TALDOR	transaldolase 1		NM_006755	6888
204620_s_at	CSPG2; VERSICAN	chondroitin sulfate proteoglycan 2 (versican)		NM_004385	1462
213733_at	MYO1F	BF740152	4542
214152_at	PIGB	AU144243	9488
210715_s_at	SPINT2; Kop; HAI2; HAI-2	serine protease inhibitor, Kunitz type, 2		AF027205	10653
212807_s_at	SORT1	BE742268	6272
217837_s_at	VPS24; NEDF; CGI-149	vacuolar protein sorting 24		NM_016079	51652
200808_s_at	ZYX	zyxin		NM_003461	7791
209575_at	IL10RB; CRFB4; CRF2-4; D21S58; D21S66; CDW210B; IL-10R2	interleukin 10 receptor, beta precursor		BC001903	3588
220034_at	IRAK3; IRAK-M	interleukin-1 receptor-associated kinase 3		NM_007199	11213
202788_at	MAPKAPK3; 3PK; MAPKAP3	mitogen-activated protein kinase-activated protein kinase 3		NM_004635	7867
205147_x_at	NCF4; MGC3810; P40PHOX	neutrophil cytosolic factor 4 (40kD) isoform 1; neutrophil cytosolic factor 4 (40kD) isoform 2		NM_000631	4689
209473_at	ENTPD1	AV717590	953
212268_at	SERPINB1; EI; LEI; PI2; MNEI; M/NEI; ELANH2	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1		NM_030666	1992
209616_s_at	CES1; CEH; CES2; HMSE; SES1; HMSE1	carboxylesterase 1 (monocyte/macrophage serine esterase 1)		S73751	1066
202888_s_at	ANPEP; CD13; LAP1; PEPN; gp150	membrane alanine aminopeptidase precursor		NM_001150	290
208270_s_at	RNPEP; DKFZP547H084	arginyl aminopeptidase (aminopeptidase B)		NM_020216	6051
201118_at	PGD; 6PGD	phosphogluconate dehydrogenase		NM_002631	5226
200824_at	GSTP1; PI; DFN7; GST3; FAEES3	glutathione transferase		NM_000852	2950
212657_s_at	IL1RN	AW083357	3557
89476_r_at	NPEPL1	AA398062	79716
201095_at	DAP	death-associated protein		NM_004394	1611
208700_s_at	TKT; TKT1	transketolase		L12711	7086
201483_s_at	SUPT4H1; SPT4H	suppressor of Ty 4 homolog 1		BC002802	6827
203175_at	RHOG; ARHG	ras homolog gene family, member G		NM_001665	391
201470_at	GST01; P28; GSTTLp28	glutathione-S-transferase omega 1		NM_004832	9446
215706_x_at	ZYX	zyxin		BC002323	7791
215489_x_at	HOMER3	AI871287	9454
208699_x_at	TKT	BF696840	7086
218945_at	MGC2654; FLJ12433	hypothetical protein MGC2654		NM_024109	79091
200941_at	HSBP1	heat shock factor binding protein 1		AK026575	3281
202096_s_at	BZRP; MBR; PBR; PBR-S	peripheral benzodiazapine receptor isoform PBR; peripheral benzodiazapine receptor isoform PBR-S		NM_000714	706
212043_at	TGOLN2; TGN38; TGN46; TGN48; TGN51; TTGN2; MGC14722	trans-golgi network protein 2		AK025557
208074_s_at	AP2S1; AP17; CLAPS2; AP17-DELTA	adaptor-related protein complex 2, sigma 1 subunit isoform AP17; adaptor-related protein complex 2, sigma 1 subunit isoform AP17delta		NM_021575	1175
219256_s_at	SH3TC1; FLJ20356	SH3 domain and tetratricopeptide repeats 1		NM_018986	54436
202671_s_at	PDXK; PKH; PNK; C21orf97	pyridoxal kinase		NM_003681	8566
211047_x_at	AP2S1; AP17; CLAPS2; AP17-DELTA	adaptor-related protein complex 2, sigma 1 subunit isoform AP17; adaptor-related protein complex 2, sigma 1 subunit isoform AP17delta		BC006337	1175
218606_at	ZDHHC7; ZNF370; FLJ10792; FLJ20279	zinc finger, DHHC domain containing 7		NM_017740	55625
204099_at	SMARCD3; Rsc6p; BAF60C; CRACD3	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 isoform 2; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 isoform 1		NM_003078	6604
207809_s_at	ATP6AP1; 16A; CF2; ORF; Ac45; XAP3; XAP-3; ATP6S1; VATPS1; ATP6IP1	ATPase, H+ transporting, lysosomal accessory protein 1 precursor		NM_001183	537
221059_s_at	CHST6; MCDC1	carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6		NM_021615	4166
205863_at	S100A12; p6; CGRP; MRP6; CAAF1; ENRAGE	S100 calcium-binding protein A12		NM_005621	6283
201379_s_at	TPD52L2; D54; hD54	tumor protein D52-like 2 isoform e; tumor protein D52-like 2 isoform f; tumor protein D52-like 2 isoform a; tumor protein D52-like 2 isoform b; tumor protein D52-like 2 isoform c; tumor protein D52-like 2 isoform d		NM_003288	7165
213902_at	ASAH1	AI379338	427
206130_s_at	ASGR2; L-H2; ASGP-R; Hs.1259	asialoglycoprotein receptor 2 isoform a; asialoglycoprotein receptor 2 isoform b; asialoglycoprotein receptor 2 isoform c		NM_001181	433
219549_s_at	RTN3; ASYIP; NSPL2; NSPLII	reticulon 3 isoform a; reticulon 3 isoform b; reticulon 3 isoform c; reticulon 3 isoform d		NM_006054	10313
204214_s_at	RAB32	RAB32, member RAS oncogene family		NM_006834	10981
203081_at	CTNNBIP1; ICAT	beta-catenin-interacting protein ICAT		NM_020248	56998
200736_s_at	GPX1; GSHPX1; MGC14399	glutathione peroxidase 1 isoform 1; glutathione peroxidase 1 isoform 2		NM_000581	2876
200866_s_at	PSAP; GLBA; SAP1	prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)		M32221	5660
M3.4	Total = 323 transcripts	1	Overexpressed
107	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
208841_s_at	G3BP2	Ras-GTPase activating protein SH3 domain-binding protein 2 isoform a; Ras-GTPase activating protein SH3 domain-binding protein 2 isoform b			AB014560	9908
201385_at	DHX15; DBP1; HRH2; DDX15; PRP43; PrPp43p	DEAH (Asp-Glu-Ala-His) box polypeptide 15			NM_001358	1665
221502_at	KPNA3	AL120704	3839
212200_at	KIAA0692	KIAA0692 protein			AB014592	5451
212180_at	CRKL	v-crk sarcoma virus CT10 oncogene homolog (avian)-like			AK000311
209689_at	FLJ10996; MGC13033	hypothetical protein FLJ10996	BC005078	83609
221493_at	TSPYL1; SIDDT	hypothetical protein	AL136629	7259
214467_at	GPR65; TDAG8; hTDAG8	G protein-coupled receptor 65	NM_003608	8477
218263_s_at	LOC58486	Buster1 transposase-like protein		NM_021211	58486
201934_at	PR02730	N92524	80335
215716_s_at	ATP2B1; PMCA1	plasma membrane calcium ATPase 1 isoform 1a; plasma membrane calcium ATPase 1 isoform 1b			L14561	490
202265_at	BMI1; RNF51; MGC12685	B lymphoma Mo-MLV insertion region			NM_005180	648
203303_at	TCTE1L; TCTEX1L	t-complex-associated-testis-expressed 1-like			NM_006520	8971
201031_s_at	HNRPH1; hnRNPH	heterogeneous nuclear ribonucleoprotein H1			NM_005520	3187
209654_at	KIAA0947	KIAA0947 protein	BC004902	23379
210346_s_at	CLK4	AF212224
204512_at	HIVEP1; MBP-1; ZNF40; PRDII-BF1	human immunodeficiency virus type I enhancer binding protein 1			NM_002114	3096
204009_s_at	KRAS2	W80678	3845
55692_at	ELM02	W22924	63916
208896_at	DDX18; MrDb	DEAD (Asp-Glu-Ala-Asp) box polypeptide 18			BC003360	8886
207956_x_at	APRIN; AS3; CG008; FLJ23236; KIAA0979	androgen-induced prostate proliferative shutoff associated protein			NM_015928	23047
207996_s_at	C18orf1	chromosome 18 open reading frame 1 isoform gamma 1; chromosome 18 open reading frame 1 isoform gamma 2; chromosome 18 open reading frame 1 isoform beta 1; chromosome 18 open reading frame 1 isoform alpha 1; chromosome 18 open reading frame 1 isoform alpha			NM_004338	753
221596_s_at	DKFZP564O0523	hypothetical protein DKFZp56400523		AL136619	84060
212706_at	RASA4; GAPL; CAPRI; KIAA0538	RAS p21 protein activator 4	AB011110	10156
202653_s_at	AXOT; MARCH-VII; DKFZP586F1122	axotrophin	BC003404	64844
208661_s_at	TTC3; DCRR1; RNF105; TPRDIII	tetratricopeptide repeat domain 3		D84294	7267
212366_at	ZNF292	AA972711	23036
212984_at	BE786164
212569_at	KIAA0650	AA868754	23347
214855_s_at	GARNL1; GRIPE; TULIP1; KIAA0884; DKFZp566D133;	GTPase activating Rap/RanGAP domain-like 1 isoform 1; GTPase activating Rap/RanGAP domain-like 1 isoform 2			AL050050	26134
214363_s_at	MATR3	AA129420	9782
202853_s_at	RYK; RYK1; D3S3195	RYK receptor-like tyrosine kinase precursor			NM_002958	6259
212855_at	KIAA0276	KIAA0276 protein	D87466	23142
202386_s_at	LKAP; KIAA0430; A-362G6.1	limkain b1 isoform 1; limkain b1 isoform 2			NM_019081
213372_at	LOC152559	AW173157
221020_s_at	MFTC	mitochondrial folate transporter/carrier			NM_030780	81034
217812_at	YTHDF2; HGRG8; NY-REN-2	high glucose-regulated protein 8		NM_016258	51441
221559_s_at	MIS12; hMis12; MGC2488; 2510025F08Rik	MIS12 homolog	BC000229	79003
208127_s_at	SOCS5; CIS6; CISH6; Cish5; SOCS-5; KIAA0671	suppressor of cytokine signaling 5		NM_014011	9655
209187_at	DR1	AW516932	1810
202918_s_at	PREI3; 2C4D; MOB1; MOB3; CGI-95; MGC12264	preimplantation protein 3 isoform 1; preimplantation protein 3 isoform 2		AF151853	25843
209451_at	TANK; TRAF2; I-TRAF	TRAF interacting protein TANK isoform a; TRAF interacting protein TANK isoform b		U59863	10010
217863_at	PIAS1; GBP; DDXBP1; GU/RH-II	protein inhibitor of activated STAT, 1		NM_016166
215696_s_at	KIAA0310	KIAA0310 protein	BC001404	9919
221905_at	CYLD; EAC; CDMT; CYLD1; HSPC057; KIAA0849	cylindromatosis (turban tumor syndrome)		AJ250014	1540
209666_s_at	CHUK; IKK1; IKKA; IKBKA; TCF16; NFKBIKA; IKK-alpha	conserved helix-loop-helix ubiquitous kinase			AF080157	1147
212920_at	AV682285
218172_s_at	DER1	derlin-1	NM_018630	55493
213212_x_at	AI632181
213227_at	PGRMC2	BE879873	10424
203250_at	RBM16; KIAA1116	RNA-binding motif protein 16	NM_014892	22828
218352_at	RCBTB1; GLP; CLLD7; CLLL7; FLJ10716	regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 1			NM_018191	55213
212927_at	SMC5L1; KIAA0594	SMC5 protein	AB011166	23137
201713_s_at	RANBP2; NUP358	RAN binding protein 2	D42063	5903
221257_x_at	FBX038; MOKA; Fbx38; SP329	F-box protein 38 isoform a; F-box protein 38 isoform b			NM_030793	81545
212006_at	UBXD2; UBXDC1; KIAA0242	UBX domain containing 2	D87684	23190
218386_x_at	USP16; UBP-M	ubiquitin specific protease 16 isoform b; ubiquitin specific protease 16 isoform a			NM_006447	10600
211375_s_at	ILF3; MMP4; MPP4; NF90; NFAR; TCP80; DRBP76; NFAR-1; MPHOSPH4; NF-AT-90	interleukin enhancer binding factor 3 isoform b; interleukin enhancer binding factor 3 isoform a; interleukin enhancer binding factor 3 isoform c			AF141870	3609
203403_s_at	RNF6	ring finger protein 6 isoform 1; ring finger protein 6 isoform 2			NM_005977	6049
218649_x_at	SDCCAG1; NY-CO-1; FLJ10051	serologically defined colon cancer antigen 1			NM_004713	9147
209724_s_at	ZFP161	AL534416	7541
214709_s_at	KTN1; CG1; KNT; KIAA0004	kinectin 1	Z22551	3895
212588_at	PTPRC	AI809341	5788
219031_s_at	CGI-37; HSPC031	Saccharomyces cerevisiae Nip7p homolog			NM_016101	51388
218499_at	MST4; MASK	serine/threonine protein kinase MASK			NM_016542	51765
218674_at	FLJ13611	hypothetical protein FLJ13611	NM_024941	80006
216944_s_at	ITPR1; IP3R; IP3R1; Insp3r1	inositol 1,4,5-triphosphate receptor, type 1			U23850	3708
221568_s_at	LIN7C; VELI3; LIN-7C; MALS-3; LIN-7-C; FLJ11215	lin-7 homolog C	AF090900	55327
217833_at	SYNCRIP; pp68; NSAP1; GRY-RBP; dJ3J17.2	synaptotagmin binding, cytoplasmic RNA interacting protein			NM_006372
212231_at	FBXO21; FBX21; KIAA0875; DKFZp434G058	F-box only protein 21 isoform 2; F-box only protein 21 isoform 1			AK001699	23014
213070_at	AV682436
208671_at	TDE2; TDE1L; TMS-2; KIAA1253	tumor differentially expressed 2			AF164794	57515
201486_at	RCN2; E6BP; ERC55; ERC-55	reticulocalbin 2, EF-hand calcium binding domain			NM_002902	5955
201437_s_at	EIF4E; CBP; EIF-4E; EIF4EL1	eukaryotic translation initiation factor 4E			NM_001968	1977
221970_s_at	DKFZP586L0724	AU158148	25926
218098_at	ARFGEF2; BIG2; dJ1164I10.1	ADP-ribosylation factor guanine nucleotide-exchange factor 2			NM_006420
212536_at	ATP11B; ATPIF; ATPIR; KIAA0956; MGC46576; DKFZP434J238; DKFZP434N1615	KIAA0956 protein	AB023173	23200
206695_x_at	ZNF43; HTF6; KOX27; ZNF39L1	zinc finger protein 43 (HTF6)	NM_003423	7594
203301_s_at	DMTF1; DMP1; hDMP1	cyclin D binding myb-like transcription factor 1			NM_021145	9988
202673_at	DPM1; MPDS; CDGIE	dolichyl-phosphate mannosyltransferase polypeptide 1			NM_003859	8813
211946_s_at	XTP2; BAT2-iso; KIAA1096	HBxAg transactivated protein 2	AL096857	23215
201769_at	ENTH; EPN4; EPNR; Clint; EPSINR; KIAA0171	enthoprotin	NM_014666	9685
221751_at	AL565516
201603_at	PPP1R12A; MBS; MYPT1	protein phosphatase 1, regulatory (inhibitor) subunit 12A			NM_002480	4659
213025_at	FLJ20274	AL134904	55623
218566_s_at	CHORDC1; CHP1	cysteine and histidine-rich domain (CHORD)-containing, zinc binding protein 1			NM_012124	26973
209022_at	STAG2	AK026678	10735
222204_s_at	RRN3; DKFZp566E104	RRN3 RNA polymerase I transcription factor homolog			AL110238	54700
200899_s_at	MGEA5; MEA5; KIAA0679	meningioma expressed antigen 5 (hyaluronidase)			NM_012215	10724
209115_at	UBE1C; UBA3; hUba3; MGC22384; DKFZp566J164	ubiquitin-activating enzyme E1C isoform 1; ubiquitin-activating enzyme E1C isoform 2; ubiquitin-activating enzyme E1C isoform 3			AL117566	9039
218432_at	FBX03; FBA; FBX3; DKFZp564B092	F-box only protein 3 isoform 1; F-box only protein 3 isoform 2			NM_012175	26273
201260_s_at	SYPL; H-SP1	synaptophysin-like protein isoform a; synaptophysin-like protein isoform b			NM_006754	6856
209028_s_at	ABI1; E3B1; NAP1; ABI-1; SSH3BP1	abl-interactor 1			AF006516	10006
201672_s_at	USP14; TGT	ubiquitin specific protease 14			NM_005151	9097
216321_s_at	NR3C1; GR; GCR; GRL	nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)			X03348	2908
205269_at	LCP2	AI123251	3937
221229_s_at	FLJ20628; DKFZp564I2178	hypothetical protein FLJ20628			NM_017910	55006
213000_at	ZCWCC3; NXP2; ZCW5; KIAA0136	zinc finger, CW-type with coiled-coil domain 3			AP000693	23515
203531_at	BF435809
218096_at	LPAAT-e; FLJ11210	acid acyltransferase-epsilon			NM_018361	55326
203378_at	PCF11; KIAA0824	pre-mRNA cleavage complex II protein Pcf11			AB020631	51585
212450_at	KIAA0256	KIAA0256 gene product			D87445	9728
203347_s_at	M96; MTF2	putative DNA binding protein			NM_007358	22823
201699_at	PSMC6; P44; p42; SUG2; CADP44; MGC12520	proteasome 26S ATPase subunit 6			NM_002806	5706
215245_x_at	FMR1	AA830884	2332
212633_at	KIAA0776	AW298092	23376
218577_at	FLJ20331	hypothetical protein FLJ20331			NM_017768	55631
218878_s_at	SIRT1; SIR2L1	sirtuin 1			NM_012238	23411
M3.5	Total = 19 transcripts	3	Overexpressed
0	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
217052_x_at	AK024108
208749_x_at	FLOT1	flotillin 1	AF085357	10211
200630_x_at	SET	AV702810	6418
M3.6	Total = 233 transcripts	2	Overexpressed
76	Underexpressed

Systematic	Commo	Product			Genbank	Locus
202603_at	ADAM10	N51370	102
214895_s_at	ADAM10	AU135154	102
200723_s_at	M11S1; GPIAP1	membrane component, chromosome 11, surface marker 1 isoform 1; membrane component, chromosome 11, surface marker 1			NM_005898	4076
218973_at	EFTUD1; FAM42A; FLJ13119; HsT19294	elongation factor Tu GTP binding domain containing 1			NM_024580	79631
205078_at	PIGF; MGC32646; MGC33136	phosphatidylinositol glycan, class F isoform 1; phosphatidylinositol glycan, class F isoform 2			NM_002643	5281
217815_at	SUPT16H; FACT; CDC68; FACTP140; FLJ10857; FLJ14010;	chromatin-specific transcription elongation factor large subunit			NM_007192	11198
204215_at	C7orf23; MGC4175; MM-TRAG SPT16/CDC68	chromosome 7 open reading frame 23			NM_024315	79161
213149_at	DLAT	AW299740	1737
202970_at	DYRK2	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 1; dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 isoform 2			Y09216
201633_s_at	CYB5-M	AW235051	80777
203073_at	COG2; LDLC	component of oligomeric golgi complex 2			NM_007357	22796
209600_s_at	ACOX1; MGC1198; PALMCOX	acyl-Coenzyme A oxidase isoform a; acyl-Coenzyme A oxidase isoform b			S69189	51
200687_s_at	SF3B3; RSE1; SAP130; SF3b130; STAF130; KIAA0017	splicing factor 3b, subunit 3, 130kDa			NM_012426	23450
206572_x_at	ZNF85; HPF4; HTF1	zinc finger protein 85 (HPF4, HTF1)			NM_003429	7639
217939_s_at	AFTIPHILIN; FLJ20080; FLJ23793; MGC33965	aftiphilin protein isoform c; aftiphilin protein isoform b; aftiphilin protein isoform a			NM_017657	54812
203201_at	PMM2; CDG1; CDGS	phosphomannomutase 2	NM_000303	5373
208716_s_at	LOC54499	putative membrane protein	AB020980	54499
204185_x_at	PPID; CYPD; CYP-40; MGC33096	peptidylprolyl isomerase D	NM_005038	5481
212216_at	KIAA0436; FLJ16627	putative prolyl oligopeptidase			AB007896	9581
211337_s_at	76P	gamma tubulin ring complex protein (76p gene)			BC000966	27229
204172_at	CPOX; CPX; HCP	coproporphyrinogen oxidase	NM_000097	1371
205055_at	ITGAE; CD103; HUMINAE	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)			NM_002208	3682
203306_s_at	SLC35A1; CST; HCST; CMPST; inactive	solute carrier family 35 (CMP-sialic acid transporter), member A1			NM_006416	10559
204683_at	ICAM2; CD102	intercellular adhesion molecule 2 precursor			NM_000873	3384
202654_x_at	AXOT; MARCH-VII; DKFZP586F1122	axotrophin	NM_022826	64844
207627_s_at	TFCP2; LSF; LBP-1C; TFCP2C	transcription factor CP2	NM_005653	7024
209366_x_at	CYB5	cytochrome b-5	M22865	1528
202663_at	AI005043
214179_s_at	NFE2L1	H93013	4779
217921_at	H97940
219017_at	ETNK1; EKI; EKI1	ethanolamine kinase 1	NM_018638	55500
201128_s_at	ACLY; ATPCL; CLATP	ATP citrate lyase isoform 1; ATP citrate lyase isoform 2			NM_001096	47
212264_s_at	KIAA0261; FOE	KIAA0261	D87450	23063
204642_at	EDG1; ECGF1; EDG-1; S1PR1; CHEDG1; D1S3362	endothelial differentiation, sphingolipid G-protein-coupled receptor, 1			NM_001400	1901
200683_s_at	UBE2L3; E2-F1; L-UBC; UBCH7; UbcM4	ubiquitin-conjugating enzyme E2L 3 isoform 1; ubiquitin-conjugating enzyme E2L 3 isoform 2			NM_003347	7332
201500_s_at	PPP1R11; HCGV; HCG-V; TCTE5; TCTEX5	protein phosphatase 1, regulatory (inhibitor) subunit 11 isoform 1; protein phosphatase 1, regulatory (inhibitor) subunit 11 isoform 2			NM_021959	6992
218313_s_at	GALNT7; GalNAcT7; GALNAC-T7	polypeptide N-acetylgalactosaminyltransferase 7			NM_017423	51809
207490_at	TUBA4; FLJ13940	tubulin, alpha 4	NM_025019	80086
200979_at	BF739979
211547_s_at	PAFAH1B1; LIS1; MDCR	platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45kD)			L13387	5048
214582_at	PDE3B	phosphodiesterase 3B, cGMP-inhibited			NM_000753	5140
204634_at	NEK4; NRK2; STK2	NIMA (never in mitosis gene a)-related kinase 4			NM_003157	6787
219283_at	C1GALT2	core 1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase 2			NM_014158	29071
205263_at	BCL10; CLAP; mE10; CIPER; c-E10; CARMEN	B-cell CLL/lymphoma 10	AF082283	8915
205202_at	PCMT1	protein-L-isoaspartate (D-aspartate) O-methyltransferase			NM_005389	5110
201746_at	TP53; p53; TRP53	tumor protein p53	NM_000546	7157
206989_s_at	SFRS2IP; SIP1; CASP11; SRRP129	splicing factor, arginine/serine-rich 2, interacting protein			NM_004719	9169
218538_s_at	MRS2L; HPT	MRS2-like, magnesium homeostasis factor			NM_020662	57380
218646_at	FLJ20534	hypothetical protein FLJ20534			NM_017867	54969
200703_at	DNCL1; LC8; PIN; DLC1; DLC8; hdlc1	cytoplasmic dynein light polypeptide			NM_003746	8655
213246_at	C14orf109	AI346504	26175
213063_at	FLJ11806	N64802	79882
203284_s_at	HS2ST1; KIAA0448	heparan sulfate 2-O-sulfotransferase 1			NM_012262	9653
202451_at	GTF2H1; BTF2; TFIIH	general transcription factor IIH, polypeptide 1, 62kDa			BC000365	2965
201359_at	COPB; DKFZp761K102	coatomer protein complex, subunit beta			NM_016451	1315
209384_at	PROSC	AA176833	11212
213853_at	ZCSL3	zinc finger, CSL domain containing 3			AL050199
202297_s_at	RER1	RER1 homolog			AF157324	11079
212507_at	RW1; PRO1048; KIAA0257	D87446	23505
204613_at	PLCG2	phospholipase C, gamma 2 (phosphatidylinositol-specific)			NM_002661	5336
201634_s_at	CYBS-M	cytochrome b5 outer mitochondrial membrane precursor			NM_030579	80777
201240_s_at	KIAA0102	KIAA0102 gene product			NM_014752	9789
201295_s_at	WSB1; SWIP1; WSB-1	WD SOCS-box protein 1 isoform 1; WD SOCS-box protein 1 isoform 3; WD SOCS-box protein 1 isoform 2			NM_015626	26118
200996_at	ACTR3; ARP3	ARP3 actin-related protein 3 homolog			NM_005721	10096
211760_s_at	VAMP4; VAMP24	vesicle-associated membrane protein 4			BC005974	8674
200994_at	IPO7; RANBP7	importin 7			AL137335	10527
201985_at	KIAA0196	KIAA0196 gene product			NM_014846	9897
201518_at	CBX1; M31; MOD1; HP1-BETA; HP1Hs-beta	chromobox homolog 1 (HP1 beta homolog Drosophila )			NM_006807	10951
201098_at	COPB2; beta'-COP	coatomer protein complex, subunit beta 2 (beta prime)			NM_004766	9276
201479_at	DKC1; NAP57; NOLA4; XAP101; dyskerin	dyskerin			NM_001363	1736
202811_at	STAMBP; AMSH	STAM binding protein			NM_006463	10617
200050_at	ZNF146; OZF	zinc finger protein 146			NM_007145	7705
201472_at	VBP1; PFD3; PFDN3; VBP-1	von Hippel-Lindau binding protein 1			NM_003372	7411
205898_at	CX3CR1; V28; CCRL1; GPR13; CMKDR1; GPRV28; CMKBRL1	chemokine (C-X3-C motif) receptor 1			U20350	1524
213102_at	ACTR3	Z78330	10096
201661_s_at	ACSL3; ACS3; FACL3; PR02194	acyl-CoA synthetase long-chain family member 3			NM_004457	2181
212412_at	AV715767
203008_x_at	TXNDC9; APACD	ATP binding protein associated with cell differentiation			NM_005783	10190
M3.7	Total = 80 transcripts	2	Overexpressed
16	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
202266_at	TTRAP; EAP2; AD022; MGC9099; dJ30M3.3	TRAF and TNF receptor-associated protein		NM_016614	51567
214096_s_at	SHMT2	AW190316	6472
201966_at	NDUFS2	NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase)		NM_004550	4720
203721_s_at	CGI-48	CGI-48 protein		NM_016001	51096
211061_s_at	MGAT2; GNT2; CDGS2; GNT-II; GLCNACTII	alpha-1,6-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase		BC006390	4247
200045_at	ABCF1; ABC27; ABC50; EST123147	ATP-binding cassette, sub-family F, member 1		NM_001090	23
203576_at	BCAT2; BCAM; BCT2	branched chain aminotransferase 2, mitochondrial		NM_001190	587
221622_s_at	HT007	uncharacterized hypothalamus protein HT007		AF246240	55863
205644_s_at	SNRPG; SMG	small nuclear ribonucleoprotein polypeptide G		NM_003096	6637
218288_s_at	MDS025; MDS011	hypothetical protein MDS025		NM_021825	60492
201697_s_at	DNMT1; MCMT; CXXC9	DNA (cytosine-5-)-methyltransferase 1		NM_001379	1786
201176_s_at	ARCN1; COPD	archain		NM_001655	372
219220_x_at	MRPS22; GIBT; GK002; C3orf5; RPMS22; MRP-S22	mitochondrial ribosomal protein S22		NM_020191	56945
202520_s_at	MLH1; FCC2; COCA2; HNPCC; hMLH1; HNPCC2; MGC5172	MutL protein homolog 1		NM_000249	4292
211070_x_at	DBI; ACBP; ACBD1	diazepam binding inhibitor		BC006466	1622
201241_at	DDX1; DBP-RB	DEAD (Asp-Glu-Ala-Asp) box polypeptide 1		NM_004939	1653
208985_s_at	EIF3S1; eIF3-p35; eIF3-alpha	eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa		BC002719	8669
202911_at	MSH6; GTBP; HNPCC5	mutS homolog 6		NM_000179	2956
M3.8	Total = 182 transcripts	1	Overexpressed
33	Underexpressed

Systematic	Common _Affy	Product		Genbank	LocusLink
213670_x_at	WBSCR20C	AI768378	15540
203551_s_at	COX11; COX11P	COX11 homolog		NM_004375	1353
215743_at	RPP38	AL134489	10557
217902_s_at	HERC2; jdf2; p528; D15F37S1; KIAA0393	hect domain and RLD 2		NM_004667	8924
212944_at	AK024896
212126_at	BG391282
201837_s_at	STAF65 (gamma); ART1; KIAA0764	SPTF-associated factor 65 gamma		AF197954	9913
204142_at	HSRTSBETA	rTS beta protein isoform 2; rTS beta protein isoform 1		NM_017512	55556
203135_at	TBP; GTF2D; SCA17; TFIID; GTF2D1	TATA box binding protein		NM_003194	6908
212037_at	PNN; DRS; SDK3	pinin, desmosome associated protein		Y09703	5411
212454_x_at	HNRPDL	AI762552	9987
206150_at	TNFRSF7; T14; CD27; S152; Tp55; MGC20393	tumor necrosis factor receptor superfamily, member 7 precursor		NM_001242	939
202979_s_at	ZF	HCF-binding transcription factor Zhangfei		NM_021212	58487
215307_at	AL109722
213703_at	LOC150759	W95043
212914_at	CBX7	AV648364
203944_x_at	BTN2A1; BTF1; BT2.1	butyrophilin, subfamily 2, member A1 isoform 1 precursor; butyrophilin, subfamily 2, member A1 isoform 2 precursor		NM_007049	11120
221264_s_at	TARDBP	TAR DNA binding protein		NM_031214	81927
218557_at	NIT2	nitrilase family, member 2		NM_020202	56954
221626_at	ZNF506; DKFZp761G1812	AL136548
213213_at	DATF1	AL035669	11083
219698_s_at	METTL4; HsT661; FLJ23017	methyltransferase like 4		NM_022840	64863
213653_at	AW069290
212179_at	C6orf111; FLJ14752; FLJ14992; bA98I9.2; DKFZp564B0769	chromosome 6 open reading frame 111		AL080186	25957
219169_s_at	TFB1M; CGI75; mtTFB; CGI-75	transcription factor B1, mitochondrial		NM_016020	51106
40569_at	ZNF42; MZF1; MZF-1; MZF1B	zinc finger protein 42 isoform 1; zinc finger protein 42 isoform 2		M58297	7593
220081_x_at	HSD17B7; PRAP; MGC12523; MGC75018	hydroxysteroid (17-beta) dehydrogenase 7		NM_016371	51478
218373_at	FTS; FT1; FLJ13258	fused toes homolog		NM_022476	64400
202220_at	KIAA0907	NM_014949	22889
220035_at	NUP210; GP210; POM210; FLJ22389; KIAA0906	nucleoporin 210		NM_024923	23225
209007_s_at	NPD014; DJ465N24.2.1	NPD014 protein isoform 2; NPD014 protein isoform 1		AF267856	57035
218343_s_at	GTF3C3; TFIIIC102; TFIIICgamma; TFiiiC2-102	general transcription factor IIIC, polypeptide 3, 102kDa		NM_012086	9330
213483_at	KIAA0073	KIAA0073 protein		AK025679	23398
204352_at	TRAF5; RNF84; MGC:39780	TNF receptor-associated factor 5		NM_004619	7188
M3.9	Total = 261 transcripts	0	Overexpressed
135	Underexpressed

Systematic	Common _Affy	Product			Genbank	LocusLink
204236_at	FLI1; EWSR2; SIC-1	Friend leukemia virus integration 1			NM_002017	2313
201501_s_at	GRSF1	G-rich RNA sequence binding factor 1			NM_002092	2926
213883_s_at	BBP	AA012917	83941
203629_s_at	COG5	AU152134	10466
209199_s_at	MEF2C	N22468	4208
208289_s_at	EI24; PIG8; TP53I8	etoposide induced 2.4			NM_004879	9538
204333_s_at	AGA; AGU	aspartylglucosaminidase precursor			NM_000027	175
209382_at	POLR3C; RPC3; RPC62	polymerase (RNA) III (DNA directed) polypeptide C (62kD)			U93867	10623
211987_at	top2B; topIIB	DNA topoisomerase II, beta isozyme			NM_001068	7155
204274_at	EBAG9	AA812215	9166
212585_at	OSBPL8; ORP8; OSBP10	oxysterol-binding protein-like protein 8 isoform b; oxysterol-binding protein-like protein 8 isoform a			AB040884	11488
217724_at	PAI-RBP1	AF131807	26135
218452_at	SMARCAL1; HARP; HHARP	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like 1			NM_014140	50485
212648_at	DHX29; DDX29	DEAH (Asp-Glu-Ala-His) box polypeptide 29			AL079292	54505
200988_s_at	PSME3; Ki; PA28G; REG-GAMMA; PA28-gamma	proteasome activator subunit 3 isoform 1; proteasome activator subunit 3 isoform 2			NM_005789	10197
209786_at	HMGN4; NHC; HMG17L3; MGC5145	high mobility group nucleosomal binding domain 4			BC001282	10473
209943_at	FBXL4; FBL4; FBL5	F-box and leucine-rich repeat protein 4			AF176699	26235
201990_s_at	CREBL2	cAMP responsive element binding protein-like 2			NM_001310	1389
218460_at	FLJ20397	hypothetical protein FLJ20397			NM_017802	54919
217858_s_at	ARMCX3; ALEX3; MGC12199	ALEX3 protein			NM_016607	51566
221744_at	HAN11	WD-repeat protein			AK026008	10238
203983_at	TSNAX; TRAX	translin-associated factor X			NM_005999	7257
201034_at	ADD3	BE545756	120
205771_s_at	AKAP7; AKAP18	A-kinase anchor protein 7 isoform alpha; A-kinase anchor protein 7 isoform gamma; A-kinase anchor protein 7 isoform beta			AL137063	9465
218536_at	AF052167
210111_s_at	PNAS-138			AF277175
219485_s_at	PSMD10; p28	proteasome 26S non-ATPase subunit 10 isoform 1; proteasome 26S non-ATPase subunit 10 isform 2			NM_002814	5716
219007_at	NUP43; p42; FLJ13287; bA350J20.1	nucleoporin 43kDa			NM_024647	79700
201517_at	NCBP2; NIP1; CBP20	nuclear cap binding protein subunit 2, 20kDa			BC001255	22916
209206_at	SEC22L1	AV701283	9554
213154_s_at	BICD2; KIAA0699	bicaudal D homolog 2 isoform 1; bicaudal D homolog 2 isoform 2			AB014599	23299
207305_s_at	KIAA1012; HsT2706	KIAA1012			NM_014939	22878
209247_s_at	ABCF2; ABC28; M-ABC1; HUSSY-18; EST133090; DKFZp586K1823	ATP-binding cassette, sub-family F, member 2 isoform b; ATP-binding cassette, sub-family F, member 2 isoform a			BC001661	10061
212476_at	CENTB2; ACAP2; CNT-B2; KIAA0041	centaurin, beta 2			D26069	23527
65472_at	AI161338
201833_at	HDAC2; RPD3; YAF1	histone deacetylase 2			NM_001527	3066
219296_at	ZDHHC13; HIP14L; HIP3RP; FLJ10852; FLJ10941; MGC64994	zinc finger, DHHC domain containing 13 isoform 2; zinc finger, DHHC domain containing 13 isoform 1			NM_019028	54503
218699_at	RAB7L1	BG338251	8934
222103_at	ATF1	AI434345	466
200902_at	15-Sep	15 kDa selenoprotein isoform 1 precursor; 15 kDa selenoprotein isoform 2 precursor			NM_004261	9403
213390_at	C19orf7; KIAA1064	KIAA1064 protein			AB028987	23211
218396_at	VPS13C	vacuolar protein sorting 13C protein			NM_017684	54832
203048_s_at	KIAA0372	BE566023	9652
203537_at	PRPSAP2; PAP41	phosphoribosyl pyrophosphate synthetase-associated protein 2			NM_002767	5636
201036_s_at	HADHSC; SCHAD	L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain			NM_005327	3033
203566_s_at	AGL; GDE	amylo-1,6-glucosidase, 4-alpha-glucanotransferase isoform 1; amylo-1,6-glucosidase, 4-alpha-glucanotransferase 4-alphisoform 1; amylo-1,6-glucosidase, 4-alpha-glucanotransferase isoform 2; amylo-1,6-glucosidase, 4-alpha-glucanotransferase isoform 3			NM_000645	178
218593_at	RBM28; FLJ10377	RNA binding motif protein 28			NM_018077	55131
202318_s_at	SENP6; SSP1; SUSP1; KIAA0797	SUMO1/sentrin specific protease 6			AF306508	26054
218838_s_at	FLJ12788	hypothetical protein FLJ12788			NM_022492	64427
212150_at	KIAA0143	AA805651	23167
218147_s_at	AD-017; FLJ14611	glycosyltransferase AD-017			NM_018446	55830
200760_s_at	JWA	N92494	10550
211971_s_at	LRPPRC; LSFC; GP130; LRP130; CLONE-23970	leucine-rich PPR motif-containing protein			AF052133	10128
218684_at	LRRC5; FLJ10470	leucine rich repeat containing 5			NM_018103	55144
201624_at	DARS	aspartyl-tRNA synthetase		NM_001349	1615
214198_s_at	DGCR2	AU150824	9993
218989_x_at	SLC30A5; ZNT5; ZTL1; ZNTL1; ZnT-5; MGC5499; FLJ12496; FLJ12756	zinc transporter ZTL1	NM_022902	64924
200860_s_at	KIAA1007; AD-005	KIAA1007 protein isoform a; KIAA1007 protein isoform b			BC000779	23019
217886_at	EPS15	BF213575	2060
208953_at	KIAA0217	KIAA0217 protein	BC003381	23185
205052_at	AUH	AU RNA-binding protein/enoyl-Coenzyme A hydratase precursor			NM_001698	549
202215_s_at	NFYC; HSM; CBFC; HAP5; CBF-C; NF-YC; H1TF2A	nuclear transcription factor Y, gamma			NM_014223	4802
202038_at	UBE4A; UFD2; KIAA0126	ubiquitination factor E4A			NM_004788	9354
212530_at	NEK7	NIMA (never in mitosis gene a)-related kinase 7			AL080111	14060
212499_s_at	C14orf32; MISS; MGC23138; c14_5346	MAPK-interacting and spindle-stabilizing protein			AK025580
201375_s_at	PPP2CB	protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform			NM_004156	5516
209486_at	SAS10	disrupter of silencing 10		BC004546	57050
218491_s_at	THY28; MY105; MDS012; HSPC144; MGC12187	thymocyte protein thy28 isoform 1; thymocyte protein thy28 isoform 2			NM_014174	29087
218212_s_at	MOCS2; MPTS; MCBPE; MOCO1	molybdopterin synthase large subunit MOCS2B; molybdopterin synthase small subunit MOCS2A			NM_004531	4338
210962_s_at	AKAP9; PRKA9; CG-NAP; YOTIAO; AKAP350; AKAP450; HYPERION; KIAA0803	A-kinase anchor protein 9 isoform 2; A-kinase anchor protein 9 isoform 4; A-kinase anchor protein 9 isoform 1; A-kinase anchor protein 9 isoform 3			AB019691	10142
203513_at	FLJ21439; KIAA1840	hypothetical protein FLJ21439			NM_025137	80208
213027_at	AU146655
38892_at	KIAA0240	D87077	23506
203690_at	TUBGCP3; Spc98p	spindle pole body protein		NM_006322	10426
209551_at	MGC11061	hypothetical protein MGC11061		BC004875	84272
202850_at	ABCD3; ABC43; PMP70; PXMP1	ATP-binding cassette, sub-family D, member 3			NM_002858	5825
203738_at	FLJ11193	AI421192	55322
209200_at	MEF2C	N22468	4208
201326_at	CCT6A	BE737030	908
218128_at	NFYB	AI804118	4801
218962_s_at	FLJ13576	hypothetical protein FLJ13576			NM_022484	64418
209143_s_at	CLNS1A; CLCI; ICln; CLNS1B	chloride channel, nucleotide-sensitive, 1A			AF005422	1207
204314_s_at	CREB1; MGC9284	cAMP responsive element binding protein 1 isoform A; cAMP responsive element binding protein 1 isoform B			NM_004379	1385
201778_s_at	KIAA0494	NM_014774	9813
202664_at	AI005043
204354_at	POT1; hPot1; DKFZP586D211	POT1 protection of telomeres 1 homolog			NM_015450	25913
212640_at	LOC201562	AV712602
203787_at	SSBP2; HSPC116	single-stranded DNA binding protein 2			NM_012446	23635
202346_at	HIP2; LIG; HYPG	huntingtin interacting protein 2			NM_005339	3093
215548_s_at	SCFD1; RA410; KIAA0917; STXBP1L2; C14orf163	vesicle transport-related protein isoform a; vesicle transport-related protein isoform b			AB020724	23256
212513_s_at	USP33; VDU1; KIAA1097; MGC16868	ubiquitin specific protease 33 isoform 1; ubiquitin specific protease 33 isoform 2; ubiquitin specific protease 33 isoform 3			AB029020	23032
212486_s_at	N20923
212904_at	KIAA1185	KIAA1185 protein	AB033011	57470
204020_at	PURA	BF739943	5813
203465_at	MRPL19; RLX1; RPML15; MRP-L15; KIAA0104; MGC20675	mitochondrial ribosomal protein L19			NM_014763	9801
212943_at	KIAA0528	KIAA0528 gene product	AB011100	9847
201296_s_at	WSB1; SWIP1; WSB-1	WD SOCS-box protein 1 isoform 1; WD SOCS-box protein 1 isoform 3; WD SOCS-box protein 1 isoform 2			NM_015626	26118
202214_s_at	CUL4B; KIAA0695	cullin 4B	NM_003588	8450
218179_s_at	FLJ12716	FLJ12716 protein isoform a; FLJ12716 protein isoform b			NM_021942	60684
214670_at	ZNF36	AA653300	7586
222201_s_at	CASP8AP2; CED-4; FLASH; RIP25; FLJ11208; KIAA1315	CASP8 associated protein 2			AB037736	9994
201218_at	CTBP2	C-terminal binding protein 2 isoform 1; C-terminal binding protein 2 isoform 2			NM_001329	1488
204980_at	CLOCK; KIAA0334	clock	NM_004898	9575
208882_s_at	DD5	U69567	51366
201817_at	KIAA0010	NM_014671	9690
221196_x_at	C6.1A	c6.1A	NM_024332	79184
201493_s_at	PUM2	BE778078	23369
202956_at	ARFGEF1; BIG1; P200; ARFGEP1; D730028018Rik	brefeldin A-inhibited guanine nucleotide-exchange protein 1			NM_006421	10565
218842_at	FLJ21908	hypothetical protein FLJ21908		NM_024604	79657
203253_s_at	KIAA0433	KIAA0433 protein	NM_015216	23262
214113_s_at	RBM8A	AI738479	9939
212299_at	NEK9; Nek8; NERCC; NERCC1; MGC16714; DKFZp434D0935	NIMA related kinase	9	AL117502	91754
200992_at	IPO7; RANBP7	importin 7	AL137335	10527
203689_s_at	FMR1	AI743037	2332
209323_at	PRKRIR; DAP4; P52rIPK	protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, repressor of (P58 repressor)			AF081567	5612
218322_s_at	ACSL5; ACS2; ACS5; FACL5	acyl-CoA synthetase long-chain family member 5 isoform a; acyl-CoA synthetase long-chain family member 5 isoform b			NM_016234	51703
38290_at	RGS14	regulator of G-protein signalling 14			AF037195	10636
34031_i_at	CCM1; CAM; KRIT1	krev interaction trapped 1		U90268	889
213090_s_at	TAF4	AI744029	6874
218545_at	FLJ11088; p56	hypothetical protein FLJ11088		NM_018318	55297
209268_at	VPS45A; H1; VSP45; VPS45B; VPS54A; VSP45A; H1VPS45	vacuolar protein sorting 45A		AF165513	11311
203743_s_at	TDG	thymine-DNA glycosylase		NM_003211	6996
218047_at	OSBPL9; ORP9; FLJ12492;	oxysterol-binding protein-like protein 9 isoform			NM_024586	11488
FLJ14629; FLJ14801; FLJ32055; FLJ34384; MGC15035	e; oxysterol-binding protein-like protein 9 isoform a; oxysterol-binding protein-like protein 9 isoform b; oxysterol-binding protein-like protein 9 isoform c; oxysterol-binding protein-like protein 9 isofor
221873 at	ZNF143	AW162015	7702
211784_s_at	BC006181
201448 at	TIA1	TIA1 protein isoform 1; TIA1 protein isoform 2			NM_022037
221931_s_at	SEC13L	AV701173	81929
221931_s_at	KIAA0372	KIAA0372	NM_014639	9652
201503 at	G3BP	BG500067	10146
203791 at	DMXL1	Dmx-like 1	NM_005509	1657
219363_s_at	CGI-12	CGI-12 protein	NM_015942	51001
202491_s_at	IKBKAP: FD; DYS; IKAP	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein			NM_003640	8518
201589_at	SMC1L1; SMCB; SB1.8; DXS423E; KIAA0178; SMC1alpha	SMC1 structural maintenance of chromosomes 1-like 1			D80000	8243
213238_at	ATP10D	AI478147	57205
209523_at	TAF2; TAF2B; CIF150; TAFII150	TBP-associated factor 2		AK001618	6873

Table 13: Module-by-module comparison of genes expression levels in liver transplant recipients vs. healthy volunteers. Liver transplant recipients (n=22) vs. Healthy Volunteer (n=27) - training set Mann Whitney U test p-value<0.05, no mtc

M1.1	Total = 69 transcripts		p<0.05	1
				42

216510_x_at	0.9535944	293.8852	0.68922555	230.9773	0.037
211908_x_at	0.90837705	178.65926	0.48615247	121.38636	0.0333
214916_x_at	1.0085313	918.9667	0.7224307	673.1591	0.0316
216853_x_at	0.9532237	192.05556	0.65257263	144.11365	0.0284
211881_x_at	1.0114585	395.59628	0.8215793	334.8909	0.0215
217148_x_at	0.9987921	1299.385	0.76691246	1122.8818	0.0191
211641_x_at	0.93511134	363.24442	0.6844703	278.39545	0.016
216576_x_at	0.9978868	505.27032	0.610412	395.1182	0.0134
217480_x_at	0.97234654	896.04816	0.7454202	709.15	0.00755
214768_x_at	0.98825425	465.96667	0.7120667	329.78638	0.00661
211650_x_at	0.78916377	269.76294	0.31672192	166.3909	0.00577
217227_x_at	1.0972255	284.1741	0.84450734	249.20454	0.00378
217179_x_at	0.92833304	451.8037	0.578116	359.58636	0.00352
211798_x_at	1.0213583	531.3816	0.56347245	331.82272	0.00085
221931_s_at	1.0176613	8300.245	0.24382864	4918.7866	0.000849
215121_x_at	0.98634666	9623.081	0.48235297	6273.741	0.000715
215118_s_at	1.0840191	703.87775	0.5814518	406.17273	0.000459
215777_at	0.9363759	87.022224	0.5081718	52.359093	0.000459
211644_x_at	1.0106673	871.6556	0.5211471	570.0091	0.000382
221253_s_at	1.035757	1441.9109	0.7921406	1241.8682	0.000348
215379_x_at	1.0907915	2435.1445	0.6510944	2274.6091	0.000262
221931_s_at	0.93837446	385.98148	0.6499519	293.54544	0.000216
209138_x_at	1.0315566	8949.182	0.5179802	5852.959	0.000178
215214_at	1.0720766	222.12222	0.620685	140.14091	0.000146
216984_x_at	1.025168	841.889	0.5098904	503.11816	0.000146
217281_x_at	1.0657202	226.53333	0.35082975	118.431816	0.000146
221739_at	0.97063583	1171.1519	1.1927835	1448.1772	0.000146
216401_x_at	0.93514395	426.41113	0.35121965	219.93636	0.000107
214777_at	0.8662704	399.81854	0.3215993	206.45456	0.000107
215176_x_at	1.0185648	1924.6481	0.52285767	1201.3545	0.00009
209374_s_at	0.9966258	5095.5405	0.59940046	3293.0908	0.000063
217258_x_at	0.9936845	222.2	0.43583792	126.109085	0.00005
215946_x_at	0.9841579	1175.8036	0.53852904	764.5227	0.00005
214677_x_at	1.0062306	9875.494	0.46147978	5883.8677	0.00004
213502_x_at	0.989173	2057.2258	0.58787936	1328.241	0.00001
214669_x_at	0.9705455	2949.4036	0.49041447	1899.9272	0.00000
211645_x_at	1.0296928	1275.4926	0.5159448	875.50006	0.00000
205267_at	1.0090047	1391.5444	0.55226755	816.43634	0.00000
214836_x_at	1.0482535	1661.7258	0.61028546	1019.04095	0.00000
221651_x_at	1.0553	14163.74	0.58122855	8642.6045	0.00000
221671_x_at	1.0026699	14210.46	0.52689755	8358.081	0.00000
221931_s_at	1.0306439	4548.656	0.25486428	2239.9727	0.00000
212592_at	1.0268843	1194.1445	0.35290387	647.8092	0.00000
M1.2	Total = 96 transcripts			1	Overexpressed
				25	Underexpressed

Healthy Normalized	Raw	Liver Transplant Normalized	Raw	p-value
202708_x_at	1.0291246	703.4631	1.293131	928.1227	0.037	Overexpressed
215492_x_at	1.0371836	505.05554	0.84501696	420.0091	0.0333	Underexpressed
220496_at	0.93682235	459.94073	0.72206074	372.5818	0.0333	Underexpressed
209806_at	0.9521103	2293.4187	0.81702846	2045.5999	0.0299	Underexpressed
207815_at	1.1267686	381.02594	0.6693667	246.11362	0.0247	Underexpressed
221931_s_at	0.9734153	322.73703	0.818861	272.37726	0.0227	Underexpressed
221931_s_at	0.9424713	1687.637	0.7506878	1352.9364	0.0203	Underexpressed
203680_at	1.0543469	1530.6296	0.7015139	1100.2819	0.0181	Underexpressed
221931_s_at	0.971758	136.51112	0.7027385	106.4591	0.0181	Underexpressed
221931_s_at	0.9768981	2615.9995	0.62159055	1791.5591	0.0151	Underexpressed
220336_s_at	0.9005469	229.16667	0.70483	178.05453	0.0134	Underexpressed
204115_at	1.0053754	1191.0223	0.5847472	852.1319	0.0134	Underexpressed
201278_at	0.9849579	355.89264	0.8393757	310.1182	0.0134	Underexpressed
206167_s_at	0.9658439	181.8778	0.6749217	132.58638	0.00707	Underexpressed
221931_s_at	0.99204427	153.80742	0.71427935	116.05909	0.00661	Underexpressed
221931_s_at	1.0480876	1498.8186	0.7536483	1140.0544	0.00557	Underexpressed
205442_at	0.9410932	403.21854	0.53875446	268.2682	0.00468	Underexpressed
203817_at	0.9738554	329.04446	0.6397933	240.97728	0.00406	Underexpressed
221931_s_at	1.0526993	317.59625	0.76514447	233.68182	0.00178	Underexpressed
212813_at	1.0291963	436.27036	0.7281337	334.1091	0.00164	Underexpressed
206283_s_at	0.97842056	356.47775	0.68749416	263.33636	0.00129	Underexpressed
217963_s_at	0.9497207	2299.615	0.5692195	1455.3591	0.00129	Underexpressed
221211_s_at	1.0132638	973.77783	0.60756016	625.14105	0.00085	Underexpressed
218999_at	0.9999457	590.4556	0.6729006	404.76367	0.000119	Underexpressed
221931_s_at	1.0227504	1134.2667	0.78785646	880.1727	0.00007	Underexpressed
221556_at	0.9153534	344.37778	0.6053534	225.53183	0.00002	Underexpressed

Module-by-module comparison of genes expression levels in liver transplant recipients vs. healthy volunteers. Liver transplant recipients (n=22) vs. Healthy Volunteer (n=27) - training set Mann Whitney U test p-value<0.05, no mtc
M1.1 Total = 69 transcripts	p<0.05	1	Overexpressed
M1.1 Total = 69 transcripts	42	Underexpressed

LocusLink	Common	Product			Genbank
216510_x_at	IgH VH	immunoglobulin heavy chain			AB035175	3507
211908_x_at	IGHM	IgM	M87268	3507
214916_x_at	IGHM	BG340548	3507
216853_x_at	IGLJ3	immunoglobulin light chain variable region			AF234255	28831
211881_x_at	IGLJ3	VEGF single chain antibody			AB014341	28831
217148_x_at	IGLV	immunoglobulin lambda variable region			AJ249377	28831
211641_x_at	IGH@	immunoglobulin heavy chain V-region			L06101	3507
216576_x_at	immunoglobulin kappa light chain variable region			AF103529
217480_x_at	IGKV1oR15-118; IGKVP2; IGKV1oR118	M20812
214768_x_at	IGKC	BG540628	3514
211650_x_at	IGHM	L34164	3507
217227_x_at	IGL@	immunoglobulin lambda light chain VJC region			X93006	3535
217179_x_at	IGL@	immunoglobulin lambda light chain			X79782	3535
211798_x_at	IGLJ3	single-chain antibody			AB001733	28831
221931_s_at	IGHM	immunoglobulin A1-A2 lambda hybrid GAU heavy chain			S55735	3507
215121_x_at	IGLJ3	AA680302	28831
221931_s_at	AW519168
215777_at_	AW405975
211644_x_at	IGKC	L14458	3514
221253_s_at	TXNDC5; ERP46; UNQ364; EndoPDI; MGC3178	thioredoxin domain containing 5 isoform 2; thioredoxin domain containing 5 isoform 1			NM_030810	81567
215379_x_at	IGLJ3	AV698647	3535
221931_s_at	ITM2C; E25; BRI3; E25C; ITM3; BRICD2C	integral membrane protein 3			NM_030926	81618
209138_x_at	IGLJ3	M87790	28831
215214_at	IGL@	H53689	3535
216984_x_at	IGLJ3	immunoglobulin light chain V-J region			D84143	28831
217281_x_at	IGHV	immunoglobulin heavy chain variable region			AJ239383	3502
221739_at	IL27w	AL524093	56005
216401_x_at	IGKV	immunoglobulin kappa chain variable region			AJ408433
214777_at	IGKC	BG482805	3514
215176_x_at	IGKC	AW404894	3514
221931_s_at	IGHM; MU	IGHM protein			BC001872	3507
217258_x_at	IGL	immunoglobulin lambda chain			AF043583
215946_x_at	LOC91316	AL022324	91316
214677_x_at	IGLJ3	X57812	28831
213502_x_at	IGLL3; 16.1	lambda L-chain C region			X03529	91316
214669_x_at	IGKC	BG485135	3514
211645_x_at	IgK	immunoglobulin kappa-chain VK-1			M85256	3514
205267_at_	POU2AF1; BOB1; OBF1; OCAB; OBF-1	POU domain, class 2, associating factor 1			NM_006235	5450
214836_x_at	IGKC	BG536224	3514
221651_x_at	IGKC	Unknown (protein for MGC:12418)			BC005332	3514
221671_x_at	IGKC	M63438	3514
211430_s_at	IGHG3	M87789	3502
212592_at	IGJ	AV733266	3512
M1.2	Total = 96 transcripts	1	Overexpressed
25	Underexpressed

LocusLink	Common	Product		Genbank
202708_s_at	HIST2H2BE; GL105; H2B.1; H2B/q; H2BFQ	H2B histone family, member Q		NM_003528	8349
215492_x_at	PTCRA	AL035587	17155
220496_at	CLEC2	C-type lectin-like receptor-2		NM_016509	51266
209806_at	HIST1H2BK; H2B/S; H2BFT; H2BFAiii	H2B histone family, member T		BC000893	85236
207815_at	PF4V1; PF4A; CXCL4V1; PF4-ALT; SCYB4V1	platelet factor 4 variant 1		NM_002620	5197
214039_s_at	LAPTM4B	T15777	55353
208690_s_at	PDLIM1; CLIM1; CLP36; ELFIN; CLP-36; hCLIM1	PDZ and LIM domain 1 (elfin)		BC000915	9124
203680_at	PRKAR2B; RII-BETA	cAMP-dependent protein kinase, regulatory subunit beta 2		NM_002736	5577
207808_s_at	PROS1; PSA	protein S (alpha)		NM_000313	5627
215071_s_at	H2AFL	AL353759	8334
220336_s_at	GP6; GPIV; GPVI	glycoprotein VI (platelet)		AB043821	51206
204115_at	GNG11	guanine nucleotide binding protein (G protein), gamma 11		NM_004126	2791
201278_at	N21202
206167_s_at	ARHGAP6; RHOGAP6; rhoGAPX-1	Rho GTPase activating protein 6 isoform 2; Rho GTPase activating protein 6 isoform 3; Rho GTPase activating protein 6 isoform 5; Rho GTPase activating protein 6 isoform 4; Rho GTPase activating protein 6 isoform 1		NM_001174	395
221027_s_at	PLA2G12A	phospholipase A2, group XIIA		NM_030821	81579
215111_s_at	TGFB1I4; TSC22; MGC17597	transforming growth factor beta 1 induced transcript 4 isoform 2; transforming growth factor beta 1 induced transcript 4 isoform 1		AK027071	8848
205442_at_	KIAA0626	NM_021647	9848
203817_at	GUCY1B3	W93728	2983
201280_s_at	DAB2; DOC2; DOC-2	disabled homolog 2		NM_001343	1601
212813_at	JAM3	AA149644	83700
206283_s_at	TAL1; SCL; TCL5	T-cell acute lymphocytic leukemia 1		NM_003189	6886
217963_s_at	NGFRAP1; Bex; BEX3; NADE; HGR74; DXS6984E	nerve growth factor receptor (TNFRSF16) associated protein 1 isoform b; nerve growth factor receptor (TNFRSF16) associated protein 1 isoform a		NM_014380	27018
221211_s_at	C21orf7; TAK1L	chromosome 21 open reading frame 7		NM_020152	56911
218999_at	FLJ11000	hypothetical protein FLJ11000		NM_018295	55281
209586_s_at	HTCD37	TcD37 homolog		AF123539	58497
221556_at	CDC14B	AU145941	8555

Claims

A method of identifying a subject with melanoma comprising:
determining two or more melanoma vectors of expression, wherein the two or more melanoma vectors of expression comprise the expression level of six or more genes over-expressed, under-expressed or combinations thereof selected from module M1.1 and module M1.2 of Table 12; and

displaying each of the melanoma expression vectors with a separate identifier.
The method of claim 1, further comprising the step of detecting one or more polymorphisms in the six or more genes.
The method of claim 1 further comprising a method for displaying melanoma transcriptome vector data comprising:
separating one or more genes into one or more modules to visually display an aggregate gene expression vector value for each of the modules; and

displaying the aggregate gene expression vector value for overexpression, underexpression or equal expression of the aggregate gene expression vector value in each module.
A method of identifying a subject with immunosuppression associated with transplants comprising:
determining two or more immunosuppression vectors of expression; and

displaying each of the immunosuppression vectors of expression with a separate identifier, wherein each immunosuppression vector of expression comprises levels of expression of six or more genes selected from module M1.1 and module M1.2 of Table 13.
The method of claim 4, further comprising the step of detecting one or more polymorphisms in the one or more immunosuppression vector of expression.
The method claim 4 or 5, wherein the one or more immunosuppression vectors of expression are derived from a leukocyte.
The method of any one of claims 4 to 6 comprising:
separating six or more genes into two or more modules to visually display, as an aggregate, a vector of expression for each of the modules; and

displaying the vector of expression for overexpression, underexpression or equal expression of the vector of expression in each module.
The method of any one of claims 1 to 7, wherein the six or more genes comprise genes related to platelets, platelet glycoproteins, platelet-derived immune mediators, MHC/ribosomal proteins, MHC class I molecules, Beta 2-microglobulin, ribosomal proteins, hemoglobin genes or combinations thereof and/or genes related to interferon-inducible genes, signaling molecules, kinases, RAS family members or combinations thereof.
The method of any one of claims 1 to 8, wherein the expression level comprises mRNA expression level, protein expression level or both mRNA expression level and protein expression level.
The method of any one of claims 1 to 9, wherein the expression level-comprises a mRNA expression level and is quantitated by a method selected from the group consisting of polymerase chain reaction, real time polymerase chain reaction, reverse transcriptase polymerase chain reaction, hybridization, probe hybridization and gene expression array.
The method of any one of claims 1 to 10, wherein the expression level is determined using at least one technique selected from the group consisting of polymerase chain reaction, heteroduplex analysis, single stand conformational polymorphism analysis, ligase chain reaction, comparative genome hybridization, Southern blotting, Northern blotting, Western blotting, enzyme-linked immunosorbent assay, fluorescent resonance energy-transfer and sequencing.
The method of claim 3 or 8, wherein overexpression is identified with a first identifier and underexpression is identified with a second identifier.
The method of claim 3 or 8, wherein overexpression is identified with a first identifier and underexpression is identified with a second identifier, wherein the first identifier is a first color and the second identifier is a second color, wherein first and second identifiers are superimposed to provide a combined color.
A computer readable medium comprising computer-executable instructions for performing the method of claim 1.